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Abstract 
 
Gram-negative infection has been linked to hospital water although few studies have 
examined whether water systems are reservoirs of nosocomial pathogens. This study 
investigated longitudinal recovery of the opportunistic pathogens Pseudomonas aeruginosa, 
Stenotrophomonas maltophilia and Acinetobacter baumannii from water outlets of a 
haematology unit and evaluated Point-Of-Use Filtration (POU-F) as a control measure. 
In a two-year double cross-over trial, water samples and swabs were taken weekly from 39 
showers/taps on the unit. Four study phases alternated between non-filtered (Phases 1 & 3), 
and filtered outlets (Phases 2 & 4) using Pall Aquasafe
TM
 14-day filters. In Phases 1 & 3; 
99% of 1396 samples yielded bacterial growth, with colonies generally too numerous to 
count. Target species were isolated from 22% of water samples (P. aeruginosa 14%; S. 
maltophilia 10%) and 10% of swabs. P. aeruginosa was particularly associated with 
handwash stations and S. maltophilia with showers. A. baumannii was not isolated. With 
POU-F; 22% of 1242 samples yielded bacterial growth (mean CFU/100ml ,4.6). S. 
maltophilia was isolated only once from water but never from outlet swabs. PCR typing 
identified clusters of isolates colonizing different outlets over time but no clear association 
between water and patient isolates was identified. The incidence of Gram negative infections 
remained low throughout the study. 
Without POU-F, water from taps/showers represented a source of bacteria including the 
target species. POU-F substantially reduced the frequency and number of target species 
from every outlet, and merits further investigation as an intervention to protect 
immunocompromised patients from opportunistic pathogens.  
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1. Introduction 
1.1 Healthcare Associated Infections (HCAI) 
The term Healthcare-associated Infection (abbreviated as HCAI or HAI) has largely 
replaced others such as Hospital-acquired Infection (also known as HAI), 
nosocomial infection and hospital-onset infection and is a more modern reflection of 
the range of settings in which people receive health-related attention. The term 
Healthcare-associated Infection is defined as any infectious agent acquired as a 
consequence of a person’s treatment by a healthcare provider, or which is acquired 
by a healthcare worker in the course of their duties (From National Audit Office 
(NAO) report Reducing Healthcare-associated Infections in Hospitals in England, 
2009, quoting from the Health Act 2006: Code of Practice for the Prevention and 
Control of Healthcare-associated Infections). This has replaced the previous 
definition of an infection that was neither present nor incubating at the time of 
entering a hospital (NAO, 2009). 
 
The significance of HCAI is well documented as increased morbidity and mortality 
among patients, increased financial burden on health services, and also greater use 
of antibiotics giving rise to antibiotic resistant strains of HCAI pathogens. A number 
of factors promote infection in a hospitalised patient, including decreased immunity, 
invasive medical procedures and devices, old age, underlying disease and 
immunosuppressive treatment such as chemotherapy for the treatment of 
malignancy (WHO, 2002). 
 
The results of the third national prevalence survey of healthcare-associated 
infections in England were released by the Hospital Infection Society in March 2007   
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and reported that 8.2% of patients have a healthcare associated infection (from a 
survey of 190 acute hospitals in England in 2006 involving 58,000 patients) a 
reduction from 9.2% in the first national prevalence survey in 1980 (Hospital 
Infection Society (HIS) Press Release 8th March 2007 (HIS, 2007). While there is no 
national aggregate for the data collection of HCAI, the Department of Health in 2004 
confirmed that 300,000 was the best estimate that could be made for the number of 
HCAI in England (NAO 2009). 
 
Table 1. Main Causes of Healthcare-associated Infections in England  
 
Type of Infection 
Percentage 
of all HCAI 
Risk Factors 
Main Causative 
Organisms 
Urinary Tract 
Infections (UTI) 
20% 
80% of HCAI UTI are associated 
with urinary catheters (method 
and duration of catheterisation 
and susceptibility of patient.) 
Gram negative  
bacteria especially 
E. coli 
Lower  Respiratory 
Tract Infections 
20% 
Mechanical ventilation; cumulative 
risk of infection increases with 
duration of ventilation. 
Acinetobacter 
species,  
S. aureus 
Gastrointestinal  22% 
The gut may become colonised 
with C. difficile which may 
establish an infection if normal gut 
flora is disrupted by broad 
spectrum antibiotics. The elderly 
are at particular risk. 
70% of HCAI gastro- 
intestinal infections 
were caused by 
C. difficile 
Surgical Site 
Infection 
14% 
Duration of surgery, surgical 
technique, preparation, presence 
of foreign material, length of 
hospital stay and antibiotic 
prophylaxis. 
S. aureus ~50%, 
P. aeruginosa 
Other Gram negative  
bacteria  
Bacteraemia 7% 
Approx. 44% associated with 
invasive devices. 
E. coli and other 
Gram negative 
bacteria, 
S. aureus 
Skin & Soft Tissue 
Infections 
10% 
Management of open wounds and 
pressure sores. 
S. aureus 
Other 7% 
Includes infections of bones and 
joints and the central nervous 
system. Often linked to surgical or 
invasive procedures. 
 
 
Table 1 shows data taken and adapted from National Audit Office: Reduction of 
Healthcare-associated Infections in Hospitals in England 2009  
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The majority of HCAI are caused by bacteria, with the greatest public awareness 
being of methicillin resistant Staphylococcus aureus (MRSA) bloodstream infections 
and the gastrointestinal infection caused by Clostridium difficile (CDI). 
 
These two bacterial species have been the focus of government led control 
campaigns and were reported by the NAO in 2006 to represent 15% of all HCAI 
(NAO, 2009). These campaigns have resulted in falls of MRSA bacteraemia. A 
baseline for MRSA bacteraemia was set for the 2003-2004 financial year at 1,925 
reports. In the most recently published HPA quarterly epidemiology report (July – 
September 2011) which gives the mandatorily reportable MRSA bacteraemia, and 
C. difficile infection data; there was an 86.2% decrease in reports relative to the 
baseline for the former and for the latter decrease from a baseline quarterly average 
of 13,875 reports in 2007-2008 to 4,981 reports in July-September 2011, a 64.1% 
reduction (HPA: Quarterly Epidemiological Commentary: Mandatory MRSA 
bacteraemia & C. difficile infection July-September 2011 (HPA, 2011c). 
 
Infection prevention and control is seen as the responsibility of all within the 
healthcare setting and has a level of high importance within the National Health 
Service (NHS) and there are numerous policies and guidance documents in 
existence (Table 2). National evidence-based guidelines for the prevention of HCAI 
within the NHS were commissioned by the Department of Health (DH) and 
published in 2001. These standard principles for prevention of HCAI, include 
guidance on hospital environmental hygiene, hand hygiene and the use of personal 
protective equipment among others. Other aids to HCAI prevention include 
surveillance, for example, mandatory reporting of MRSA bacteraemia in England 
since 2001 and CDI in over 65’s since 2004 with enhanced surveillance from 2007   
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in all patients aged ≥2 years, along with auditing compliance with key policies and 
procedures for preventing HCAI. 
 
Table 2: Key National Guidelines on Preventing HCAI 
 
(Guidelines for Professionals, HCAI (HPA, 2010b)  
 
  
 Clean, Safe Care - Reducing MRSA and other healthcare associated 
infections 
 Health Act 2009 23 February 2010 
 The Health Act 2006: Code of Practice for the prevention and control of 
healthcare associated infection, October 2006 
 Epic2: National evidence-based guidelines for preventing healthcare-
associated infections in NHS hospitals in England. J Hosp Infect. 2007; 
65 (suppl 1)   
 The Epic Project: Developing national evidence-based guidelines for 
preventing healthcare association infections phase 1: guidelines for 
preventing hospital-acquired infections 
 Pellow CM, Pratt RJ, Loveday HP et al (2004): The epic project; updating 
the evidence for national evidence-based guidelines for preventing 
healthcare association infections in NHS hospital in England.  A report 
with recommendations 
 National Institute of Clinical Excellence: Infection control, prevention of 
healthcare-associated infection in primary and community care (National 
Institute of Clinical Excellence guideline). June 2003 
 Department of Health: Infection Control Guidance for Care Homes. Dept 
Health/ICNA/Public Health Medical Environmental group, June 2006 
 Department of Health: Delivery Programme to Reduce Healthcare 
Associated Infections, 2006. Includes: Essential steps in safe clean care, 
Going further faster   
 Ward V, Wilson J, Taylor L, Cookson B, Glynn A  Preventing hospital-
acquired infection - Clinical guidelines PHLS 1997 ISBN 0 901144 
41 X 
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1.1.2 Transmission and Persistence of Bacteria within the Hospital Environment 
and Hospital Hygiene 
 
The hospital environment is a mix of animate and inanimate components and can 
become a reservoir for potentially pathogenic bacteria for patients, staff and visitors 
alike (Hargiss, 1980). The routes of transmission for microorganisms are varied. 
Bacteria may come from endogenous sources, i.e. from the patients themselves, or 
exogenously from others or the environment. Bacteria can be dispersed from these 
reservoirs (e.g. coughs and sneezes from colonised or infected patients or from 
water outlets) to susceptible hosts (see Figure 1). 
 
Figure 1. The Chain of Infection 
 
Adapted from The Chain of Infection, representation of how a patient can acquire an 
infection from someone else, from HPA General Information on Healthcare 
Associated Infection (HPA) 
 
  
INFECTIOUS 
AGENT 
RESERVOIR 
PORTAL OF EXIT 
MODE OF 
TRANSMISSION 
SUSCEPTIBLE HOST 
PORTAL OF ENTRY 
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Bacteria associated with HCAI have been isolated from many different areas of the 
hospital environment. Teng et al (2009), found that 90% of 180 medical charts on a 
surgical ICU and >70% on a surgical ward in Taiwan were found to be contaminated 
with pathogenic or potentially pathogenic bacteria including coagulase negative 
staphylococci (CNS), multi-drug resistant Acinetobacter baumannii, 
Stenotrophomonas maltophilia and Klebsiella pneumoniae (Teng et al., 2009). 
Environmental contamination has also been shown to increase the likelihood of 
infection of a new room occupant. By placing a patient in a room which had been 
previously occupied by an individual with MRSA or vancomycin-resistant 
enterococci (VRE), the likelihood of the new patient becoming infected increased 
from 2.9% for a patient occupying a room with no prior MRSA case to 3.9% with a 
previously MRSA occupied room; for VRE the likelihood increased from 2.8 to 4.5% 
(Huang et al., 2006). 
 
A number of hospital-associated pathogens are also able to survive for long periods 
of time outside a human host. While some Gram positive bacteria are often able to 
resist desiccation due to their cell wall structure or their ability to sporulate, some 
Gram negatives can survive for extended periods within the environment. A. 
baumannii, isolates, which are frequently multiply antibiotic-resistant, can survive for 
long periods on inanimate surfaces and is often isolated from the clinical 
environment. Jawad et al., (1998), found an average survival time of 27 days for 
outbreak strains of A. baumannii on dry surfaces while other investigators were able 
to demonstrate a survival time of 4 months (Jawad et al., 1998; Wendt et al., 1997). 
P. aeruginosa can also survive on inanimate surfaces for long periods of ≤16 
months, and on a dry floor, ≤5 weeks (Kramer et al., 2006). This is in contrast to 
many other Gram negative bacteria which are often highly susceptible to desiccation 
7 
 
in dry environments: e.g. Helicobacter pylori can survive on surfaces for ≤90 
minutes (Bohmler et al., 1996). 
 
Both water and air harbour microorganisms and there are strategies to prevent 
transmission via these routes. Hospital patients are frequently exposed to 
waterborne microorganisms as they can exist in many moist reservoirs. Persistence 
within the hospital environment, particularly in the intensive care unit, poses a 
significant risk for the transmission of these organisms to susceptible patients. 
 
Because of the risk of patient acquisition of pathogenic bacteria from the hospital 
environment much emphasis has been placed on hospital cleanliness and a number 
of initiatives launched as a result (see Table 3). Hand hygiene has very much been 
the focus of government and NHS guidance to health care workers and visitors 
alike. The national “cleanyourhands” was launched by the National Patient Safety 
Agency (NPSA) in 2004 to improve hand hygiene practised by NHS staff. The 
process of hand washing has evolved to include alcohol-based gel products along 
with hand washing using soap and water in an attempt to interrupt the transmission 
of infection cycle from health care workers (HCW) to patients. Personal Protective 
Equipment (PPE) such as gloves, aprons and face masks are also available for 
HCW as routine for many procedures and also when attending to patients nursed in 
source isolation (“barrier nursing”). The type of PPE is selected on the basis of the 
risk of transmission of the organism: the seriousness of any infection resulting from 
such transmission, and the risk of contamination of the HCW or their clothing (DH, 
2001), for example patients colonised or infected with MRSA or Clostridium difficile 
or individual with suspected or confirmed tuberculosis.  
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Alongside the personal hygiene responsibilities of individual healthcare workers and 
the encouragement for a likewise attitude for both patients and visitors, is attention 
to the cleanliness of the hospital itself. Many novel approaches have been 
developed to augment traditional cleaning methods. These include ultramicrofibre 
cloths, mops containing biocides, UV irradiation, impregnation of materials with 
heavy metals and ionisation. Other interventions involve patient care such as cohort 
nursing, isolation rooms, ventilation, screening of patients for carriage of pathogens 
such as MRSA, ensuring good nutrition and, for prevention of C. difficile infection, 
administration of probiotics. Interventions to reduce acquisition of water-borne 
pathogens include point-of-use filters, thermal shock, UV-light and copper-silver 
ionisation. Air filtration (HEPA filtration) and optimised ventilation can reduce the 
number of air-borne pathogens such as the fungus Aspergillus, as well as bacteria 
such as MRSA and P. aeruginosa (Curtis, 2008). 
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Table 3.  New national initiatives and their associated costs  
 
 
Table 3 shows the associated costs of the national initiatives for tackling HCAI 
adapted from the NAO’s “Reducing Healthcare Associated Infections in Hospitals in 
England” (2009). 
 
However, it is very difficult to validate or instigate a risk assessed method for 
hospital cleanliness. Visual assessment is not a robust method and judgement the 
impression of cleanliness is made more difficult when there is clutter and excess 
equipment etc. on a ward. Microbiological methods and ATP bioluminescence have  
Initiative Aims Cost 
Modern Matrons 
(2004) 
The improvement of clinical care 
standards, ensure best practice in 
infection control and provide a clean 
environment for care. 
Approximately £56 
million per year 
 
(Infection control is 30 
per cent of their 
workload) 
Cleanyourhands 
Campaign 
 (2004) 
To improve the availability of alcohol 
hand rub at the point of patient care, 
increase compliance with hand hygiene 
and also auditing of hand hygiene. 
£2.5 million 
Saving Lives  
(2006) 
To provide the tools and resources for 
hospital trusts to embed robust infection 
prevention and control measures across 
their organisation. 
Not possible to 
separately identify 
The Code of Practice 
(part of the Health Act 
2006) 
This sets out statutory criteria by which 
managers of NHS organisations are to 
ensure that patients are cared for in a 
clean environment, where the risk of 
HCAI is kept as low as possible. 
Not possible to 
separately identify 
The Improvement Teams 
(2006) 
Provide support to trusts in achieving 
reductions in MRSA bloodstream 
infections. Including support that ranges 
from visits to telephone advice. 
£3 million per year 
The Deep Clean 
(2008) 
Improvements in cleanliness and patient 
confidence. 
£62.6 million 
Technology Programme 
(2008) including the Rapid 
Review Panel (2004) 
Speed up the process of assessment 
and adoption of technologies to further 
help prevent HCAI. 
£25,000 for the panel 
and £10 million per year 
from 2008-09 onwards 
MRSA Screening 
(from April 2009) 
To reduce the carriage of MRSA in 
patients admitted electively or acutely to 
hospital. 
Approximately £130 
million per year from 
2010-11 
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been investigated as measures of cleanliness from which benchmark standards can 
be derived (Dancer, 2011). 
 
1.1.3 A Changing Population 
The medical historian Sir Roy Porter is quoted as saying ‘Whenever we change the 
way we live, new diseases arise’. As humans evolve and through societal and 
technological adaptations, they are exposed to new risks. Such changes have 
included alcohol and drug abuse, travel to new locations and unsafe sex and have 
resulted in exposure to previously unrecognised risks (Figure 2).  
Figure 2. Factors Leading to the Emergence of Infectious Disease 
 
 
 
 
 
 
 
 
 
“Changes in society, technology, environment and microorganisms are leading to 
increases in host susceptibility and/or disease transmission and the evolution of new 
or drug resistant microorganisms.” (Cohen, 2000) 
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One of the most important demographic changes has been the increasing 
population of susceptible individuals: the aging population and those with underlying 
medical conditions (Cohen, 2000). An example of longer survival with a serious and 
immune-compromising illness is the increase in the five-year survival for people with 
Hodgkin lymphoma which, between 1960 – 1980, increased from 40 to 76% as a 
result of more effective chemotherapy, in 2010 this was reported to have increased 
further to 85% (American Cancer Society, 2010). The predicted survival rates in 
England and Wales for ≥10-year survival have increased from 49% in the early 
1970’s to around 78% (Cancer Research UK: “Long-term Survival for Once-Deadly 
Cancers Doubles”, 2010). This is but one example of the changing nature of patient 
categories whose likelihood of surviving previously fatal disease is increased as a 
result of advances in therapy which, paradoxically, place them at increased risk or 
serious, sometimes life-threatening HCAI. 
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1.2 Haematological Malignancy, Immunocompromise and 
Infection 
 
1.2.1 Altered Immunity 
The immune status of an individual can become altered either temporarily or 
permanently through disease or therapy. A state of immunodeficiency affects the 
risk of susceptibility to infection and the duration and the type of immunodeficiency 
affects a patient’s vulnerability to infection. High risk patients, for example those with 
a very low absolute neutrophil count of 0.5 109/L include patients with AIDS; 
haemopoietic stem cell transplant recipients; asplenics; and individuals with 
congenital severe immunodeficiency or haematological malignancies (as a result of 
the primary pathology or as a consequence of treatment). 
 
Treatment for haematological malignancy has become increasingly complex and 
intensive over the last 10 years with the use of monoclonal antibody therapies in 
combination with chemotherapy regimens becoming accepted standard practice for 
many conditions. In addition the introduction of reduced intensity and umbilical cord 
allogeneic stem cell transplantation has increased the numbers of patients receiving 
highly immunosuppressive therapies. 
 
As the number of immunocompromised patients has increased, the changing 
epidemiologies of infection and antimicrobial resistance have made infections in 
compromised hosts a persistent problem (Donowitz et al., 2001). 
  
13 
 
1.2.2 Neutropenia 
Neutropenia, either iatrogenic or secondary to underlying disease, is defined by the 
absolute neutrophil count (ANC) relative to an average ANC for healthy adults of 1.5 
x 109/L. Moderate neutropenia lies between 0.5 - 1 x 109/L and severe neutropenia 
is defined as an ANC of below 0.5 x 109/L. The risk of infection increases with 
duration of neutropenia and patients neutropenic for ≥10 days are considered high 
risk (BSAC, Management of the Immunocompromised Patient). The neutropenic 
state was first described as a major defence defect by Bodey et al (1966) when they 
demonstrated that an ANC of 0.5 -1 x 109/L correlates with increases in the 
incidence of severe infection, the length of the fever duration and also the number of 
days of antibiotic therapy (Bodey et al., 1966). A number of studies have also shown 
that the risk of infection is increased by the duration (and degree) of neutropenia 
(Hughes et al., 1997; Link et al., 1999; Pizzo, 1993). The 
immunocompromised/neutropenic patient is vulnerable to a wider range of micro-
organisms than non-immunocompromised individuals, and the diagnosis of infection 
can be more difficult because of atypical presentation, often with fever as the only 
sign of infection. 
 
1.2.3 Haematological Malignancies  
Haematological malignancies are a group of cancers which affect the haemopoietic 
and lymphoreticular systems (blood, bone marrow and lymph nodes). Individuals who 
develop such conditions should be treated on a dedicated haematology unit. The 
treatment of these disorders is complex and often involves intensive, high dose 
chemotherapy regimens. This causes marked myelosuppression which produces 
profound effects on the innate and acquired immune systems rendering patients 
vulnerable to infection caused by a wide range of microorganisms including those   
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which would not normally cause infections in non-immunocompromised individuals, 
so-called opportunistic infections. 
 
In a study of 2142 cases of febrile neutropenia resulting from cancer chemotherapy, 
the frequencies of Gram positive, Gram negative and polymicrobial bacteraemias 
were 57%, 34% and 10% respectively, mortality rates were 5%, 15% and 13% 
respectively showing the significance of Gram negative or polymicrobial bacteraemias 
(Klastersky et al., 2007). It is therefore essential that these patients, whom often 
experience prolonged stays in hospital, are as protected as much as is possible from 
contracting a hospital acquired infection. 
 
1.2.4 Treatment of Patients with Malignancy 
The onset of fever in a neutropenic patient is always taken seriously and treated 
promptly because of the possibility that this may be the first, and perhaps only, 
manifestation of a potentially life-threatening infection (Shepherd et al., 2009). Febrile 
neutropenia has been associated with reduced survival as a consequence not only of 
infectious complications, but other factors such as delays in resuming anti-neoplastic 
chemotherapy treatment or dose reductions in such treatment (Lo and Cullen, 2006). 
Timely commencement of empiric antibiotic therapy in febrile cancer patients is critical 
as prior to the use of empiric therapy, mortality associated with Gram negative 
infection was close to 80% (Chang et al., 1976). Difficulties in identifying bacteraemia 
at the onset of infection in neutropenic patients led to the administration of broad-
spectrum antibiotics on first signs of temperature and without further microbiological 
evidence (Klastersky, 2009).  
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In 1973, the European Organisation for Research and Treatment of Cancer (EORTC) 
founded the International Antimicrobial Therapy Group (IATG), to gain a better 
understanding of infections in cancer patients. This group observed that between 
1978 - 1994 eight therapeutic trials (documenting nearly 800 cases of bacteraemia) 
noted a decrease in mortality rates from 21 to 7% (Viscoli, 2002). 
 
“Principles of Management of Infection in the Immunocompromised Patient” (British 
Society for Antimicrobial Chemotherapy), states that patients with profound 
neutropenia are at special risk of infection and should be treated as medical 
emergencies, a fever ≥38oC in a patient which persists for ≥2 hours should be treated 
with intravenous broad-spectrum antimicrobial chemotherapy. It is an irony that use of 
empirical broad-spectrum antibiotics has become a risk factor for infections caused by 
resistant bacteria. 
 
1.2.5 The Changing Nature of Bacterial Infectious Agents in Cancer Patients 
 
Several shifts in the aetiological agents causing infections in neutropenic patients 
have been noted. Staphylococcus aureus was the most frequently isolated 
bacterium in immunocompromised patients during the early 1950s and 1960s 
(Hersh et al., 1965). Following antimicrobial chemotherapy targeted at Gram positive 
bacteria, Gram negative bacilli became predominant. During the 1970’s 
approximately 70% of bacteraemias in patients with febrile neutropenia and cancer 
were caused by Gram negative pathogens (Zinner, 1999) and Gram negative 
enterobacteria were the cause of 30 - 50% of all ICU-associated isolates 
(Trautmann et al., 2005). However, this was followed by a well-documented shift 
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from Gram negative bacilli back to bacteraemia caused by Gram positive cocci 
(Pfaller et al., 1999; Zinner, 1999). 
 
While there are many reasons for this change, one of these is almost certainly the 
use of prophylactic antimicrobials, especially fluoroquinolones, in neutropenic 
patients. The possibility however, that there will be a shift back to Gram negative 
infections in haematological malignancy patients cannot be discounted (Cattaneo et 
al., 2008). 
 
1.2.6 Use of Central Venous Catheters 
Patients with haematological malignancy often have a central venous catheter 
inserted into the superior vena cava (also known as a Hickman Line), via a skin 
tunnel. This is to facilitate intensive treatment and allows for safety and ease of 
administration of chemotherapy drugs, blood products, antibiotics and, if necessary, 
intravenous feeding. It can also be used to draw blood for laboratory testing. 
However complications relating to the insertion and long term presence of lines may 
occur. These commonly include haemorrhage and bruising relating to the insertion, 
thrombosis and infection. Catheter-related blood stream infections (CRBSI) are a 
frequent cause of morbidity and mortality for these patients. 
 
Chee et al (2008) described the predominance of Gram negative bacteria in 
Hickman line-related infections in patients with haematological malignancy. Of 273 
patients, 61 developed CRBSI, 68% of these infections (during periods of non-
neutropenia) were Gram negative. The most common Gram negative isolate in this   
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study was Stenotrophomonas maltophilia (26%) followed by Klebsiella spp. and 
Acinetobacter spp. (both 16%). Coagulase-negative staphylococci (CNS) were the 
most common Gram positive isolate. During neutropenic episodes, CRBSI are still 
more commonly caused by Gram positive pathogens (Chee et al., 2008). 
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1.3 Antibiotic Resistance and HCAI Pathogens  
 
A golden age of antibiotic drug discovery occurred between the 1930’s and the 
1960’s. However, the advent of antibiotic resistance rapidly followed the introduction 
of all classes into clinical practice (see Figure 3)(Hogberg et al., 2010). The need for 
new antibiotics to combat the threat of antimicrobial resistance, contrasts sharply 
with the lack of research and development of new antimicrobial compounds by 
pharmaceutical companies (DeMaria, 2005; Hogberg et al., 2010; Norrby et al., 
2005; Talbot et al., 2006). 
 
Figure 3. Antibiotic introduction and the development of resistance  
 
(from Hogberg et al, 2010)  
19 
 
There are a number of reasons why pharmaceutical companies have reduced 
research and development activities in respect of new antibiotics: long time lines for 
development; spread of antibiotic resistance which can limit the market life of a 
product; low profit margins as a result of short treatment times and the effects of 
stewardship programmes to restrict the use of new agents (Hogberg et al, 2010). A 
recent study by the European Centre for Disease Prevention and Control (ECDC) 
and the European Medicines Agency (EMA), found that there is likely to be no major 
breakthrough in new antibiotic classes during the coming years as very few 
antibacterial agents will enter clinical development (ECDC/EMA, 2009). 
 
Antibiotic resistance is either acquired through mutation, via gene exchange or is 
inherent, as seen in many environmental bacteria. Selective pressures upon the 
organisms from the hospital environment are also a factor in the acquisition of 
resistance. Antibiotic resistance was designated as an “emerging” infectious 
disease issue by the 4th Decennial International Conference on Nosocomial and 
Healthcare-associated Infections involving the United State Congress, the Institute 
of Medicine and the CDC (Emerging Infectious Diseases, 2001) and is now 
considered a major public health issue. This has come as a result of “bacterial 
evolution finally surpassing the human capacity to create new antimicrobial agents” 
(Rahal et al., 2002). 
 
One concern, particularly in healthcare institutions, is the evolution of “superbugs”, 
bacteria which can exhibit resistance to multiple classes of antibiotics and which are 
associated with increased morbidity, mortality and costs arising from prolonged 
length of stay and treatment. These include the extended-spectrum β-lactamase 
producing (ESBL) bacteria first described in the 1980’s and which confer resistance   
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to most β-lactam antibiotics including monobactams such as aztreonam and 
extended-spectrum cephalosporins. The latter are “workhorse” antibiotics used 
widely in hospital practice for a wide range of infections including those caused by 
members of the Enterobacteriaceae.  
 
Agents of the carbapenem class are important therapeutic options for the treatment 
of ESBL-associated infections and therefore the emergence of carbapenem-
resistance genes such as Klebsiella pneumoniae carbapenamase (KPC) is 
significant. KPC enzymes are mostly found in members of the Enterobacteriaceae 
but also in P. aeruginosa (Yigit et al., 2001). More recently another carbapenemase, 
NDM-1 has been described (Yong et al., 2009). 
 
The Department of Health issued a National Resistance Report in January 2009 to 
warn of an increasing number of carbapenem-resistant strains of 
Enterobacteriaceae in UK hospital patients. Significantly these patients had often 
received medical treatment abroad, in particular, the Indian subcontinent. Between 
2008 – 2009, 22 bacterial isolates with the NDM-1 gene were isolated in 19 patients 
(from 17 hospitals) and comprised 14 K. pneumoniae isolates, Escherichia coli (4); 
Citrobacter freundii (2); Enterobacter cloacae (1) and Morganella morganii (1). All 
were shown to be clonally diverse, except for one instance of possible patient-
patient transmission, suggesting repeated importation to the UK from the Indian 
subcontinent. This original group of 22 bacteria represented the largest single group 
of carbapenemase producers (HPA “Multi-resistant hospital bacteria linked to India 
and Pakistan”, 2009). The significance of this is that carbapenems are often the only 
agent active against MDR bacteria, in particular those with ESBL, therefore these 
strains are of major concern. The emergence of NDM-1 has caused a call for a  
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publically funded global antibiotic surveillance system rather than just national or 
regional systems (Walsh and Toleman, 2012). 
 
There is great diversity in the use of the terms multi-, extensively- and pan-drug 
resistance, and the issue was addressed at a joint initiative by the ECDC and the 
CDC which formed a group of experts to create a standardised nomenclature to 
describe the acquired resistance profiles seen in bacteria such as S. aureus, 
P. aeruginosa, Acinetobacter spp., Enterococcus spp. and Enterobacteriaceae 
(other than Salmonella and Shigella) which are often responsible HCAI. The agreed 
definitions are: 
MDR: Multidrug-resistant, non-susceptibility to at least one agent in three or 
more antimicrobial categories. 
XDR: Extensively drug-resistant, non-susceptibility to at least one agent in 
all but two or fewer antimicrobial categories (the isolates remain susceptible 
to only one or two categories. 
PDR: Pandrug-resistant, non-susceptibility to all agents in all antimicrobial 
categories. 
The group added that appropriate categorisation is ensured by testing isolates 
against nearly all of the antimicrobial agents within each of the categories 
(Magiorakos et al., 2012).  
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1.3.1 Gram negative HCAI Pathogens 
In recent years, Gram positive bacteria have caused considerable problems in 
healthcare settings with VRE and MRSA receiving much attention. There is now 
however, an awareness that Gram negatives could again become the greater public 
health concern with rapidly increasing antibiotic resistance often conferred by 
horizontal gene transfer of plasmids and a lack of new antibiotics under 
development (Kumarasamy et al., 2010). 
 
In 2006, Harris et al reported that infection control practitioners, hospital 
epidemiologists, clinicians, and hospital administrators were struggling to control 
multidrug resistant Gram-negative bacteria such as Pseudomonas aeruginosa, 
Acinetobacter baumannii, Klebsiella pneumoniae, and Enterobacter spp. The 
Antimicrobial Availability Task Force set up in the United States in 2003 identified 
six “particularly problematic” pathogens; two Gram positives: MRSA and VRE, the 
fungus Aspergillus spp. and the Gram negative bacteria: A. baumanni, 
P. aeruginosa and ESBL-producing Enterobacteriaceae (Slama, 2008). Two other 
Gram negative bacteria were noted with increasing frequency as being particularly 
problematic pathogens: Stenotrophomonas maltophilia and Burkholderia cepacia 
(Gales et al., 2001; McGowan, 2006). 
 
Gram negative pathogens, particularly resistant strains, play an important role in the 
hospital setting. Surveillance by the American National Nosocomial Infection 
Surveillance System from 1986 - 2003 found that Gram negative bacteria were 
isolated from 65 to 80% of all cases of ICU-acquired pneumonia; 40 to 60% of all 
ICU-acquired surgical-site infections; approximately 70% of ICU-acquired UTI’s and 
25 to 30% of all ICU-acquired bloodstream infections (Gaynes and Edwards, 2005).  
23 
 
Stenotrophomonas maltophilia and Burkholderia cepacia are two examples of non-
fermentative Gram negative bacteria which both commonly colonise and cause 
infection in critically ill patients (Berthelot et al., 2005; Nseir et al., 2006) and whose 
prevalence has increased (Safdar and Rolston, 2007). The combination of acquired 
and inherent antibiotic resistance seen in bacteria such as S. maltophilia and 
P. aeruginosa makes infections caused by these agents hard to treat. This is also a 
group with an ever changing taxonomic status, genera now known as 
Stenotrophomonas, Burkholderia and Brevundimonas all used to be considered as 
belonging to the genus Pseudomonas. 
 
With antibiotic resistance becoming such a large public health issue, there is now 
much emphasis on the appropriate use of antibiotics with several global campaigns. 
The CDC has the Get Smart: Know when Antibiotics Work campaign and the 
European Centre for Disease Prevention and Control (ECDC) launched the 
European Antibiotic Awareness Day on 18 November 2010 to promote prudent 
antibiotic use encouraging antibiotic use only when needed, the importance of using 
the correct dose, checking dosage intervals and duration of the course. This 
information was made available to the general public, primary care prescribers and 
hospital prescribers (ECDC website 2010). The World Health Organisation also had 
the Antimicrobial Resistance: No Action Today, No Cure Tomorrow awareness 
campaign in their 2011 World Health Day which was aimed at combating the spread 
of antibiotic resistance by encouraging a consolidation of effort to avoid regression 
to a pre-antibiotic era (WHO, 2011).  
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1.4 The Genus Pseudomonas  
The Pseudomonas genus contains one of the most diverse groups of bacteria on 
the planet, with members being found in many natural habitats: terrestrial, marine 
and freshwater and in close association with animals and plants (Spiers et al., 
2000). The first investigators to study systematically this widely diverse group were 
Stanier, Palleroni and Douderoff who, in 1966, described the biochemical, 
physiological and nutritional diversity of 267 strains of aerobic pseudomonads and 
produced a number of core groupings within the genus (Stanier et al., 1966). 
Another significant study from the same year was Mandel’s work on the 
deoxyribonucleic acid base composition which found that the DNA contains between 
58 - 69% guanine and cytosine with P. aeruginosa containing 67.2% g/c content 
compared with P. fluorescens with 59.4% (Mandel, 1966). The current Euzeby’s List 
of Prokaryotic Names with Standing in nomenclature – Genus Pseudomonas; lists 
185 species  with 13 subspecies belonging to the genus Pseudomonas (Euzeby, 
1997). 
 
1.4.1 Taxonomy and Nomenclature of Pseudomonas aeruginosa 
The genus Pseudomonas was originally named in 1894 by Walter Migula who 
worked at the Karlsruhe Institute in Germany from 1893 - 1904. His first description 
of the bacterium is brief and inaccurate, for example, describing it incorrectly as a 
spore forming species (Palleroni, 2010). In 1973 the bacterium was classified into 
five rRNA homology groups which have subsequently undergone considerable 
revision with species now belonging to the genus Pseudomonas in homology group 
1. This includes P. aeruginosa, P. putida, P. fluorescens and P. stutzeri among 
others. The four remaining homology groups were reclassified into separate genera 
(including Stenotrophomonas (previously Xanthomonas), Burkholderia,  
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Sphingomonas, Comamonas). Cellular fatty acid composition is an aid to 
distinguishing between Pseudomonas and other related genera (Kiska, 1999). The 
genus name Pseudomonas has a Greek translation of “false unit’, and aeruginosa 
refers to the colour of the colonies on certain media (Palleroni, 2010). 
 
1.4.2 Pseudomonas aeruginosa 
Pseudomonas aeruginosa is generally considered to be the most important human 
pathogen of the genus but other members are also medically relevant, such as 
P. stutzeri, P. putida, P. fluorescens and P. mendocina which emphasises the 
importance of accurate identification of the species in the clinical setting 
(Spasenovski et al., 2009). 
 
Pseudomonas aeruginosa infections place a heavy burden on the health-care 
system. While primarily known as an opportunistic pathogen, the bacterium also 
causes infection in otherwise healthy individuals in, for example, community-
acquired infections such as ”swimmers ear” and folliculitis (which results following 
colonisation of hair follicles), both caught by exposure to contaminated water. 
However, P. aeruginosa is more commonly identified as an infectious agent in 
individuals whose immune status has become compromised such as patients with 
burns or AIDS or in individuals with cystic fibrosis. It is also a pathogen in ventilated 
patients and those with indwelling catheters reflecting the bacterium’s ability to 
colonise plastic devices. Pneumonia and blood stream infections are among the 
more serious infections associated with this bacterium. There is much information 
on the ecology of this bacterium but there is conflicting evidence as to whether 
endogenous or exogenous sources are more important in the acquisition of 
infection.  
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As a commensal bacterium, P. aeruginosa can be found in the lower gastro- 
intestinal tract (GIT) of humans and less commonly from the pharynx, mouth and 
urethra (Todar, 2008). Colonisation of the GIT is thought to be the most important 
reservoir of P. aeruginosa for patients in an ICU setting with the mortality rate for 
those with intestinal colonisation being significantly highly than those without 
(Bertrand et al., 2001). This is most likely due to translocation of the bacterium to 
extraintestinal sites such as the respiratory tract or bloodstream and this is thought 
to be important in the development of bacteraemia in cancer patients as 
translocation is more likely following chemotherapy-induced neutropenia and GIT 
mucosal damage (Koh, 2005; Pizzo, 2002). 
 
However, the interplay between endogenous and exogenous sources of 
P. aeruginosa is complex and a number of studies have attempted to examine 
whether colonisation is endogenous or follows exogenous acquisition. A 1998 study 
by Bergmans et al investigated the sequential epidemiology of 10 ICU patients who 
went on to develop VAP. Samples were collected from the oropharynx, trachea, 
stomach and rectum and isolates of P. aeruginosa were genotyped using pulsed 
field gel electrophoresis (PFGE). In 9/10 patients the isolate was first identified in 
samples from the oropharynx indicating that oropharangeal colonisation was the 
likely first step in infection and not translocation from the gut. This was in contrast to 
the rectal isolates which were found before onset of VAP on only two occasions. 
Furthermore, five of the patients had strains which were clonally related to those of 
neighbouring patients and the authors concluded that it was possible that the 
healthcare workers in contact with the patients or their associated equipment may 
have been the vector of transmission (Bergmans et al., 1998).  
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1.4.3 Pseudomonas spp. and Pseudomonas aeruginosa Bacteraemia 
Pseudomonas aeruginosa is one of the most common causes of hospital-acquired 
infection and is increasingly resistant to many antibiotics (HPA, 2010c). In a study of 
314 patients infection with the bacterium was reported to have a higher mortality 
rate for bacteraemic infection than methicillin-sensitive and methicillin-resistant 
S. aureus (Osmon et al., 2004). The Health Protection Agency’s, Health Protection 
Report published July 2011 reported the incidence of Pseudomonas spp. 
bacteraemia in England, Wales and Northern Ireland using data from a voluntary 
surveillance scheme for 2006 - 2010. Between 2006 - 2008 there was an 8% 
increase in Pseudomonas spp. bacteraemia reported to the HPA which was 
followed by a 4% decrease from 2008 - 2010 with a total of 3,807 reports in 2010. In 
2010, 90% of the Pseudomonas spp. bacteraemia isolates were identified to species 
level, of these 93% were P. aeruginosa. 
 
The overall incidence of Pseudomonas spp. bacteraemia for England, Wales and 
Northern Ireland in 2010 was 6.7 cases/100,000 population, higher than the 
previous report covering 2005-2009 (6.3 cases/100,000). The 2005-2009 report also 
described the distribution of Pseudomonas spp. bacteraemia by region and showed 
that the Yorkshire and Humberside region had the second highest incidence with 
7.8/100,000, only exceeded by London (9.6/100,000). This had decreased to 
approximately 6.5/100,000 in the later report dropping the region from second 
highest to sixth. Both reports showed Pseudomonas spp. bacteraemia was more 
common in males in all age groups with the highest rates noted in males ≥65 at 38 
cases/100,000 (HPA, 2011b).  
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Figure 4. Pseudomonas spp. and S. maltophilia and other related species bacteraemia 
reports: 2006 to 2010 
 
(taken from HPA: Pseudomonas spp. and Stenotrophomonas maltophilia 
bacteraemia in England, Wales, and Northern Ireland, 2006 to 2010 report, 2011) 
 
1.4.4 Antibiotic Resistance in Pseudomonas aeruginosa 
The importance of P. aeruginosa as a nosocomial pathogen is underlined by multi-
drug resistance. The bacterium may possess a number of inherent or acquired 
resistance mechanisms including drug exclusion and enzymatic inactivation. 
 
Exclusion of antibiotics was long considered to be due to the impermeability of the 
cell (Livermore, 2002). However, this was disproved by the discovery of an efflux   
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pump MexAB-OprM, a mechanism for the efflux from the cell of β-lactams, 
fluoroquinolones, macrolides, chloramphenicol, tetracycline, trimethoprim, 
sulphonamides, novobiocin and other agents such as detergents and dyes (Benz 
and Hancock, 1981). Inherent resistance to β-lactams is also conferred by the 
inducible ampC β-lactamase enzyme (induced by antibiotics such as ampicillin and 
cefalothin) which hydrolyses the drugs which induce it (Livermore, 1995). 
 
In a UK questionnaire survey of 20 clinical microbiology experts investigating the 
perception of organisms of greatest impact because of antibiotic resistance; 
P. aeruginosa was deemed the second most important bacterium (Bywater and 
Casewell, 2000). 
 
1.4.5 Pseudomonas aeruginosa and the Hospital Environment 
Within the hospital, P. aeruginosa is found in numerous reservoirs including 
disinfectants (Lanini et al., 2011; Wishart and Riley, 1976), bath basins (Johnson et 
al., 2009), bath toys (Buttery et al., 1998), water-baths used to thaw frozen plasma 
(Muyldermans et al., 1998), contaminated nebulizers (Cobben et al., 1996), 
bronchoscopes (DiazGranados et al., 2009; Shimono et al., 2008) and even teddy 
bears on paediatric wards (Hughes et al., 1986). As can be seen from these 
examples, many of the reservoirs are aqueous or associated with high moisture 
content. There have been many studies linking Pseudomonas aeruginosa directly 
with tap water, hydrotherapy and recreational swimming pools (Aspinall and 
Graham, 1989; Moore et al., 2002; Trautmann et al., 2001) and many others linking 
P. aeruginosa colonization and HAI to water in the hospital environment, 
investigations of which have been summarised in Table 4. 
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Table 4. Key Examples of Pseudomonas spp. Nosocomial Infections linked to Water Sources 
Country Detail Time Period Aqueous  Source Reference 
Northern Ireland, 
United Kingdom 
Six infections of premature neonates and 
a further five skin colonisations on a 
neonatal ICU 
Three weeks, January 
2012 
Sink taps. (Wise, 2012) 
Northern Ireland, 
United Kingdom 
Infection and death of one neonate on a 
neonatal ICU 
December, 2011 Single tap within unit. 
(BBC News (27
th
 
January 2012)  
England, United 
Kingdom  
Nine patients colonised from which six 
developed febrile neutropenia 
1 month  
Contaminated drinking water 
dispenser on a bone marrow 
transplant unit. 
(Wong et al., 2011) 
Italy 
Eighteen cases of infection were 
identified in a haematology unit in Italy 
2006 – 2007 Triclosan soap dispenser. (Lanini et al., 2011) 
Canada 
36 patients  (ICU of transplant unit), 17 
of whom died within 3 months due to 
outbreak of MDR P. aeruginosa 
December 2004 through 
March 2006 
Hand hygiene sink drains. Using 
fluorescence, drain content splash 
was shown to reach 1 meter from the 
sink. 
(Hota et al., 2009) 
Germany 
Outbreak of HCAI in 6 ICU’s of a single 
hospital: 15 infections and four 
colonisations 
6 weeks Contaminated bottled still water 
(Eckmanns et al., 
2008) 
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France 
38 patients (colonisation) on a medical 
ICU 
27 weeks 
(May - Nov 2003) 
Patient colonization via tap water and 
the hands of health care workers 
(Rogues et al., 
2007) 
France 
8 children with central venous catheter 
(CVC) related infections with either 
P. aeruginosa or P. putida 
Jan-April, 2005 
Contaminated water outlets (showers) 
and detergent – disinfectant solution 
on a oncohaematology paediatric  unit 
(Aumeran et al., 
2007) 
USA 
2 neonates developed septicaemia with 
P. putida 
February, 2001 
Contaminated heparin flush solutions 
prepared in a hospital pharmacy 
(Perz et al., 2005) 
Switzerland 
132 patient colonisation and infections 
on ICU’s 
1 Year Water taps (Blanc et al., 2004) 
Germany 
Endemic infections in surgical ICU 
affecting 5 patients 
7 months Colonized water taps 
(Trautmann et al., 
2001) 
France 27 infections; 9 colonisations 16 month period 
Wash basins and nutrition solutions 
contaminated with tap water 
(Bert et al., 1998) 
France 14 cases of urinary tract infection Jan-April, 2005 Tap water 
(Ferroni et al., 
1998) 
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1.5 The Genus Stenotrophomonas  
The genus Stenotrophomonas comprises of at least 13 species which are found 
throughout the environment. The commonly encountered species, 
Stenotrophomonas maltophilia is associated with humans and plants and is used for 
bioremediation of pollutants (Ryan et al., 2009). 
 
Other species within the genus are: Stenotrophomonas humi, Stenotrophomonas 
terrae and Stenotrophomonas dokdonensis isolated from soil and 
Stenotrophomonas koreensis isolated from compost (Heylen et al., 2007; Yang et 
al., 2006; Yoon et al., 2006). Stenotrophomonas rhizophilia is associated with plants 
and two other species have come from more industrial sources: Stenotrophomonas 
acidamimiphila was isolated from an anaerobic sludge blanket reactor and 
Stenotrophomonas nitritireducens was isolated from biofilters from waste gas 
treatment (Assih et al., 2002; Finkmann et al., 2000; Wolf et al., 2002). 
 
An isolate later described as Stenotrophomonas africana was first isolated from the 
cerebrospinal fluid of a HIV-positive man in Rwanda and was initially considered to 
be distinct from S. maltophilia (Drancourt et al., 1997). However, further 
investigation revealed that the two actually belonged to the same taxon and 
S. africana was recognised as a synonym for S. maltophilia (Coenye et al., 2004). 
 
1.5.1 Nomenclature of Stenotrophomonas maltophilia 
This bacterium was first isolated from pleural fluid in 1943 and named Bacterium 
bookeri (Hugh and Ryschenkow, 1961). Following further studies it then became   
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known as Pseudomonas maltophilia in 1960 (Hugh and Ryschenkow, 1961). The 
type strain ATCC 13637 was isolated in April 1958 from an oropharyngeal swab of a 
patient with oral cancer. In 1983, the bacterium was transferred to the genus 
Xanthomonas and renamed Xanthomonas maltophilia (Palleroni and Bradbury, 
1993). However, this was disputed due to distinct differences between other 
members of the genus and X. maltophilia. This included phenotypic differences, for 
example, flagella, pigment production, fatty acid composition and DNA base 
composition (van Zyl and Steyn, 1992). In 1993 a transfer from the genus 
Xanthomonas to a genus Stenotrophomonas (meaning “a unit feeding on few 
substrates”) was proposed (Palleroni and Bradbury, 1993). This gave the first 
comprehensive description of the genus including characteristics such as nutritional 
spectrum, optimal growth temperature and colony morphology, Stenotrophomonas 
maltophilia was also recognised as the most commonly isolated pseudomonad, 
after P. aeruginosa, in the clinical laboratory. 
 
1.5.2. Stenotrophomonas maltophilia 
Stenotrophomonas maltophilia is a bacterium which is ubiquitous in the environment 
which, despite limited pathogenic potential, has been gaining notoriety as an 
important nosocomial pathogen, partly due to its inherent antibiotic resistance. It is 
associated with a wide spectrum of clinical manifestations including bloodstream 
infections and ventilator-associated pneumonia. Infection with S. maltophilia is 
associated with high mortality rates (Khardori et al., 1990). Risk factors for infection 
include prolonged hospitalisation, mechanical ventilation, use of broad-spectrum 
antibiotics, indwelling catheters, prematurity or an otherwise immunocompromised 
status (Abbassi et al., 2009).  
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Stenotrophomonas maltophilia has also been isolated from the inanimate hospital 
environment and can often be found in fluids used in the hospital setting, for 
example S. maltophilia caused an outbreak of bacteraemia in patients undergoing 
bone marrow transplantation which was associated with incorrectly replacement of 
hand washing soap with a moisturiser which was then used by a healthcare worker 
to wash their hands (Klausner et al., 1999). Respiratory tract carriage of 
S. maltophilia has been reported in patients with cystic fibrosis and the bacterium 
has been isolated from hospitalised oncology patients with diarrhoea as well as the 
hands of hospital personnel (Apisarnthanarak et al., 2003; Denton and Kerr, 1998; 
Schable et al., 1991). 
 
A recurring theme from studies of S. maltophilia is the phenotypic and genotypic 
variations seen among clinical isolates (Berg et al., 1999; Higgins et al., 2001). 
From a study of 10 S. maltophilia bacteraemia isolates, three 16S rRNA gene 
sequence types were observed (Avison et al., 2001) permitting division of 
S. maltophilia into three types: A, B and C; Type A is suspected to be more 
infectious than the others and is typified by strain K279a (Crossman et al., 2008). 
K279a, cultured from the blood of an elderly man undergoing chemotherapy on an 
oncology ward in a UK hospital shortly before his death, has undergone complete 
genome sequencing. Sequencing revealed a total chromosome size of 4,851,126 
bp with no plasmids, G + C content of 66.7% and a collection of antimicrobial and 
heavy metal resistance genes making it not only of clinical concern but indicating 
that the bacterium can act as a reservoir for antimicrobial resistance genes 
(Crossman et al., 2008).  
35 
 
This study also concludes that analysis of the genome of S. maltophilia (K279a) 
does not suggest a very highly virulent organism (Crossman et al., 2008). However, 
virulence factors that have been observed in S. maltophilia include extracellular 
enzymes such as phospholipase and its ability to degrade cell membranes and a 
large number of pili/fimbriae genes that aid in adhesion and biofilm formation, 
factors possibly important in lung colonisation of cystic fibrosis patients and also 
antibiotic resistance (Crossman et al., 2008; de Oliveira-Garcia et al., 2002; 
Pompilio et al., 2011). A 2006 study found an autonomously replicating DNA 
molecule in clinical isolates of S. maltophilia; this was sequenced and among the 
seven open reading frames a phage genome carrying a zonula occludens like toxin 
gene (zot) identical to the toxin Zot in Vibrio cholera was found. The study 
concludes that this could be S. maltophilia’s first possible recognised virulence 
factor from clinical isolates (Hageman et al., 2006). 
 
1.5.3 Stenotrophomonas maltophilia Bacteraemia 
Bacteraemia attributable to S. maltophilia is often seen in cancer and burns 
patients. Risk factors for infection other than the immunosuppression include 
indwelling catheters and antecedent antibiotic use (Boktour et al., 2006). The Health 
Protection Agency has reported a 41% decrease of S. maltophilia bacteraemia from 
2006 - 2010 and an overall incidence of 0.8 cases/100,000 population in England, 
Wales and Northern Ireland. The Yorkshire and Humberside region had the fourth 
highest region-specific rates for in England with approximately 0.78 cases/100,000 
(HPA). See Figure 4 for further details of S. maltophilia bacteraemia.  
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1.5.4 Stenotrophomonas maltophilia Antibiotic Resistance 
Stenotrophomonas maltophilia displays resistance to most antimicrobials in current 
clinical use including β-lactams, aminoglycosides, macrolides and quinolones. 
Resistance is conferred by either multi-drug resistance efflux pumps or inactivating 
enzymes. Multi-drug resistance (MDR) is often mediated in Gram negatives by 
resistance-nodulation-division (RND) efflux pumps and S. maltophilia possesses 
smeABC and smeDEF (Alonso and Martinez, 2000; Zhang et al., 2001). It is 
possible that the SmeDEF efflux pump could be overexpressed in the presence of 
the biocide triclosan, a common ingredient of cleaning solutions, coatings of hospital 
devices and oral hygeine products (Sanchez et al., 2004). Antibiotic modifying 
enzymes of strain K279a include L1 and L2 β-lactamase genes giving resistance to 
all classes of β-lactams including the penicillins, cephalosporins and carbapenems 
but not to the monobactams (Avison et al., 2001); and also APH (3’)-11 and AAC 
(6’1)-Iz aminoglycoside modifying enzymes (Lambert et al., 1999; Okazaki and 
Avison, 2007). 
 
Antibiotic treatment of infections caused by the bacterium is also complicated by its 
inherent resistance to many classes of antibiotics. In the UK survey of 20 clinical 
microbiology experts referred to in section 1.4.4 S. maltophilia was perceived to be 
the ninth organism of greatest impact because of restricted treatment options 
(Bywater and Casewell, 2000). 
 
Of 2076 strains of S. maltophilia collected worldwide during the 1997-2003 SENTRY 
Antimicrobial Surveillance Programme, Trimethoprim-sulfamethoxazole (co-
trimoxazole) was found to be the most potent of the few remaining treatment 
options, with the β-lactams ceftazidime and ticarcillin-clavulanic acid both   
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compromised by resistance in many isolates. Some of the newer fluoroquinolones 
have good in vitro efficacy, levofloxacin being most active with only 6.5% resistance 
(Sader 2005). The SENTRY study (1997-1999) examined the resistance profiles of 
842 S. maltophilia isolates from five different worldwide locations to some of these 
agents and revealed marked variations between regions. For example, resistance to 
trimethoprim/sulfamethoxazole ranged from only 2% in Latin America and Canada 
to 10% in Europe (Gales et al., 2001). 
 
1.5.5 Stenotrophomonas maltophilia and the aqueous environment 
Stenotrophomonas maltophilia is ubiquitous in the environment and is especially 
associated with water. Numerous studies have reported isolation of the bacterium 
from water sources in various health care facilities (see Table 5). It has been 
isolated from incubators (Abbassi et al., 2009), nebulizers (Denton et al., 2003), 
dental unit reservoirs (Arvanitidou et al., 2003; Szymanska, 2007) and 
haemodialysis water (Montanari et al., 2009). See Table 5 for examples of 
nosocomial infections linked to water. 
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Table 5. Key Examples of S. maltophilia Nosocomial Infections linked to Water 
Country Detail Time Period Water Source Ref 
Tunisia 
Respiratory infections in infants in a 
neonatal intensive care unit (unstated 
number). 
22 months, 
Dec. 2003 – Sept. 
2005 
One PFGE type A isolated from a  
washbasin. Another type isolated from 
water in an incubator. 
(Abbassi et al., 
2009) 
Israel 
Soft tissue necrosis 
Two deaths of neutropenic patients. 
Unstated date, 
infections occurred at 
the same time 
Tap of patient room. 
(Sakhnini et al., 
2002) 
USA 
Cluster of colonisation and infections in a 
surgical intensive care unit (S. maltophilia 
isolated from 7 patients). 
5 months 
Contamination of potable water 
leading to colonisation of the faucet 
aerators. 
(Weber et al., 1999) 
USA 
Three cases of bacteraemia in bone 
marrow transplant recipients, all patients 
died. 
3 weeks, July – 
August, 1999 
Health-care worker who washed with 
moisturiser instead of hand-wash. 
(Klausner et al., 
1999) 
Canada 
12 infected & 2 colonised: blood, 
respiratory & central line. 
1 year period Patient ventilators. (Alfieri et al., 1999) 
Netherlands 
4 colonisations, 1 infection resulting in 
death: endotracheal aspirates. 
March – May, 1996 Tap water. (Verweij et al., 1998) 
39 
 
1.6 The Genus Acinetobacter  
The Acinetobacter genus was first described by Brisou and Prevot in 1954. It is a 
very diverse genus with at least 30 members that can be found in many 
environments including soil, food, sewage, drinking and surface waters and also 
importantly, as colonizers of the skin of healthy humans (Bergogne-Berezin and 
Towner, 1996; Towner, 2009). DNA-DNA hybridisation has revealed at least 21 
different DNA homology groups within the genus (Schreckenberger, 1999), these 
are now referred to as ‘geno-species’. Community-associated Acinetobacter 
infections are rare, and are mostly associated with antibiotic susceptible strains 
(HPA, 2010a). However, some geno-species can cause serious infection, and are 
an increasing problem in the hospital environment; an issue compounded by their 
ability to survive for long periods on dry surfaces and their multi-drug resistance 
(Jawad et al., 1998; Webster et al., 2000; Wendt et al., 1997). 
 
The species most commonly involved in HCAI is Acinetobacter baumannii (geno-
species 2), a species first proposed by Bouvet and Grimont in 1986 based on DNA 
hybridisation homology. However, A. baumannii is not clearly distinguished from 
Acinetobacter groups 1, 3 and 13 using this technique and these are also difficult to 
distinguish from one another by genotypic and phenotypic methods. The species 
Acinetobacter calcoaceticus, A. baumannii, geno-species 3 and geno-species 13TU 
are thus collectively referred to as the A. calcoaceticus-A. baumannii (Acb) complex 
(Dijkshoorn et al., 2007). 
 
The second European Prevalence of Infection in Intensive Care (EPIC II) Study 
conducted on 8th May 2007 recruited 1,265 ICU’s across 75 countries and involved 
13,796 adult patients of which 51% were classified as having an infection on the day   
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of the study of which 62% were caused by Gram negative bacteria and of these, 
Acinetobacter spp. was the fourth most common isolate. Also noted was 
geographical variance with isolation of the types of organisms isolated; 
Acinetobacter spp. ranging from 3.7% in North America to 19.2% in Asia. Isolation 
of Acinetobacter spp. in Western Europe was 5.6% (Vincent et al., 2009). 
 
1.6.1 Acinetobacter baumannii 
Acinetobacter baumannii has become a highly multi-drug resistant pathogen which, 
along with its ability to survive drying for long periods, can allow it to become 
endemic within the hospital environment (Enoch et al., 2008). It is associated with 
infection in particular groups including cancer and surgical patients, those with 
severe burns and those undergoing mechanical ventilation (Koprnova et al., 2001a; 
Koprnova et al., 2001b). More recently it has been reported in wound infections, and 
has become a notable problem in American and Canadian soldiers wounded in Iraq 
and Afghanistan (Hospenthal et al., 2011; Petersen et al., 2007; Tien et al., 2007). 
 
A number of different environmental sources have been linked to the spread of 
A. baumannii but contamination of the hospital environment is often associated with 
proximity of a colonised or infected patient. Investigation during an outbreak 
originating from an ICU recovered Acinetobacter spp. from 12% of air samples from 
wards with colonised patients, as well as recovery from sink traps and bedside 
cabinets in the same areas (Crombach et al., 1989). Another outbreak investigation 
also found extensive environmental contamination with Acinetobacter spp. being 
recovered from 13% of settle plates in the vicinity of colonised patients in the 
vicinity. The bed linen from colonised patients was consistently positive for the 
bacterium’s recovery. Following discharge of a patient, persistent environmental   
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contamination was documented for ≤13 days (Sherertz and Sullivan, 1985). Other 
sources from which Acinetobacter spp. have been recovered during outbreak 
investigations include inert surfaces, patient mattresses and water taps (Pina et al., 
1998). 
 
1.6.2 HPA Acinetobacter Spp. Bacteraemia Reports 
Data from the HPA voluntary surveillance database for 2006 - 2010 for 
Acinetobacter spp. bacteraemia in England, Wales and Northern Ireland indicate a 
32% decrease in total reports. Subdivision of bacteraemia according to species 
level was A. baumannii (58%), Acinetobacter lwoffii (44%), Acinetobacter 
haemolyticus (4%) and Acinetobacter junii (3%) [see Figure 5]. For the two 
commonest Acinetobacter spp. associated with bacteraemia, A. baumannii and 
A. lwoffii,; the age distribution of affected patients showed two main peaks: in the 
very young (<1 year) and the elderly (>64  years) possibly reflecting that these two 
age groups are more likely to require ICU treatment than those in other age groups. 
Acinetobacter lwoffii was more likely to be seen in ages 1 - 14. The overall 
incidence of Acinetobacter spp. bacteraemia was 1.38 cases/100,000 population in 
England, Wales and Northern Ireland with the Yorkshire & Humber region at 
approximately 1.2 cases/100,000 (HPA, 2011a). 
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Figure 5.  Bacteraemia results reported to the voluntary surveillance database for 
England, Wales and Northern Ireland 2006 – 2010 
 
 
 
(Taken from HPA: Acinetobacter spp. bacteraemia, England, Wales, and Northern 
Ireland: 2006 to 2010) 
 
1.6.3 Antibiotic Resistance in Acinetobacter spp. 
Acinetobacter spp. manifest resistance mechanisms to most classes of antibiotics 
alongside a remarkable ability to acquire new determinants. Of all species, 
A. baumannii has been described as a “global public health threat” (Perez et al., 
2007). Acinetobacter spp. are highly naturally transformable, for example,  
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Acinetobacter baylyi strain ADP1 is up to 100 times as competent as calcium 
chloride treated Escherichia coli (Metzgar et al., 2004). Resistance to antibiotics is 
mediated by many mechanisms which are also seen in other Gram negative 
pathogens such as changes to outer membrane proteins and efflux pumps (Slama, 
2008). Acinetobacter spp. also possess many enzymes conferring resistance to 
numerous antibiotics including many β-lactamases and aminoglycoside modifying 
enzymes (Bonomo and Szabo, 2006). 
 
Acinetobacter spp. have become progressively resistant to aminoglycosides, 
quinolones, penicillins and cephalosporins (Coelho et al., 2004). In 2001, a UK 
survey found that 85% of Acinetobacter isolates were resistant to cephalosporins 
but the carbapenems imipenem and meropenem, colistin and sulbactam were still 
active against 90% of isolates (Henwood et al., 2002). However, there have been a 
number of reports that carbapenem resistance is increasing (Irfan et al., 2008; 
Zarrilli et al., 2009). Within the UK, carbapenem and multiply resistant A. baumannii 
strains (C-MRAB): The South East Clone, OXA-23 clone 1 and OXA-23 clone 2, 
have spread rapidly within and between hospitals from 2003 – 2004 (HPA, 2009; 
Turton et al., 2004). The 2006 – 2010 HPA report described a significant rise in 
imipenem resistance (21% to 27%) in A. baumannii while cefotaxime (a third 
generation cephalosporin) resistance decreased from 88% to 83%. All other 
antimicrobial susceptibilities remained fairly consistent (HPA, 2011a). 
 
1.6.4 Acinetobacter baumannii and the Aqueous Environment 
The genus Acinetobacter has environmental habitats in the soil and water and it has 
been estimated that Acinetobacter spp. could account for 0.001% of the total 
heterotrophic aerobic population of soil and water (Bauman, 1968). They are also   
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known to be found in heavily polluted water and also near the surface of freshwater 
and freshwater at the point of entering the sea and at densities of 10 cfu/4 100mL of 
freshwater and 106/100ml raw sewage (Droop, 1977; Lacroix and Cabelli, 1982). 
Outbreaks of Acinetobacter spp. in hospitals have occasionally been linked directly 
to water. A contaminated preparation of morphine was the source of an outbreak of 
bacteraemia (Lee et al., 2007), and tap aerators were identified as the cause of an 
outbreak of A. junii in paediatric oncology patients (Kappstein et al., 2000). While 
only a small number of infections due to Acinetobacter spp. have been linked to 
water, some of these have involved hospital water supplies (see Table 6). 
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Table 6. Key examples of Acinetobacter spp. Nosocomial Infections linked to Water 
 
Country Detail Time Period Water Source Reference 
USA 
A. calcoaceticus outbreak – 
associated with peritoneal dialysis 
4 months following 
1 June, 1975  
Water bath used to warm bottles of 
peritoneal dialysate was reservoir for 
bacteria 
(Abrutyn et al., 1978) 
France 
A. baumannii - 38 patients 
(colonised or infected skin wounds) 
2 years 
Wide contamination of the patient’s 
rooms including water tap 
(Pina et al., 1998) 
Germany 
A. junii – blood cultures from 3 
children 
June – 
September, 
1994 
Tap water aerators 
(Kappstein et al., 
2000) 
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1.7 Water 
 
1.7.1 History of Water Treatment 
The importance of clean water has been recognised for millennia. Ancient Greek 
and Sanskrit writings describe methods of water treatment including straining, 
filtration through charcoal, boiling and exposure to sunlight, and the Egyptians used 
the chemical alum to clarify water as early as 1500 B.C. (EPA: The History of 
Drinking Water Treatment [2000]). As populations and therefore urbanisation and 
cities grew, the need for large quantities of water and water quality became 
important with early Roman engineers providing extensive and elaborate water 
supplies for major cities (ADWG, 2004). 
 
The urbanisation and industrialisation of Britain put a huge demand on the water 
supplies and epidemics of cholera and typhoid affected the country. Dr John Snow 
described the role of water as the transmission vector for cholera. His investigation 
of the London cholera outbreak of 1854 included three London Water suppliers: one 
of which supplied filtered water, one which supplied water from a cleaner stretch of 
the river Thames and the third which supplied water from a heavily polluted area of 
the Thames (Snow, On The Mode of Communication of Cholera, 2nd Edition, 1855). 
By analysing the fatalities and the geographical locations of the victims and the 
areas water pumps, Snow was able to establish the likely source as a pump on 
Broad Street and to demonstrate cholera as being a waterborne disease as when he 
removed the water pump handle the outbreak was halted. In 1859 filtration of river-
sourced water became legally enforced in London, this then became common 
practice throughout Europe (ADWG, 2004).  
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Contamination of drinking water remains the cause of endemic and epidemic cholera 
and typhoid in the latter half of the 20th Century: typhoid in Pristina, former 
Yugoslavia, cholera in South Africa and cholera again in Peru in 1991 (Yugoslav 
Typhoid Commission, 1964, Kustner et al, 1991, Anderson, 1991). The most recent 
pandemic is the 7th cholera epidemic, initially identified in Indonesia in 1961 and 
spreading rapidly to countries in Asia, Europe, Africa and eventually Latin America in 
1991: a region which had been free from cholera for more than a century and where 
it caused 400,000 cases and over 4000 deaths 
(WHO: www.who.int/topics/cholera/impact/en/). 
 
Endogenous cholera has not occurred in the UK for many years, and is seen, albeit 
rarely, in returning travellers (HPA: Cholera, 2010). Typhoid fever is acquired almost 
exclusively abroad following consumption of contaminated food and water (HPA: 
Typhoid, 2010). However, these two bacteria are not the only causes of 
gastrointestinal illness caused by waterborne species, other bacterial species 
include Shigella spp, Campylobacter spp and E. coli, all predominantly caused by 
faecal contamination of the water source; other microorganisms such as the 
protozoon Cryptosporidium parvum are also responsible for waterborne 
gastrointestinal illnesses. 
 
1.7.2 Overview of Water Treatment and Management 
Water for public use typically comes from two main sources: surface water collected 
in purpose-built reservoirs, and underground water collected from sunken wells etc. 
More than 99% of the UK’s population receives water by piped main supplies of 
treated water, ≤1% being served by private supplies (DWI, 2003). All sources of   
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water can potentially be contaminated with any number of pollutants including 
factory waste, agricultural waste and human or animal effluent. Before human 
consumption, water supplies must be treated and maintained so that they are fit for 
human consumption (i.e. potable). The water treatment process consists of several 
stages which attend to the removal of suspended matter, chemicals harmful to 
health, and microorganisms from the raw water (see Figure 6). 
 
The potable water supply in the UK is not required to be sterile and many 
microorganisms can be found in it although only a few are the subject of legislation 
relating to their presence. Indicators of faecal contamination: Escherichia coli, 
Clostridium perfringens and Cryptosporidium, are prevented from entering the water 
distribution networks by several different treatment processes. 
 
Figure 6. Diagram of a typical water treatment process 
 
(Taken from The Open University, Water Treatment) 
 
Primary treatment involves water entering a preliminary settlement tank, screening is 
a process which removes fallen branches, leaves and other materials from the water 
and prevents large debris from entering the settlement tank that may damage or   
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interfere with further treatment processes. Several stages follow including 
flocculation and clarification: the removal of smaller impurities such as dirt and 
bacteria by adding a chemical (a coagulant) such as aluminium or iron sulphate 
which combines the smaller substances to form larger particles (floc) which are then 
removed by simple mechanical methods. Flotation allows floc to be removed by 
bubbling air through the water and floating the floc to the surface for removal and 
any material still remaining is removed when the water enters a sedimentation tank, 
allowing matter to settle at the bottom of the tanks forming a layer of sludge at the 
bottom. The next stage in the process is coarse filtration, often through layers of 
sand and gravel or other suitable media such as anthracite, which act as strainers 
removing the final traces of any remaining particles (see Figure 7). Filtration can be 
done by a simple slow sand filter or by a rapid gravity filter with a much faster flow 
rate. In areas which are known to have Cryptosporidium oocysts present in the water 
supplies, additional membrane filters maybe added to the filtration process to reduce 
the risk of outbreaks of cryptosporidiosis. 
 
Figure 7. A Section through a Slow Sand Filter 
 
(Taken from The Open University, Filtration)  
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As the previous steps cannot guarantee absolute removal of microorganisms, a 
further disinfection step remains. This is most commonly done by chlorination of the 
water. Hypochlorous acid (HOCl) is the usual agent used and is a strong oxidising 
agent, reacting with all substances in the water which can be oxidised (e.g. nitrites to 
nitrates). Chlorine penetrates the microbial cell and kills the microorganisms. 
However, suboptimal chlorine treatment or the presence of a mucoid extracellular 
polysaccharide matrix allows some microorganisms to survive within the potable 
water supplies (Grobe et al., 2001; Shrivastava et al., 2004). Chlorine is used as a 
disinfectant worldwide and has greatly reduced risk of waterborne illness. A decision 
from Peruvian water officials in 1991 not to chlorinate the national drinking water 
was blamed for a cholera epidemic which swept through Peru and many other South 
and Central American countries claiming thousands of lives (Anderson, 1991). 
 
1.7.3 Legionella pneumophila and Control of the Organism 
Legionnaire’s disease is an uncommon form of pneumonia caused by the bacterium 
Legionella. Cases are often reported in isolation but outbreaks are also known to 
occur; the most often affected are males over 50 years of age, smokers and the 
immunocompromised. The bacterium can survive within alveolar macrophages and 
other host cells. Legionnaire’s disease is the more serious form of legionellosis and 
is fatal in 10-15% of cases within the general population; this becomes higher in at-
risk groups of patients. Incubation ranges from 2 – 10 days but more rarely, 
symptoms may develop ≤3 weeks after exposure (HPA). 
 
The illness was first identified in 1977 following an outbreak of unidentified 
pneumonia which occurred in veterans of the American Legion in a hotel in 
Philadelphia, USA in 1976; 221 people were treated for infection and 34 people   
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died. The Legionella bacterium was identified and isolated from the hotel’s air-
conditioning system; infection was thought to have occurred following inhalation of 
contaminated aerosols. The bacterium is able to grow and reproduce in water at 
temperatures between 20 - 50oC. 
 
The public health implications of legionellosis have resulted in regulations aimed at 
controlling Legionella spp. The Approved Code of Practice – L8 has “special legal 
status” and is considered as being law; the Health & Safety at Work Act (1974) 
legally enforces L8. Otherwise known as ACoP-L8, this document was produced 
originally in 1999 and is now in the Third Edition (2000) by the Health and Safety 
Executive (HSE) and is entitled “Legionnaire’s Disease: the control of Legionella 
bacteria in water systems” (HSE, 2000). The document gives practical guidance 
using sections 2, 3, 4 & 6 of the Health & Safety at Work Act, 1974 which covers 
risks from Legionella bacteria arising from work activities; and also regulations 6, 7, 
8, 9 & 12 of Control of Substances Hazardous to Health, 1999 (COSHH) which 
covers a framework of risk assessment and action designed to control the risks from 
many hazardous substances including biological agents such as the Legionella 
bacterium (ACoP L8, 3rd Edition, pages 2, 5, 7 & 10). 
 
The document gives guidance for those with responsibilities for the control of 
premises (e.g. employers and those providing residential accommodation). As a 
result those responsible have legal duties which they comply with and should: 
 Perform a risk assessment: identify and assess the sources of risk (e.g. 
water temperature, the means of disseminating aerosols, are there 
susceptible people) 
 Have a prepared scheme for prevention or control of the risk  
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 Implement, monitor and control the risks  
 Keep records of precautions 
 Appoint a person to be managerially responsible 
(ACoP L8, pg7). 
 
The Code of Practice applies to Legionella control during any undertaking of work 
activity and also to premises connected with trade, business or any other 
undertaking where water is used, stored or has a means of creating aerosols which 
may be inhaled. The document is divided into two parts, the first covering the scope 
and application of the code of practice and the second giving guidance on the 
control of Legionella in water systems; this includes the different systems (e.g. 
cooling towers, hot and cold systems etc.), monitoring and treatment and control 
programmes (temperature, biocides, ionisation) and also actions to be taken in the 
event of an outbreak. Mandatory reporting of incidents (including outbreaks) of 
Legionnaire’s disease is through the Reporting of Injuries, Diseases and Dangerous 
Occurrences Regulations (RIDDOR 1995), where the Health & Safety Executive are 
notified. 
 
There is more specific guidance for healthcare premises. Engineering Health 
Technical Memoranda (HTM) give healthcare-specific technical engineering 
guidance for the safe and efficient operation of healthcare facilities. There are nine 
core subjects which are covered by HTM-00 to HTM-08 and are applicable to new 
and existing sites and for the various stages in the building lifecycle; HTM-04 gives 
guidance to managers within healthcare, estates and operations on the legal 
requirements, maintenance, storage and distribution of water supplies. A section of 
HTM-04 is HTM-04-01: “The control of Legionella, hygiene, “safe” hot water, cold   
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water and drinking water systems”, this is further divided into Part A: Design, 
Installation and Testing and Part B: Operational Management. Recommendations of 
HTM04-01 include use of thermostatic mixing valves to prevent scalding and use of 
non-touch taps in surgical, food preparation and general washroom areas. 
Examples of methods used by hospitals to control Legionella include water system 
treatments such as chlorine dioxide and copper-silver ionisation and are discussed 
further in section 1.8.6. 
 
1.7.4 Key Legislation pertaining to Water Standards, International and European 
 
Legislation and guidelines for water standards come in at many levels from 
guidelines such as those issued by the World Health Organisation (WHO) down to 
local organizations such as the Yorkshire Cancer Network and the guidelines they 
issue to support and promote improvements in cancer care within West and North 
Yorkshire. 
 
The WHO issues guidelines rather than regulations due to the perceived 
inappropriateness of issuing regulations on an international level resulting in scant 
resources being spent on issues which are not necessarily appropriate for all nations 
(WHO Guidelines for Drinking Water). Developing nations have limited resources at 
their disposal and must have the freedom to choose for themselves where these are 
spent and while their levels of HCAI maybe much higher than in developed nations 
(30-40%) and people often have more restricted access to safe, clean water, these 
may not be seen as where their resources should be best spent (WHO, 2005).  
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The European Union issues the requirements that all European Union member 
states must adhere to, these regulations (directives) are the minimum standard to 
which countries must regulate their water systems. Member states are then able to 
build upon these regulations to make them more relevant or more stringent for their 
nation. Key aspects include: 
 EU Drinking Water Directive (DWD) 98/83/EC – is based on advice from 
WHO Guidelines.  
 The Directive requires the European Commission to review standards every 
5 years to take into account changes in the WHO Guidelines 
 EU Drinking Water Directive requires: 
- Water quality standards 
- Monitoring and analysis (continued) 
- Public reporting of data 
- Use of treatment chemicals and materials in contact with water 
- Action must be taken if standard levels are exceeded 
 Each EU member state must translate the EU requirements and place into 
local laws. 
 Approximately 80% of the water industry’s legislation comes from the 
European Parliament (Water UK, European Directives) 
 EU Water Framework Directive (WFD) 2000/60/EC, regulators and 
environmental protection agencies responsible for preventing pollution of 
water resources protect and improve the quality of raw water. 
 Other EU Directives influencing the UK water industry are: 
- Environmental Liability Directive 
- Waste Framework Directive 
- Ground Water Directive 
- Marine Strategy Directive  
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- Soil Framework Directive 
- Bathing Water Directive 
- Pesticides Directive 
- Directive on European Quality Standards in the Field of Water Policy 
and Amending Directive 2000/60/EC 
- Sewage Sludge Directive 
- IPPC Directive (Integrated Pollution Prevention and Control) 
 
(Water UK, How the Quality of Drinking Water is assured, 2006; Water UK, 
European Directives) 
 
1.7.5 UK Water Regulations and Agencies 
Each household in England and Wales uses approximately 165 litres of water per 
person per day. In order to supply this need plus the needs of industry, the UK water 
and wastewater industry draws water from over 650 reservoirs, 1500 boreholes and 
600 river abstraction points, collecting, treating and supplying 16 billion litres of 
water per day (Water UK, 2009). This water must be fit for human consumption. 
 
All aspects of water management have regulations and many agencies exist to 
advise, spread knowledge and understanding, and enforce these regulations. The 
Department for Environment Food and Rural Affairs (DEFRA) deals with all aspects 
of water policy in England and works with other agencies such as the Environment 
Agency who deal with environmental issues such as water recycling and managing 
water resources; OFWAT is responsible for regulating financial and economical 
aspects of the water industry and ensures the public interests are safeguarded.  
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The quality of potable water within the UK is kept within strict national standards; 
these standards are derived from the European Union (EU) Drinking Water Directive 
(98/83/EC), “The objective of the Drinking Water Directive (DWD) is to protect the 
health of the consumers in the European Union and to make sure the water is 
wholesome and clean”. In order to achieve this, the Directive has set a list of 
parameters for all members of the EU to monitor and test for, in both drinking water 
supplies and water for the food industry (includes water offered for sale in bottles or 
other containers). This consists of 48 chemical and microbiological standards, while 
these standards are the minimum for member states within the EU to which they 
must comply, additional requirements can be made for the monitoring of other 
substances relevant to them (See Table 7). 
 
Responsibility for the quality of drinking water in England and Wales belongs to the 
Drinking Water Inspectorate (DWI) formed in 1990 following privatisation of the 
water industry. The DWI is part of DEFRA but its Chief Inspector acts independently 
of government. The objective of DWI is to maintain public confidence in the safety 
and quality of public water supplies through exercising its powers of reporting, audit, 
inspection, enforcement and prosecution. Also, drinking water Inspectors are 
scientists/engineers with water supply and quality monitoring experience, therefore 
DWI also has a role in providing government with advice on water supply and quality 
matters (Drinking Water Safety, Guidelines to Health and Water Professionals, pg3, 
2009). 
 
The DWI also approves and processes applications for products to be used along 
the water supply route, before and after the treatment works and along the 
distribution system to the point of delivery to a premise. DWI implements Article 10   
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of the DWD 98/83/EC in respect to the substances and materials used in preparation 
and delivery of water to the point of delivery. Applications for approval submitted to 
the DWI are considered by experts in toxicology, chemistry, water treatment and 
distribution, engineering and public health to ensure that drinking water suppliers do 
not introduce or apply a substance/product into the water supplies unless the 
regulations have been met (List of Approved Products for use in Public Water 
Supply in the United Kingdom, May 2010, DWI, DWQR, DRD, DEFRA, Welsh 
Assembly Government, Pg. 5). 
 
The regulatory framework for the water supplies of England and Wales is described 
in the Water Industry Act (1991), amended by the Water Act 2003 and defines the 
DWI’s powers and duties and also the duties of water companies and licensees 
(Drinking Water Safety, Guidelines to health and water professionals, pg4, 2009). 
 
Many water-associated diseases arise from faecal contamination of water, and since 
it would be an almost impossible undertaking to monitor for each specific pathogen, 
indicator organisms are screened as markers of risk. The current UK legislation 
relies on tests for coliform bacteria, E. coli, C. perfringens and in areas with a known 
problem, Cryptosporidium (See Table 7 for details of control methods and 
parameters). Water samples are taken and tested from along the supply chain and 
randomly at the point-of-use in consumers’ premises. For example, the regulations 
for the testing of Cryptosporidium oocysts involves the continuous sampling of at 
least 40 litres/hour of already treated water going into the distribution system (DWI).  
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Water Safety Plans (WSPs) are risk management procedures put in place by water 
suppliers to ensure that standards are met; it is a multi-barrier and multi-partnership 
approach for water quality from source to tap involving all with responsibilities 
throughout the water supply process (Water UK, How the Quality of Drinking Water 
is assured, 2006). England and Wales are divided into 7 regions: Eastern, Midlands, 
Northern, Southern, Thames, Western and Wales, with 26 water companies 
supplying those regions. 
 
1.7.6 Chronology of UK Water Regulations 
 Legislation concerning water in England and Wales dates to Victorian times: 
Acts of Parliament were passed to give local authorities and companies 
powers to supply water and sewerage services to the expanding population 
 The scope of the legislation was increased through World War I and II but 
without any fundamental changes. 
 1963: Water Resources Act, abstraction and impounding of water resources 
regulated on a regional basis. Created ‘River Authorities’ responsible for 
enforcing law concerning water resources, river pollution, land drainage, 
water space recreation and fisheries. 
 1973: Water Act 1973, created 10 regional authorities defined by river 
basins. Had overall responsibility for water supply, sewerage and river basin 
management. Required to work with local authorities and statutory water 
companies. 
 1989: Water Act 1989, privatisation of the 10 water authorities water supply 
and sewerage functions, transfer of river functions to the National Rivers 
Authority (later subsumed by the Environment Agency in the Environment 
Act 1995).  
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 Water law in England and Wales was then consolidated and updated by Acts 
of Parliament: Water Industry Act 1991 amended by the Water Industry 
Act 1999 and the Water Act 2003 which deal with such matters as: 
- appointment of/economic regulation of water companies and other 
licensed water suppliers by OFWAT 
- Drinking water quality obligations (enforced by DEFRA and DWI) 
- Water supply and sewerage disposal 
- Financial charges made by water companies 
- Protection of consumers 
- Retail and common carriage competition 
 Also in secondary legislation by the Water Supply (Water Quality) 
Regulations 2000 (England) and 2001 (Wales), Amendment Regulations 
2007.  
(Water UK, Water Companies and the Law; May and Colbourne, 2009). 
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Table 7. Summary of Control Methods and requirements for Control of Waterborne Microorganisms 
 
 
Intervention Control  of Description Test Location Limits and Legislation 
 
 
Mandatory 
indicator 
microbiological 
parameters 
checked along 
water supply chain 
from water 
treatment plant to 
customer point-of-
use 
Faecal 
coliforms, 
Faecal 
streptococci, 
Clostridium 
perfringens 
 
 
 
 
Total Coliforms 
 
 
 
 
 
 
 
 
Colony counts 
at 22
o
C and 
37
o
C 
 
Presence of these organisms in water 
indicates contamination from the 
faeces of animals and immediate 
action needs to be taken to remove the 
source of the pollution. Each of these 
organisms is sampled and tested for 
individually and controlled by 
disinfection of water. 
 
 
A group of bacteria widely distributed 
through the environment via human, 
animal and vegetable matter. 
Presence indicates the need to 
investigate source of contamination. 
Controlled through disinfection of 
water. 
 
 
Water sources, service reservoirs, 
water treatment works and 
customer taps 
 
 
 
 
 
 
 
As above 
 
 
 
 
 
 
 
 
As above 
 
0 per 100 mL - 
Water Supply (Water Quality) 
Regulations 
 
 
 
 
 
 
 
0 per 100 mL 
Water Supply (Water Quality) 
Regulations 
 
 
 
 
 
 
 
“No abnormal change”  
Water Supply (Water Quality) 
Regulations 
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Intervention Control  of Description Test Location Limits and Legislation 
Cryptosporidium 
Control 
Cryptosporidium 
oocysts 
Cryptosporidium is a protozoan 
pathogen that can cause severe 
diarrhoeal illness in humans. The main 
causes of disease are C. parvum and 
C. hominis. Infection follows ingestion 
of oocysts usually from contaminated 
food or water. 
Multi-barrier approach through the 
water industry 
 
Due to difficulty of routine analysis, no 
specific standards in the European Union 
DWD or UK national regulations, 
however, there is a general requirement 
that no organism be present in sufficient 
quantities to constitute a threat to public 
health (Water UK). 
ACoP L8 
(Approved Code of 
Practice) 
Legionella 
pneumophila 
Approved Code of Practice L8 is a 
guidance document issued by the 
Health & Safety Executive providing 
advice on how to comply to health and 
safety laws regarding the control of 
Legionella and the prevention of 
Legionnaires disease 
Not specifically test orientated but 
more concerned with identification 
and control of risk: Identify areas 
which could be a risk, devise a 
plan to prevent and control the 
risk, implement, manage and 
monitor the precautions, keep 
records and employ a person to 
be responsible.  
ACoP L8 has special legal status, if it is 
proved in a court of law that the relevant 
provisions of the code had not been 
followed then the court could find you at 
fault and therefore be prosecutable.  
HTM04-01 
Legionella 
pneumophila 
Health Technical Memorandum (HTM) 
04-01 builds on the ACoP L8 providing 
additional guidance for those involved 
in Legionella control in healthcare 
facilities. Outlines the principles 
involved in design, installation and 
testing of the hot and cold water 
supplies, storage and distribution 
systems in healthcare premises and is 
applicable to old and new premises 
As above 
A requirement to protect patients, staff 
and the public. 
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1.7.7 Yorkshire Water Drinking Water Quality Report 
Yorkshire Water supplies, on average, 1,300 million litres of treated water per day to 
more than 4.7 million customers and 140,000 businesses. In the West and South 
West of Yorkshire, where Bradford is located, water is primarily supplied from 
impounding reservoirs in the Pennines. This is different to the North, East and South 
East of the region which is supplied with water from boreholes and river 
abstractions. Yorkshire Water has 83 treatment works and stores its treated water in 
381 enclosed service reservoirs or water towers. Water is then delivered through 
31,000 km of water mains. Microbiological analysis of the water is carried out from 
the treatment works, service reservoirs and randomly selected customer’s taps. 
From 220,860 tests that were carried out by Yorkshire Water in 2008, 99.97% 
complied with the Regulations (Yorkshire Water Services: Drinking Water Quality 
Report 2008). 
 
The number of tests performed and the number of tests not meeting the standards 
for the whole of the Northern Region water suppliers during 2008 was collated by the 
DWI and published in the “Drinking Water 2009, Public Water supplies in the 
Northern Region of England report”. The tests performed at the various stages along 
the water network and Yorkshire Water’s performance in regard to those tests is 
shown in Table 8.  
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Table 8.  Microbiological Tests Carried out by Northern region water suppliers* in 
2009 
 
Parameter Current Standard 
Total Number 
of tests (2009) 
Number of 
tests not 
meeting the 
standard 
Water Supplier 
not meeting the 
standard 
Water leaving water treatment works 
E. coli 0/100 mL 37,711 4 
Yorks. Water = 1 
Other(s) = 3 
Coliform 
Bacteria 
0/100 mL 37,727 27 
Yorks. Water = 5 
Other(s) = 24 
Clostridium 
perfringens  
0/100 mL 15,067 20 
Yorks. Water = 4 
Other(s) = 16 
Turbidity** 
1 Nephelometric 
Turbidity Unit 
37,686 12 
Yorks Water = 2 
Others = 10 
Water leaving service reservoirs 
E. coli 0/100 mL 49,783 6 
Yorks. Water = 2 
Other(s) = 2 
Coliform 
bacteria 
0/100 ml in 95% of 
tests at each 
reservoir 
49,783 38 
Yorks. Water = 7 
Other(s) = 31 
Water Sampled at customers taps 
E. coli 0/100 mL 36,882 8 
Yorks. Water = 3 
Other(s) = 5 
Enterococci 0/100 mL 3,313 1 
Yorks Water = 1 
Other(s) = 0 
 
* 5 water companies: Hartlepool Water, Northumbrian Water, United Utilities, 
Yorkshire Water and also part of Dee Valley Water’s operations. Also one inset 
appointment: Peel Water Networks supplying Greater Manchester.  
** Turbidity is a critical control parameter for water treatment and disinfection 
(Adapted from DWI Drinking Water 2009, Northern Region of England) 
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1.8 Point of Entry, Systemic Water Treatment and Point-of-Use 
Filtration 
 
1.8.1 Point of Entry 
At the point of delivery to premises, the responsibilities of the DWI end, and instead, 
the water supply systems within a building are dealt with by the Water Regulations 
Advisory Scheme (WRAS) under the Water Supply (Water Fittings) Regulations 
1999. The responsibility for the quality of water changes hands at the point of the 
water supply entering a building where the quality can rapidly deteriorate due to poor 
condition of pipes or badly laid out plumbing. Plumbing systems are not the 
responsibility of water suppliers; instead all plumbing work must be performed by 
trained and certified plumbers who must maintain the systems within the legal 
requirements. 
 
The organisms at the centre of regulations from the point of entry to a building is 
Legionella spp. which are found naturally in environmental water sources and also 
man-made water systems such as internal water distribution systems, cooling 
towers and air conditioning units, where conditions can favour replication of strains 
and increase the risk of Legionnaire’s disease (see section 1.7.3). 
 
1.8.2 Water Supply (Water Fittings) Regulations 1999, the Water Regulations 
Advisory Scheme (WRAS) and Water Industry Approved Plumbers Scheme 
(WIAPS) 
The Water Supply (Water fittings) Regulations 1999 came into force on the 1st July 
1999 and are national Government requirements for the design, installation and 
maintenance of plumbing systems including water fittings and water-using 
appliances in domestic and commercial properties in England and Wales. The   
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regulations apply from the point of entry to a properties underground service pipe 
(WRAS). 
 
The aim of the regulations is to prevent the inefficient use or waste of water, 
contamination of drinking water supplies and incorrect measurement of water 
supplied. Arising from the regulations are three main responsibilities: 1) prevention 
of contamination of drinking water, 2) notice of plumbing installation work must be 
given in advance and 3) plumbing systems, water fittings and water using 
appliances must be installed and maintained to comply with the requirements of the 
regulations (Southern Water). Before the regulations, water companies had their 
own Water Byelaws: a law with local or limited application under the authority of a 
higher law; which were used to safeguard the public water supply. 
 
The owners or occupiers of premises and also the person installing plumbing 
system/water fittings have legal requirements to ensure that the system complies 
with the Regulations and may be liable to prosecution or fines if they fail to correctly 
install plumbing, which can then lead to contamination of the water supplies. They 
also may have to cover the costs of correcting the mistake. It is a criminal offence to 
be knowingly in breach of the Regulations and the water company of each of the 
areas of England and Wales is responsible for enforcing the Regulations in their own 
areas. Should a breach be found then immediate remedy is required or if the breach 
poses a risk to health then the water supply can be shut off, and offenders may be 
prosecuted.  
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Under Regulation 5 of the Regulations, notification of intended work to install a new 
water system, or in a non-domestic system: alter or extend an existing system, must 
be given to the water supplier. WIAPS involves approved plumbers who can 
administer certification that the plumbing installation satisfies the 1999 Regulations. 
The benefit of this scheme to the customer is that the legal responsibilities for any 
breaches in the plumbing installation fall on the plumber and not themselves. 
Approved Plumbers are able to work without notification and consent and issues the 
customer with a certificate of compliance for the completed work. Approved 
Plumbers can be authorized by several bodies including WIAPS, the local water 
supplier or other organisations recognised by the government. Non-approved 
plumbers may not begin work without prior notification and consent and may be 
liable to prosecution in the event of non-compliance with the Regulations (Thames 
Water). 
 
Prevention of contamination of the water supply is a specific goal of the Regulations 
and can occur from a decrease in pressure causing fluids to travel back up the pipe 
against the intended direction of low. This “backflow” or “back-siphonage” can result 
in contaminants being drawn into the water supply (The Water Supply (Water 
fittings) Regulations 1999). 
 
1.8.3 Biofilms 
The water treatment process results in the microbial load of water supplies to the 
public being kept to a minimal and harmless level. However, once the water supply 
reaches its destination at the point-of-use, it can enter large and complex distribution 
networks and the conditions change from being very cold and under constant flow in   
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large diameter pipes, to much smaller diameter pipes, with increased and 
changeable temperatures (see Figure 8). 
Figure 8. Water Network from Source to End-Point Use 
 
(Pall Medical, Scientific Information)  
 
Corroded pipes and dead ends within the internal distribution network allow build-up 
of organic matter along the piping and areas of stagnation. In this section of the 
water distribution system it is possible that in a very short time a community of 
microorganisms can become established. 
 
The prevailing microbial lifestyle of bacteria in both natural and man-made 
environments is not planktonic (free-swimming) but rather a community of 
microorganisms strongly associated with a surface known as a biofilm (Lindsay and 
von Holy, 2006). Biofilms were first observed by Anthony Van Leeuwenhoek with his 
visualisation of “animalcules” from the plaque of his teeth but were not studied 
systematically until the 1970’s (Costerton et al., 1978). The biofilm formation process 
is generally accepted to occur in several distinct sequential stages: surface   
Source Water Plant                                                          User
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conditioning, reversible attachment, irreversible attachment, colonisation and 
detachment (Lindsay and von Holy, 2006) (see Figure 9). 
 
Figure 9. Diagrammatic representation of biofilm formation 
 
(Ortolano et al., 2005)  
 
The surface of the pipe to which the microorganisms become attached are 
conditioned by the adsorption of inorganic and organic substances present within the 
water supply. Attachment is determined by a number of variables: surface 
composition (e.g. pipework materials), environmental factors (such as temperature, 
pressure and water flow), bacterial species and the gene products of the bacteria 
themselves (Dunne, 2002). A number of forces are involved in this initial adhesion 
including hydrophobic, electrostatic, van der Waals and hydrodynamic forces 
(Dunne, 2002). However, electrostatic forces can actually favour the repulsion of 
bacteria if both the bacteria and the inert surface are negatively charged, an   
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exception to this rule is S. maltophilia, which has an overall positive charge at 
physiological pH and can adhere to negatively charged surfaces such as Teflon and 
glass (Jucker et al., 1996). 
 
Irreversible or secondary/locking adhesion of bacteria to surfaces involves the 
production of extracellular polymeric substances (EPS), and complexes are formed 
not only with the inert surface but also between organisms and each organism is 
firmly and irreversibly attached (Dunne, 2002; Jucker et al., 1996; Lindsay and von 
Holy, 2006). Once this process has begun colonisation and maturation of the biofilm 
occurs, the density of the biofilm increases as attached bacteria divide and new 
planktonic organisms join the structure. 
 
The application of confocal scanning laser microscopy dispels the concept of an 
homogenous biofilm. Instead images of dense layers of matrix enclosed 
microcolonies can be seen with areas of less dense matrix and water channels 
which are able to carry nutrients and take away waste products (Figure 10), 
(Costerton et al., 1994). Importantly, biofilm bacteria are more resistant to 
antimicrobial agents, be they antibiotics, disinfectants or germicides, than their 
planktonic counterparts (Costerton et al., 1978; Donlan, 2002). A number of different 
reasons have been given for the mechanisms for this inherent resistance: delayed 
penetration of the agent into the biofilm matrix, an altered growth rate of the 
organisms within the biofilm, and physiological changes of the organisms during 
biofilm growth (Donlan, 2002). 
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Figure 10. Diagrammatic image of hypothetical biofilm 
 
Image of mono- and mixed-species biofilm showing open water channels between 
microcolonies enclosing bacterial cells in a dense expolysaccharide matrix. (From 
Costerton et al., 1994) 
 
Growth is, however, limited by the immediate environment and the nutrients 
available. Once critical mass is reached, planktonic organisms leave the biofilm and 
are free to attach elsewhere (Dunne, 2002). Biofilms allow bacteria to reach higher 
cell densities than when existing in planktonic form. This build-up of large numbers 
of bacteria could potentially be a determining factor in the development of infection. 
An individual consuming or inhaling biofilm contaminated water could conceivably 
receive an infectious dose of infective organisms, since with sloughing of the 
biomass by the force of the water could potentially carry thousands of cells (Parsek 
and Singh, 2003; Stoodley et al., 2001). 
 
Another consequence of biofilms may be increased horizontal gene transfer, a 
mechanism which allows bacteria to spread antimicrobial and chlorine resistance 
mechanisms among other bacteria (Parsek and Singh, 2003). Growth in biofilm may   
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also encourage interspecies signalling, S. maltophilia can influence the behaviour of 
P. aeruginosa biofilm formation and tolerance to the polymixin class of antibiotics. As 
these two bacteria often cohabit niches, including the lungs of cystic fibrosis (CF) 
patients, this could have important consequences by influencing responses of 
patients to antibiotic treatment (Ryan et al., 2008). 
 
1.8.4 Water-borne Pathogens 
Other bacteria found in the water supplies are not subject to statutory regulation. 
These can enter the water distribution system at many and varied points. Breaks in 
pipes can allow environmental bacteria to enter the supply. Insects, rats and mice 
can also enter the supply chain and spread their microflora. Supplies can also be 
contaminated through bad weather and flooding. 
 
1.8.5 Water and the Hospital Environment 
Much emphasis has been placed on interventions intended to interrupt patient-to-
patient transmission of pathogens, such as enhanced hand hygiene and 
identification of patients colonised with methicillin-resistant Staphylococcus aureus 
(MRSA) using rapid DNA-based screening techniques. However, comparatively little 
attention has been given to the hospital environment, including water supplies, as a 
source of nosocomial pathogen of importance for patients in augmented care such 
ICU, burns, oncology, haematology. 
 
Gram-negative bacteria, including some genera associated with HAI in ICU patients 
can be readily isolated from hospital water, including water outlets within the ICU 
itself (Hapcioglua et al., 2005; Trautmann et al., 2005). For example, Arvantidou et al   
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(2003) isolated a wide range of antibiotic resistant Gram negative bacteria from 
haemodialysis water, tap and treated water in 71 Greek haemodialysis centres 
(Arvanitidou et al., 2003). Such findings have raised questions about the 
microbiological quality of water being used within wards and the risk that 
microorganisms from water sources pose to patients (Anaissie et al., 2002). Firmly 
establishing an association between sporadic or epidemic cases of infection and 
water sources was not possible in many earlier investigations used only phenotypic 
methods to compare patient and water isolates. More recently, robust genotyping 
techniques have been employed to characterize isolates and identify epidemiological 
associations (Trautmann et al., 2005). 
 
The range of aquatic reservoirs which have been implicated in HCAI is very wide 
and includes hydrotherapy pools (Moore et al., 2002), shower heads (Cordes et al., 
1981), ice machines (Labombardi et al., 2002), and disinfectant solutions (Aumeran 
et al., 2007), see Figure 11. The routes of transmission of water-associated bacteria 
is also very varied e.g. inhalation of aerosols, exposure to equipment washed with 
contaminated tap water, and irrigation of wounds with contaminated water.  
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Figure 11. A comprehensive view of a water distribution system and reservoirs for 
waterborne pathogens.  
 
(Exner et al., 2005) 
 
1.8.6 Control Methods 
Coarse water filtration occurs in municipal water treatment plants using techniques 
such as sand filtration and sedimentation. Further water filtration may occur within 
buildings on a macro scale down to very fine-scale filtration which can include 
micro-, ultra- and nano-filtration, and is used to remove undesirable contaminants 
from water. This includes particulate organic matter, chemicals and microorganisms. 
Many buildings have large filtration systems placed close to the point of entry to the 
building. These may be sized to remove coarse particulate matter or to give a 
nominal removal of bacteria. 
 
Numerous water treatment mechanisms exist including activated carbon (AC) filters 
which remover certain dissolved chemicals such as chlorine. UV-light mechanisms  
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are used to kill microorganisms but are ineffective against chemical pollutants or 
may be compromised by particulates entering a system. Reverse osmosis works by 
filtering water using pressure through a semi-permeable membrane working as 
barrier to any particles present. Such reverse osmosis systems are complex and 
may actually select out diminutive or chemically resistant organisms such as 
Ralstonia pickettii. 
 
In large buildings such as hospitals, the water distribution network is often old and 
very long and complex. Careful risk assessments of the network should mean that 
there are no dead ends where water can collect and stagnate, providing an 
environment for biofilm formation or areas where changes in water temperature can 
occur, again providing optimum growth conditions for bacteria such as Legionella 
spp. There are several mechanisms of systemic water treatment mainly aimed at 
reduction or elimination of Legionella. 
 
There are a number of approaches to the prevention of exposure of at-risk patients 
to microbially contaminated water aside from end-point-filtration. Examples include 
non-touch tap fittings. However, concerns have been expressed over these devices 
because of development of biofilms and difficultly of decontamination by chemical 
means (Halabi et al., 2001; Leprat et al., 2003; Merrer et al., 2005). Alternative 
technologies are copper and silver ionisation within the pipe network (Huang et al., 
2008), hyperchlorination of the water supplies (Helms et al., 1988) and thermal 
disinfection using heat-shock units in the water circulatory system, elevating 
temperatures to ≥73oC (Kusnetsov et al., 2003). Some of these technologies may, 
however be expensive to retro-fit in existing hospital supplies and may be ineffective 
in eradicating biofilm thus resulting  
75 
 
in outbreaks of infection. Indeed one outbreak of P. aeruginosa infection on a 
neurosurgery ICU proved refractory to control measures and was only terminated 
when the ward was closed and sinks and taps replaced (Bert et al., 1998). See 
Table 9. 
 
1.8.7 Bottled Water and Ice Machines 
There have been several investigations of the microbiological content of bottled still 
water (BSW) which brings into question its suitability for immunocompromised 
patients. Gram negative bacilli such as P. aeruginosa, S. maltophilia, 
Brevundimonas vesicularis, B. cepacia, Sphingomonas paucimobilis, Flavimonas 
orizihabitans and Moraxella spp. have been detected in commercially available 
BSW (Oie et al., 2008; Wilkinson and Kerr, 1998). 
 
Bottled still water has also been associated with a hospital outbreak in intensive 
care units. Eckmanns et al (2008) reported an outbreak of P. aeruginosa infections 
in 6 ICUs in a German university hospital traced to contaminated BSW. Samples 
were cultured and the isolates genotyped using PFGE and amplified fragment-
length polymorphism. Nineteen examples of the outbreak strain were collected from 
patients (15 infections and 4 colonisations). Four of environmental samples yielded 
P. aeruginosa but the only source of bacteria genetically indistinguishable to the 
outbreak strain was isolated from an unopened BSW. Following removal of BSW 
the outbreak was terminated (Eckmanns et al., 2008). 
 
Ice machines on hospital wards have also been associated patient colonisation or 
infection. Mycobacterium fortuitum was reported in two separate incidences of  
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increased patient colonisation with the bacteria. In both instances no further reports 
were made following the ice machines removal (Labombardi et al., 2002; Laussucq 
et al., 1988). Nosocomial legionellosis has also been traced to hospital ice 
machines and a nosocomial outbreak of Cryptosporidosis affecting 18 AIDS patients 
and causing 8 deaths was identified as originating from an ice machine (Graman et 
al., 1997; Ravn et al., 1991). 
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Table 9. Key Systemic Water Treatment and other Control methods 
 
Intervention Method of Action Comments Reference 
Chlorine dioxide (ClO2) 
Generated electrolytically from sodium 
chlorite solution and is approved by 
EPA for disinfection of potable water 
supplies. 
A potent oxidant which is bactericidal 
via oxidative disruption of cellular 
processes  
Effective in reducing the numbers of Legionella spp. in water 
systems but can take a long period of time to achieve this. 
Corrosion of the pipes may cause chlorine dioxide to be 
converted to it’s by products and reduce efficacy. System can 
be compromised by high water temperatures. Better 
permeation of biofilm than chlorine and better maintenance of 
activity over a wider range of pH than chlorine or copper-
silver ionisation. 
(Zhang et al., 2007) 
(Lin et al., 2011) 
(Srinivasan et al., 
2003) 
Hyper-chlorination 
This method can be carried out in two 
ways: shock-hyperchlorination or 
continuous-hyperchlorination. Both 
methods involve elevating chlorine 
levels. Shock-hyperchlorination 
requires the water to be drained 
afterwards to reduce the chlorine 
levels. Continuous involves elevating 
levels of chlorine to above normal and 
maintain it, often used in combination 
with thermal flush. 
A number of problems are associated with hyperchlorination 
including a corrosive impact on the distribution pipes over 
time, an inability to completely eradicate Legionella from the 
entire water distribution system with recontamination 
occurring if chlorine residual drops. Initial reduction in 
numbers can soon return to original levels. Monitoring of the 
system must be stringent along with maintenance of 
equipment.   
(Muraca et al., 1987) 
(Lin et al., 1998) 
(Lin et al., 2011) 
(Williams et al., 2011) 
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Table 9. Continued  
Intervention Method of Action Comments Reference 
Copper/silver Ionisation 
Produced by electrolysis. Copper 
ions affect the bacterial membrane 
and increase permeability allowing 
silver ions to enter the cell and 
disrupt DNA & RNA, proteins and 
respiratory enzymes 
(Lenntech 17/06/2011)   
Bactericidal against Legionella spp., P. aeruginosa,                 
S. maltophilia, and A. baumannii. A survey of 16 hospitals 
in 1995 and 2000 all reported 0% Legionella positivity 
following installation. Ions can penetrate biofilms and 
delay microbial recovery and still be effective during 
system malfunction. System can be compromised by high 
water temperatures and high water pH can interfere with 
action. Rigorous maintenance and monitoring of the 
system is required. 
(Stout and Yu, 2003) 
(Petignat et al., 2006) 
(Shih and Lin, 2010) 
(Lin et al., 2011) 
UV 
Disruption of microbial DNA using a 
UV light system used at the point-of-
entry to a building or at point of entry 
to a certain area of a plumbing 
system using a bypass to engineer 
the pipes through the UV apparatus.   
A system used to prevent contamination and not to 
disinfect an already contaminated system. The efficacy of 
UV disinfection is best when installed on the incoming 
water main of a new-build hospital water distribution 
system in which no biofilm has been established yet. Point 
of entry application means that there is no application of 
the system at the point of use. 
(Franzin et al., 2002) 
(Hall et al., 2003) 
(Lin et al., 2011) 
Thermal Flush 
Bactericidal activity by raising 
temperature in the water storage 
tanks and circulating throughout the 
system. 
To control Legionella one centre kept temperature 
between 56
O
C to 61
O
C, taps and showers in the hospital 
were flushed weekly at 65
O
C for 5 min this was adequate 
to end outbreak of legionellosis. Another centre raised 
water storage tank temperature to 70-80
O
C and circulating 
for 3 days. This was not adequate to eliminate Legionella 
spp. from water system. Also been used with success 
against P. aeruginosa. Requires thermostatic mixing 
valves in certain patient areas to avoid scalding.  
(Bukholm et al., 2002) 
(Petignat et al., 2006) 
(Darelid et al., 2002) 
(Mouchtouri et al., 2007) 
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Table 9. Continued 
 
Intervention Method of Action Comments Reference 
Point of Use Filters 
POU filters typically are presented as 
either membrane or hollow fibre 
technologies. Ideally they should 
provide a complete barrier to 
waterborne infection or may be 
suitable for either Legionella control 
or all-bacteria. Some additionally 
contain antimicrobial agents within 
the housing to minimise retrograde 
contamination. 
These products should have WRAS and/or EC approvals 
for placement in the water supply. Some are fully 
validated and have CE mark approval as medical devices. 
Recommended by the Department of Health and certain 
products have been shown to be cost effective by the 
Yorkshire Cancer Network. 
(Cervia et al., 2010) 
(Lin et al., 2011) 
(Warris et al., 2010) 
(Trautmann et al., 2008) 
(Hall et al., 2004)  
Non-touch Taps 
A sensor operated system for turning 
on taps without physical contact 
Prevent contact with the tap by 
healthcare workers and patients thus 
preventing transmission of pathogens 
to and from the hospital environment 
A problem associated with devices is that complexity of 
the materials from which they are made can promote the 
development of biofilms thus providing a reservoir for 
nosocomial species as Pseudomonas spp. and Legionella 
spp.  
Difficult to eradicate biofilm once in place. 
(Halabi et al., 2001) 
(van der Mee-Marquet et 
al., 2005) 
(Leprat et al., 2003) 
1.8.8 Point-of-use Filtration 
A number of different methods can be adopted for improving microbiological water 
quality at the point-of-use within a hospital as discussed in 1.8.6. These methods 
create enhanced water quality at the point of consumption and are often used in 
conjunction with systemic treatment involving the whole distribution network. Point-
of-use (POU) filters incorporating a sterilising grade membrane can be used to 
ensure the purity of water and used as an additional safety measure in specific 
areas. By means of an adaptor, filters can be connected to taps and showers and 
can be installed on all, or, a selected few outlets in a locations around a hospital; for 
example augmented care units such as burn units, bone marrow transplant units 
and haematology-oncology units. 
 
POU filters can be used in outbreak situations (see Table 10), or as an extra 
preventative measure in multifaceted infection control strategies. This type of filter 
can also be adopted for use in conjunction with medical equipment and in food 
preparation areas. The immediate installation and protection provided by many of 
these devices make them a quick and easy protection mechanism. These products 
maybe recyclable or disposable and have a life-span (length depending on their 
application) which can be influenced by the incoming water quality and the amount 
of sediment build up in the device. 
 
In 2004 the Yorkshire Cancer Network (Infection Group) conducted a one month trial 
on two wards at Leeds Teaching Hospitals Trust (LTHT) investigating the best 
method of providing microbiologically safe water for immunocompromised patients 
together with cost analysis. A number of criteria were examined including the 
organoleptic (i.e. the taste, colour and smell) quality of the water, the microbiological   
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quality and the cost of bought, bottled water. The overall recommendation of the 
study was that filtered water is the most appropriate option for the provision of safe 
water for immunocompromised patients. This was based on a ward of twenty patients 
receiving 4 litres of water per day at 2002 prices (YCN, 2004). 
 
Table 10:  Use of Sterilising Grade Point-of-Use (POU) Filtration as a Control Measure  
 
Pathogen Detail Conclusion Reference 
P. aeruginosa , 
P. putida 
Outbreak caused by 
contaminated water 
outlets in a paediatric 
haematology-oncology 
unit 
Several methods adopted 
to control outbreak 
including POU filtration 
(Aumeran et al., 
2007) 
P. aeruginosa 
Outbreak on haematology 
ward 
Resolution of outbreak 
using POU 
(Vianelli et al., 
2006) 
P. aeruginosa 
Outbreak on 
haematology-oncology  
ward associated with 
contaminated surface 
cleaning equipment 
Termination of outbreak 
through surface 
disinfection, chemical  
disinfection of wash-basin 
drains and POU filtration 
(Engelhart et al., 
2002) 
P. aeruginosa 
Endemic infections on a 
surgical ICU over 24 
months. Evidence of P. 
aeruginosa in water from 
97% of water samples 
Reduction of infections 
following adoption of POU 
filtration 
(Trautmann et 
al., 2008) 
L.  pneumophila, 
Mycobacterium 
gordonae 
Hot water system of 
hospital building 
colonised 
Complete elimination from 
hot water supplies 
(Sheffer et al., 
2005) 
 
 
1.8.9 Retrograde Contamination 
A concern regarding filtration devices is the potential for retrograde contamination: i.e. 
contamination of the device by splash-back from the water stream or contact with staff 
or patient hands and thus transferring bacteria to the device and potentially allowing 
colonisation (Sheffer et al., 2005; Vonberg et al., 2005). The addition of silver to the 
device, either by impregnation of the plastic itself or by a lining within the device can   
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possibly contribute to the control of this issue (Vonberg et al., 2008). Education of 
staff, patients and visitors to the correct handling of these devices is essential. 
 
1.8.10 Pall Corporation 
Pall Corporation is an international company with expertise in fluid management using 
technologies in filtration, separation and purification with markets in industry and life 
sciences. Within the healthcare market Pall Medical (Portsmouth, Hampshire) provide 
expertise in a diverse range of filtration membranes to the healthcare market for 
critical contamination control. There are many filter designs specifically engineered for 
the filtration of respiration equipment, parenteral therapy, general surgical 
applications and blood component therapy, products are also produced specifically 
for the filtration of hospital water. 
 
The Pall hospital water range extends from water system monitoring and 
environmental surveillance through to more specialised filtration technologies at the 
point of entry into buildings and at the point-of-use on taps, showers and other water 
sources. These technologies provide filtration of particles and microorganisms and 
can be easily incorporated into water safety plans. 
 
The Pall-AquasafeTM water filter range includes variants to protect against Legionella 
spp. or other waterborne microorganisms in water used for drinking or showering. 
Pall-AquasafeTM water filters carry the CE medical device mark and are designed to 
provide an instantaneous, validated, clinical barrier to the passage of a variety of 
waterborne contaminants. The design of the filters enables the devices to be quickly   
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and easily connected to either taps or showers to ensure instant protection against 
waterborne microorganisms. 
 
The tap and shower filters used in this study had a recommended maximum life-span 
of 14 days with a quick method of installation and removal. The filter unit contained a 
0.2μm pleated filter membrane validated to trap bacteria, fungi and parasites. To 
prevent retrograde contamination from water splash-back and cross-contamination 
from touch, the device housing contained a non-leaching bacteriostatic additive (see 
Table 11 and Figures 14, 15, 16 & 17). 
 
Table 11. Specifications of Pall AquasafeTM 14 Day Tap and Shower Filters 
 
 Tap Filter (AQ141S) Shower Filter (AQF3) 
Membrane Area 460 cm
2 
110 cm
2
 
Membrane Rating Double Layer 0.2μm Supor
® 
Double Layer 0.2μm Supor
® 
Flow Rate at 3 bar - 22 L/min 
Maximum Operating 
Pressure 
5 bar 5 bar 
Normal Operating Pressure 2-4 bar 2-4 bar 
Maximum Temperature  
Exposure 
70
O
C for 30 minutes over the 
life of the filter 
70
O
C for 30 minutes over the life 
of the filter 
Maximum Continuous  
Operating Temperature 
60
o
C 60
o
C 
Maximum Use Life 14 days 14 days 
 
(Information supplied by Pall Medical) 
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1.9 Overview of Current Study 
 
This study investigated the water to which immunocompromised patients are exposed 
while resident on the Annette Fox Haematology Unit (Ward 7) of the Bradford Royal 
Infirmary (BRI), and its potential to act as a reservoir for potentially infectious bacteria. 
This was done through longitudinal monitoring of the water supplies and water outlets 
of patient rooms and also the water from the kitchen outlets and used for drinking and 
ward cleaning. A baseline study established average bacterial numbers in water 
samples and whether particular target bacteria were present. These were 
Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Acinetobacter 
baumannii, all of which are problematic pathogens of immunocompromised patients 
and have been associated with water. Following the baseline study, there were four 
further phases: two with unfiltered water samples and two using Pall AquasafeTM 14 
day disposable POU filters. These phases ran alongside patient recruitment and 
patient sample collection. 
 
This study also investigated the prevalence of carriage and the molecular 
epidemiology of Gram negative bacteria in patients undergoing intensive in-patient 
based chemotherapy for haematological malignancy. Patients were investigated on 
admission for target bacterial species in their stools, throat and axillae, before they 
became neutropenic and thus more vulnerable to infection. These specimens were 
chosen as the large bowel, the mouth and the skin are the most likely portals of entry 
of environmental bacteria into the body. Other patients were enrolled to the study 
after becoming resident on the ward and on occasion, following the start of therapy. 
Weekly stool, throat and axillae were obtained throughout a patient’s hospital 
admission. Any target species isolated by the hospital diagnostic laboratory as part of 
the routine microbiological assessment of study-enrolled patients, would   
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also be saved and examined in this study. Patient isolates were compared using the 
PCR-based genotyping methods BOX-PCR and REP-PCR. This was to help 
determine whether these strains were acquired in hospital and, if so, whether they 
were spreading from patient to patient or from water source to patient or vice versa. It 
also permitted a better understanding as to whether colonisation was transient, 
intermittent or continuous and whether patients could be colonised with ≥1 of the 
target species. It also provided data on the antibiotic susceptibilities of water-
associated isolates. 
 
Additionally, the effect of POU filtration on the incidence of Gram negative infection in 
patients treated for haematological malignancy was investigated. The incidence of 
serious Gram negative bacterial infection including blood stream infections during the 
period when tap and shower filters were installed on the haematology unit was 
investigated and compared with non-filter periods. While the filters were in operation 
water sampling continued in the same manner as the non-filtered phases in order to 
assess the microbiological quality of water obtained from filtered sources. A 
comparison between incidence of colonisation and infection with the target species 
during the filtered and non-filtered phases was made.  
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1.10 Aims and Objectives of Study 
This longitudinal investigation of the water distribution system of Annette Fox 
Haematology Unit in a non-outbreak setting was a continuous study lasting nearly 
two years followed by genotyping and antibiotic sensitivity investigations. Following 
a baseline study, the first six months of the trial was conducted without filters on any 
of the ward water outlets (Phase 1); this was a control period to establish baseline 
numbers and frequencies of the target bacteria. The following six months was 
conducted with filters (Pall Aquasafe 14-day filters, Pall Medical, Portsmouth, UK), 
on each water outlet (Phase 2). The study then returned to non-filter (4 months), 
followed by a further period of filtration (Phases 3 & 4). It was hoped that it would 
be possible to establish the numbers of bacteria coming through on initial opening of 
a water outlet and also following continuous running, so reflecting the water-
associated bacteria patients were exposed to on a daily basis. 
 
Aims 
This study aimed to fill some of the gaps in knowledge regarding Gram negative 
bacteria in hospital water supplies in a non-outbreak setting with an 
immunocompromised population. It was a double cross-over study examining water 
samples taken over several set periods of time from outlets with or without filters in 
place. Alongside the collection of water samples there was also collection of patient 
samples (throat, axilla and faecal) from eligible in-patients and who had given their 
consent to participate (see 1.9.1). Target species recovered from both water and 
patient samples were compared using molecular typing techniques to see if a link 
between water and patients could be established. Antibiotic susceptibilities of water 
isolates was also investigated and compared with those of clinical isolates.  
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Objectives 
 
 To perform a short baseline study before patient recruitment to establish the 
numbers of bacteria present in water supplies from the patient rooms and 
kitchen outlets.  
 To investigate the water distribution system of the Ward over four distinct 
phases alternating between non-filtered and filtered phases.  
 To establish whether the selected target species were endemic to the water 
distribution system of Ward 7. 
 To establish the effect of point-of-use filtration on the recovery of target 
species from water samples 
 To investigate the difference between bacterial growth from the water 
samples upon immediate opening of the outlets and following a period of 
flushing. 
 To investigate the patients who gave their consent to participate in the study, 
for colonisation/infection with target species. 
 To establish whether a link exists between the target species which might be 
present in the water supplies and corresponding patient infection 
 To establish whether water-borne isolates of the selected target species 
were reservoirs for antibiotic resistance genes. 
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2. Materials and Methods 
 
2.1 Bradford Royal Infirmary, Ward 7, Patients & Eligibility Criteria  
The Bradford Royal Infirmary was established on its present site in 1936 and serves a 
population of greater than 520,000. It is a teaching hospital with approximately 800 
beds. The Annette Fox Haematology Unit was opened in September 1993 for the 
investigation and treatment of patients with haematological disorders. The unit 
contains a day case unit and dedicated patient facility. The in-patient ward has 12 
rooms, 10 of which are single occupancy and two of which are double occupancy 
creating space for 14 patients at a time. There are approximately 360 elective and 
emergency admissions annually. 
 
Patients with a wide range of haematological conditions attend Ward 7 as either in- or 
out-patients treated in the day unit. These conditions include non-malignant 
conditions such as sickle cell anaemia and haemophilia, as well as haematological 
malignancies. With such a wide range of patient pathologies there is a wide range of 
treatments given. Certain patients, particularly those with haematological 
malignancies, are an extremely vulnerable patient group, not only because of their 
underlying illness but also because of the aggressive treatments they receive. 
 
Patients eligible for entry into the study had to be aged 18 years or over, be able to 
give informed consent, and to have received a diagnosis of a haematological 
malignancy (leukaemia or lymphoma) necessitating cytotoxic chemotherapy which 
would result in a state of significant neutropenia lasting ≥7 days. 
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2.2 Layout of Ward 7 and Preparation for the Study 
Considerable preparation had to be done for this study to go ahead. All of the existing 
outlets were replaced as none of them were fitted with a screw thread which is 
essential for long-term connection of POU filters. This was a time consuming process 
which involved each room in turn to be unoccupied and sealed off from the rest of the 
ward. Following the outlet refit, the hospital deep clean team and infection control 
made the room fit for occupation by a potentially vulnerable patient. In total, 21 outlets 
were changed before the beginning of Phase 1 (non-filtered) and a further two by 
Phase 2 (filtered); the completion of this work in the patient rooms was followed by an 
evaluation of baseline levels of bacterial growth from the water supply. 
 
Ward 7 consists of a long central corridor with rooms on either side (Figure 13). On 
entry to the ward a day-patient unit and several other rooms lead off the corridors. As 
this study was designed to investigate in-patients only, these rooms were not enrolled 
in the study. Further along the corridor is the kitchen which provides drinking water for 
both staff and visitors and also cleaning water. The ward consists of twelve patient 
rooms numbered 1 – 12, with all except rooms 6 and 7 designed for single patient 
occupancy. The latter are for twin patient occupancy. All rooms have a hand-wash 
outlet in the main patient area and an en suite facility comprising a toilet, wash basin 
and shower cubicle (N.B. there is no shower cubicle in Room 5). See Appendix 6 for 
the water supply/distribution to the Bradford Royal Infirmary and Ward 7. 
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Figure 12.  Typical layout of a patient room on Ward 7 
 
 
   Fig. 13 
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Typical water outlets of a patient 
room: 
A.  Hand-wash basin 
Figure 13:  Schematic of Ward 7 Layout 
B. Bathroom consisting of wash-basin, Shower & toilet 
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Hand-wash Station 
Kitchen Sink  
Key: 
N.S. – Nurses Station 
K - Kitchen 
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The handwash stations in the patient rooms and the wash basin in the en suite 
facilities were fitted with Rada tap fittings from the Rada Healthcare Product Range 
which were provided by Kohler Mira (Cheltenham, UK). The hand wash station 
(Figure 14) is a Rada Unatherm-3-HLTM which is a wall/panel mounted device 
combined with a clinical basin and mixing valve, and features a high spout. This 
enabled the POU filters to be fitted and still allowed room for hand washing and other 
requirements. This outlet is turned on by operation of an elbow operated lever. The 
wash basin outlet (Figure 15) is a sensor operated system (Rada SenseTM) by which 
the patients have control over the temperature of the water by moving their hand 
across the face of a control panel. The control panel is wall mounted and is an infra-
red no-touch system allowing control by the patient, and has programmed timed flow 
control. The en suite showers (Figure 16) are standard showers that allow manual 
temperature control and shower head replacement. 
 
Figure 14 & Figure 15. Patient room outlets. The hand wash-station of the main patient 
area (left) and the wash basin of the en-suite bathroom with the temperature control panel 
on the bottom left. 
 
  
Fig. 15 
Fig. 14 
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Figure 16. Shower of the patient room en-suite facilities with a Pall filter (AQF3) in place. 
 
 
 
 
 
 
 
The ward also has a main kitchen area which includes a sink (Figure 17) with 
individual taps for hot and cold water plus a hand-wash station. The sink outlets are 
used to provide hot water for cleaning purposes and cold water for jugs of drinking 
water supplied to each patient throughout the day. 
 
Figure 17 The stainless steel sink in the kitchen with new, Pall filter compatible, tap outlets 
supplied by Kohler Mira with Pall 14 day AQ141S tap filters on both the hot and cold 
outlets. 
 
 
 
 
 
 
 
 
 
  
Fig. 17 
Fig. 16 
Fig 15 
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2.3 Ethical Approval 
Ethical approval for this study was sought from the NHS National Research Ethics 
Service and granted on 14th December 2007 (REC Reference No. 07/H1302/81), 
see Appendix 1 for details. This study was subsequently accepted onto the National 
Institute for Health Research Clinical Research Network (NIHR CRN) Portfolio 
(UKCRN ID: 4997), a database of “high quality clinical research studies that are 
eligible for support from the NIHR Clinical Research Network in England” (see 
www.nihr.ac.uk). 
 
2.4 Bacterial Collection 
Reference strains from culture collections were used for validation of assays and 
identification protocols and for comparison purposes against strains collected from 
water and patient samples (see Table 12). 
Table 12. Details of reference isolates used in this study  
 
Species Strain Code Origin  Ref 
Acinetobacter 
baumannii 
NCTC 12156  
(ATCC 19606) 
Urine  
(Bouvet and Grimont, 
1986) 
Burkholderia 
cepacia 
NCIMB 9085 
(ATCC 17759) 
Forest soil (Trinidad) (Stanier et al., 1966) 
Pseudomonas 
aeruginosa   
NCTC 10662 
(ATCC 25668) 
From human clinical 
origin, source unknown 
(Garrod and Waterworth, 
1969) 
Pseudomonas 
aeruginosa 
NCTC 12934  
(ATCC 27854) 
Blood culture (Gee et al., 2003) 
Stenotrophomonas  
maltophilia 
NCIMB 9203 
Oropharyngeal swab from 
patient with mouth cancer 
(Palleroni and Bradbury, 
1993) 
Stenotrophomonas 
maltophilia 
NCIMB 9204 
Stagnant water, 
Washington DC, USA 
(Palleroni and Bradbury, 
1993) 
Stenotrophomonas 
maltophilia 
K279a  
Blood Culture 
(kindly supplied by Dr 
Avison, Bristol University. 
(Okazaki and Avison, 
2007) 
(Crossman et al., 2008) 
All further bacterial isolates were collected from either the water sampling protocol 
(see section 2.8) or the patient sampling protocol (see section 2.9) from Ward 7, 
Bradford Royal Infirmary. 
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2.5 Bacterial Maintenance and Growth Media 
Reference isolates and those from Ward 7 isolated from water, outlet swabs or 
patient samples (following primary isolation on either R2A or selective media) were 
all grown on Tryptone Soy Agar (TSA) (Oxoid, Basingstoke, England), and stored at 
-70oC in Tryptone Soya Broth (TSB, Oxoid), supplemented with 15% (v/v) glycerol 
(see Table 13). All media were sterilised by autoclave for 15 mins at 121OC. 
 
2.5.1 R2A Recovery Media 
R2A agar developed by Reasoner & Geldreich (1985) was originally intended for 
recovery of bacteria from treated potable water (Reasoner and Geldreich, 1985). It 
is a low nutrient agar designed to enhance the recovery of stressed and chlorine 
damaged organisms from treated waters, thus resulting in more accurate bacterial 
counts (see Table 13). 
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Table 13: Non-Selective Media for Bacterial Maintenance and Recovery of Water 
Isolates 
 
Media Ingredients Preparation 
Nutrient Agar 
(Oxoid) 
“Lab-Lemco” powder                            
Yeast extract                                        
Peptone                                                
Sodium chloride                                   
Agar                                                    
  1g/L 
  2g/L 
  5g/L 
  5g/L 
15g/L 
Dissolve 28g in 
1 L of d(H2O) 
Tryptone Soy Agar 
(TSA) 
(Oxoid) 
Pancreatic digest of casein 
Enzymatic digest of soya bean 
Sodium chloride 
Agar 
15g/L 
  5g/L 
  5g/L 
15g/L 
 
Dissolve 40g/L 
in 1L (d)H2O 
Tryptone Soy Broth 
(TSB) 
(Oxoid) 
Pancreatic digest of casein                
Enzymatic digest of soya bean            
Sodium chloride                                  
Dipotassium hydrogen phosphate       
Glucose                                                
17g/L 
  3g/L 
  5g/L 
  2.5g/L 
  2.5g/L 
Dissolve 30g in 
1L (d)H2O 
R2A 
(Water Recovery 
Media) 
(Oxoid & Melford) 
Yeast extract                                         
Proteose peptone                                 
Casein hydrolysate                               
Glucose                                                 
Starch                                                    
Di-potassium phosphate                       
Magnesium sulphate                             
Sodium pyruvate                                   
Agar                                                   
  0.5g/L 
  0.5g/L 
  0.5g/L 
  0.5g/L 
  0.5g/L 
  0.3g/L 
  0.024g/L 
  0.3g/L 
15g/L 
Dissolve 18.1g 
in 1L (d)H20 
 
2.5.2 Differential and Selective Media 
Following primary bacterial isolation from water samples on R2A; selective and 
differential media were used to aid the detection and identification of Pseudomonas 
aeruginosa, Stenotrophomonas maltophilia and Acinetobacter baumannii (and other 
Gram negatives). The media chosen were MacConkey agar (Oxoid), Pseudomonas 
cetrimide agar (Oxoid) for P. aeruginosa, Vancomycin-Imipenem-Amphotericin B 
agar (Kerr et al., 1996) for the selection of S. maltophilia and Leeds Acinetobacter 
Media (Jawad et al., 1994) for A. baumannii.  
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2.5.3 MacConkey Agar 
MacConkey agar (Oxoid) is a selective medium used to aid the detection of Gram 
negative enteric bacteria; the addition of bile salts serves to inhibit the growth of 
most Gram positive bacteria. The medium also differentiates between lactose and 
non-lactose fermenting bacteria (See Table 14). 
 
2.5.4 Pseudomonas Cetrimide Agar (Ps-Cet) 
Pseudomonas Cetrimide Agar (Ps-Cet) was chosen for its ease of use and ability to 
encourage the production of pyocyanin from Pseudomonas aeruginosa (enhanced 
by the ingredients magnesium chloride and potassium sulphate) following 24 hours 
incubation at 37oC. Colonies displaying such pigmentation were selected and stored 
for further investigation (See Table 14). 
 
2.5.5 Vancomycin-Imipenem-Amphotericin B Agar (VIA) 
VIA was developed by Kerr et al (1996) for the selective isolation of S. maltophilia 
from polymicrobial environmental and clinical sources. Original evaluation of the 
media using faecal samples gave 100% specificity. VIA is supplemented with 
vancomycin (5 mg/L), imipenem (32 mg/L) and amphotericin B (4 mg/L) and 
includes bromothymol blue as an indicator. VIA agar is differential for S. maltophilia 
because it contains mannitol. Stenotrophomonas maltophilia does not produce acid 
from mannitol whereas other bacteria able to grow on this medium give a yellow 
halo around the colonies. Colonies without a yellow halo i.e. not producing acid from 
mannitol, were then examined and following a negative oxidase test were selected 
for further analysis (See Table 14).  
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2.5.6 Leeds Acinetobacter Medium (LAM) 
Leeds Acinetobacter medium (Jawad et al, 1994) was developed for the isolation of 
Acinetobacter spp. from clinical and environmental sources. The medium includes 
vancomycin (10 mg/L), cefsulodin (15 mg/L) and cefradine (50 mg/L) to inhibit the 
growth of other bacteria. Phenol red acts as an indicator and turns the base a 
mauve colour when growth of Acinetobacter spp. alkalinises the medium. Colonies 
producing this colour change that were also oxidase-negative were selected for 
further analysis (See Table 14). 
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Table 14: Ingredients and Preparation of Differential/Selective Media 
 
Agar Ingredients Preparation 
Additives 
Following 
Sterilisation 
MacConkey 
agar 
Peptone                         
Lactose                          
Bile salts                          
Sodium chloride              
Neutral red                     
Agar                               
20 g /L 
10 g/L 
  5 g/L 
  5 g/L 
  0.075g/L 
12 g/L 
 None 
VIA agar 
Peptone mixture             
Mannitol                          
Bromothymol blue           
Agar                                
10 g/L 
10 g/L 
  0.06 g/L 
20 g/L Mix 1 sachet with 
200 ml of (d)H2O 
Antibiotics: 
Vancomycin 
hydrochloride 
5 mg/L 
Imipenem                  
32 mg/L 
Amphotericin B           
4 mg/L 
Pseudomonas 
Cetrimide agar 
Peptone                           
Magnesium chloride          
Potassium sulphate       
Cetrimide                           
Agar                               
20 g/L 
  1.4 g/L 
10 g/L 
   0 3 g/L 
13.6 g/L 
Suspend 45.3g 
agar in 1Litre of 
(d)H2O 
Add: 10ml 
glycerol 
None 
LAM agar 
Bacteriological Agar No.1  
Acid casein hydrolysate   
Neutralised soy peptone    
Sodium chloride                 
D-(-)-fructose                     
Sucrose                               
D-mannitol                           
L-phenylalanine                  
Ferric ammonium citrate                                
Phenol red                       
10 g/L 
15 g/L 
  5 g/L 
  5 g/L 
  5 g/L 
  5 g/L 
  5 g/L 
  1 g/L 
0.4 g/L
  0.02 g/L 
 
 
 
Antibiotics: 
Vancomycin 
Hydrochloride 
10 mg/L 
 
Cefsulodin 
15 mg/L 
 
Cefradine 
50 mg/L 
100 
 
2.6 Antibiotic Storage and Preparation  
Table 15. Details of Antibiotics used in this study 
 
Antibiotic 
Media 
Details 
Supplier Details Spectrum of Activity Storage Preparation 
Cefsulodin 
LAM 
15 mg/L 
Melford 
Cephalosporin (3
rd
 generation) 
Increased activity against Gram 
negative compared with 1
st
 
generation 
Store at 2-8
o
C in powder form 
Diluent: water 
 
>98% Purity 
Cefradine 
LAM 
50 mg/L 
Sigma-Aldrich 
Cephalosporin (1
st
 generation) 
Predominantly active against Gram 
positive species 
Store at 2-8
o
C in powder form 
 
No storage following suspension 
(BSAC) 
Diluent: water 
Requires NaOH to alkalise 
and fully suspend 
 
Immediate use only 
Imipenem 
VIA 
32 mg/L 
Primaxin® – 
supplied by 
Pharmacy Dept. of 
Harrogate District 
Hospital 
Carbapenem  - activity against Gram 
negative and Gram positive bacteria 
Room Temperature in powder 
form 
 
No storage following 
reconstitution 
Diluent: water 
Immediate use only 
 
50% purity 
Vancomycin 
VIA 
5mg/L 
 
LAM 
10 mg/L 
Sigma-Aldrich 
Glycopeptide – activity against Gram 
positive bacteria 
Store at 2-8
o
C in powder form 
 
Stock solutions stable: 
1week @ 4
o
C 
3 months @ -20
o
C (BSAC) 
Diluent: water 
 
Stock preparation can be 
stored 
Amphotericin 
B 
VIA 
2.5 mg/L 
Sigma-Aldrich 
Anti-fungal 
 
Effective against fungi and 
Yeasts 
Store at 2-8
o
C in powder form 
 
Stock solutions stable: 
2-8
o
C – 1 month 
-20
o
C – 5 years 
(Product Information Sheet) 
Diluent: water 
Cannot be filter sterilised 
 
45% purity 
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2.7 Biochemical Tests 
The following tests were used in the secondary identification of bacteria isolated from 
water, outlet swabs or patient samples. 
 
2.7.1 Oxidase Test 
Following growth on primary isolation agars, a representative colony was tested for 
oxidase using Oxidase sticks (Sigma, Dorset, United Kingdom). Colonies which caused 
an immediate (or delayed reaction of ≤10 seconds) colour change in the stick from pale 
brown to deep purple were taken to be oxidase positive, and sticks giving no colour 
change were considered negative. 
 
2.7.2 Potassium Hydroxide (KOH) “String” Test 
The potassium hydroxide test is an aid to the differentiation of Gram negative and 
Gram positive bacteria. One drop of potassium hydroxide (3% w/v) is mixed with a 
loopful of growth from a plate to make a dense suspension and mixed for 60 seconds. 
The KOH breaks down the Gram negative cell wall and releases DNA. The result is a 
viscous suspension, and when the loop is removed a “string” can be seen between the 
loop and the bacterial suspension. A negative result from a Gram positive bacteria is 
indicated by no change in the viscosity of the cell suspension and no “string” being 
formed. This is not a conclusive test and if there was any doubt regarding the result of 
the test a Gram stain was performed. 
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2.7.3 API 20 NE 
The Analytical Profile Index (API), (bioMerieux, Lyon, France), series is an identification 
method designed to identify clinically relevant bacteria of many species and is widely 
used in diagnostic laboratories. The API 20 NE system was chosen as it provides 
identification of non-enteric, non-fastidious Gram negative rods likely to be recovered in 
this study including Pseudomonas spp., Acinetobacter spp. and Aeromonas spp. 
among others. 
 
The system uses a strip consisting of 20 microtubules each containing dehydrated 
substrates. These are inoculated with a suspension of the colony to be identified in 
either saline or minimal medium and then incubated. Bacterial metabolism produces 
colour changes in the substrates and the results are read and interpreted using a 
Reading Table and identification software. APIWEB Stand Alone V 1.1.0. software was 
used for this study. 
 
The full methodology for the use of the API 20 NE system is provided in the bioMerieux 
instruction leaflets provided with each identification set.  
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2.8 Water Sampling of Ward 7 (Haematology), Bradford Royal 
Infirmary 
 
The study consisted of four alternating phases: In Phases 1 & 3, unfiltered water 
samples were collected directly from each outlet. In Phases 2 & 4, water samples were 
collected from taps and showers fitted with Pall AquasafeTM 14-day disposable filters 
(supplied directly from Pall Medical, Portsmouth). See Table 24 for dates of study 
Phases. 
 
Prior to Phase 1, new taps compatible with Pall AquasafeTM filters were installed 
throughout Ward 7 (See section 2.8.1). Following this there was a trial period to allow 
establishment of a working sampling protocol. 
 
Outlets on the ward sampled were designated in the study records as follows: 
Table 16. Designation of Water Outlets 
 
Outlet Type Designation 
Kitchen sink taps (Cold & Hot) K (KC & KH) 
Handwash stations in kitchen and corridor HWS 
Handwash station in main room of patient 
room 
A 
Wash basin in patient bathroom B 
Shower in patient bathroom C 
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2.8.1 Outlet/Plumbing Alterations to Ward 7 
In order for Pall AquasafeTM filters to be compatible with the water outlets of ward 7, 
considerable plumbing working was undertaken throughout the ward. During this work 
each room was individually sealed off from the rest of the ward for workmen (Bradford 
Royal Infirmary Estates) to enter and afterwards, each room was deep-cleaned and 
inspected by the infection control team before further use. All patient rooms had a Rada 
Unatherm panel-mounted fixer tap with high neck spout fitted (outlet “A”) and the 
patient bathrooms had Rada spouts with Rada-Sense wash-basin non-touch sensors 
(outlet “B”) fitted. Both outlets “A” & “B” were controlled by Type 3 thermostatic mixing 
valves (TMV3) which met the specifications of NHS Estates D08 standard for mixing 
valves for use within health care premises in the United Kingdom. 
 
Also fitted were three TMV3 approved surgical taps (Rada Unatherm 3 Basin) with high 
neck spouts, one each for the kitchen area, central corridor and Room 5. Two taps for 
the kitchen outlets (hot and cold) and a Rada Sense Bath Kit for Room1. 
 
The en-suite shower outlets did not require any alterations for the study. 
 
2.8.2 Changing of 14-day Water Filters (Phases 3 & 4) 
Filters were changed every 14 days, old filters removed by using the quick release 
system on the adaptor which sits between the tap and the filter and disposed of in 
clinical waste bins. New filters were placed onto the adaptor and the cap covering the   
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water supply end removed with no contact being made with this part of the device. All 
filters were changed by the investigator and not by staff on the ward. 
 
Figure 18. Pall AquasafeTM 14-day disposable tap and shower filters and image showing the 
internal membrane filter of a shower unit 
 
 
 
 
 
 
 
 
Tap filters (AQ14F1S) and shower filters (AQF3) were supplied by Pall Medical 
throughout the study 
 
2.8.3 Water Collection Procedure 
All samples were taken on Monday and Tuesday mornings between 0900 and 1000. 
Before a water sample was collected, outlets were swabbed using Amies gel transport   
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swabs (Oxoid). Swabs were obtained by swabbing the immediate end of the outlet on 
the outer surface first, followed by the immediate end of the inner surface. 
 
Two water samples were collected from each outlet, an initial sample taken on 
immediate opening of the outlet (proximal water sample), and a post-flush sample 
which was collected following a 2-3 minute flush (distal water sample). Samples of 100  
mL were collected from each outlet into sterile, autoclavable water collection pots (125 
mL, Nalgene, England). 
 
2.8.4 Membrane Filtration and Growth Conditions 
Each 100 mL water sample was filtered through presterilised cellulose nitrate gridded 
membranes; 47 mm diameter: 0.45 µm (Cole Palmer, England) using three 47 mm 
magnetic filter funnels, 300 mL capacity, and a three place filter funnel manifold (all 
manufactured by Pall Life Sciences and purchased through VWR). Each sample was 
filtered through the membrane using a bench vacuum line and the membrane placed 
flat onto the surface of R2A agar (Oxoid), and incubated at 37oC for 48 hours. 
Figure 19. Filter funnel manifold with filter funnels in situ and waste water collection bottle 
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2.8.5 Colony Selection 
After 48 hours incubation, the colonies on the plate were counted and examined for 
different morphological types. Membranes with ≤300 colonies were counted; more 
frequently membranes had too many colonies to count or had confluent growth, these 
were noted as” too numerous to count”. Following enumeration colony morphologies 
were examined, two representative colonies of each morphotypes (or a section of the 
confluent growth), were picked from the R2A plate and patched onto gridded plates of 
the four media: MacConkey agar, Pseudomonas Cetrimide agar, VIA agar (Kerr et al., 
1996) and LAM agar (Jawad et al., 1994) using sterile wooden toothpicks (see Figure 
20). 
 
Colonies with the appropriate morphologies on their respective agar were streaked for 
single colonies on TSA or Nutrient agar and then stored at -70oC until required for 
further analysis. 
Figure 20. An example of a gridded plate (Ps-Cet) from which colonies growing on R2A agar 
were patched using corresponding location on each media type as an aid to identification.  
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2.8.6 Statistical Analysis 
The Fishers Exact Test (PASW V.18, SPSS Inc. Chicago, USA) was used to 
investigate recovery of P. aeruginosa and S. maltophilia in Phases 1 & 3. This was to 
test for an association of the phases and whether the sample was likely to be positive. 
The significance of any differences in recovery of the target species between the 
phases could then be established. 
 
2.9 Patient Specimens 
2.9.1 Patient Recruitment & Sampling Procedure 
Patients eligible for the study were first approached by either Dr L. Newton (consultant 
haematologist) or a haematology research nurse. Information regarding the study was 
given to the patients both verbally and in a written information sheet (Appendix 2), and 
consent was obtained through a signed consent sheet (Appendix 3). When appropriate 
(i.e. during Phases 2 & 4), patients were also requested not to make any physical 
contact with the Pall AquasafeTM filters in order to avoid contamination of the unit. 
 
Following written, informed patient consent, three specimens were collected by the 
research nurses or ward nurses and held at 4oC on the ward until collection. Swabs 
were taken from the axilla and throat; faecal samples were also collected when 
possible. The first specimens were collected following consent and every Monday or 
Tuesday.  
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Patient data recorded were: surname, date of birth (DOB), sex and hospital 
identification number. Each patient was anonymised on entry to the study and was 
given a university identification number (e.g. the first patient became P.001 and so on). 
The hospital identification number and surname were used only as an initial control to 
ensure the correct assigning of patient specimens to their respective patients. Patient 
specimens were cultured on the same selective media as the water samples and outlet 
swabs (see appendix 4 for patient records and results). 
 
2.10 Antimicrobial Susceptibility Testing  
Susceptibility to common anti-pseudomonal antimicrobials was tested using a disc 
diffusion method. Antibiotics and methods were selected from British Society for 
Antimicrobial Chemotherapy (Version 9.1) and the American Clinical and Laboratory 
Standards Institute (Version M100-S16) official guidelines for antibiotic susceptibility 
testing. All antibiotic discs were purchased from Oxoid. In brief, bacterial cultures were 
grown overnight on TSA and an inoculum was prepared in sterile water to a turbidity of 
a 0.5 MacFarland Standard. The suspension was inoculated onto either Iso-Sensitest 
agar (Oxoid) or Mueller Hinton agar (Oxoid) as per BSAC or CLSI methodology 
respectively. The discs (see Tables 17 and 18) were placed onto the lawn and 
incubated at 30OC for 24 hours and 37oC for 24 hours for S. maltophilia and 
P. aeruginosa respectively. Pseudomonas aeruginosa type strains NCTC 12934 (ATCC 
2785) and NCTC 10662 (ATCC 25668) were used as susceptible controls. Following 
incubation, the diameters of the zones of inhibition for each agent were measured and 
classified as resistant, susceptible or intermediately susceptible, as appropriate. 
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Table 17. Disc Diffusion Zone Diameter Breakpoints as Defined by BSAC (Version 9) 
and CLSI (M100-S16) for Stenotrophomonas maltophilia 
BSAC Guidelines 
  
                             Zone Diameter to nearest mm 
Antibiotic 
Disc Content 
(μg)  
R≤
 
I S≥
 
Trimethoprim/ 
sulfamethoxazole 
1.25/23.75 19 - 20 
 
CLSI Guidelines 
                            Zone Diameter to nearest mm 
Minocycline  30 ≤14 15-18 ≥19 
Levofloxacin 5 ≤13 14-16 ≥17 
Trimethoprim/ 
sulfamethoxazole  
1.25/23.75 ≤10 11-15 ≥16 
* R = Resistant, S = Susceptible, I = Intermediate 
Table 18. Disc Diffusion Zone Diameter Breakpoints as Defined by BSAC (Version 9) 
and CLSI (M100-S16) for Pseudomonas spp. and additional S. maltophilia testing 
BSAC Guidelines v9 
 
                                Zone Diameter to nearest mm 
Antibiotic 
Disc Content 
(μg) 
R≤
 
I S≥
 
Amikacin 30 15 16-18 19 
Gentamicin 10 17 - 18 
Aztreonam * 30 19 20 - 35 36 
Ceftazidime 30 23 - 24 
Colistin 25 13 - 14 
Piperacillin/tazobactam 75/10 21 22 - 25 26 
Ciprofloxacin  5 19 20-29 30 
 
CLSI Guidelines 
                                                                         Zone Diameter to nearest mm 
Minocycline 30 ≤14 15-18 ≥19 
Levofloxacin 5 16 17-21 22 
* Aztreonam – “Relates only to isolates from patients with cystic fibrosis given high dosage 
therapy to treat P. aeruginosa infection” (BSAC V9.1)  
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2.11 DNA Preparation and PCR Analysis 
2.11.1 Bacterial DNA Extraction for PCR Analysis 
A rapid, crude DNA preparation was made from bacterial cells by suspending 
approximately four small colonies of bacteria freshly sub-cultured on TSA agar in 0.4 
mL of sterile molecular-grade, nuclease-free water (VWR, Leicestershire, England). 
This was heated to 100oC for 5 minutes and then placed on ice for a further 5 minutes. 
The suspension was centrifuged for 10 minutes at 12,470 xg using a microcentrifuge. 
The supernatant was transferred to a fresh tube and stored at -20oC for PCR analysis. 
In the case of DNA preparation for genotyping PCR, DNA was extracted in the same 
manner but not frozen for storage; preparations were freshly made on each occasion. 
 
2.11.2 Polymerase Chain Reaction (PCR) 
A number of different PCR assays were used during this study including single-loci 
PCR for species-specific PCR’s for detection of S. maltophilia and P. aeruginosa, 
multiplex PCR for the combined detection of Pseudomonas genus and P. aeruginosa. 
Further PCR assays were adopted for genotyping of selected isolates. A basic PCR 
template is shown in Table 19.  
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Table 19.  PCR Cycle Template 
 
Cycle Step 
Temperature (
o
C) 
(approximate) 
Time 
(approximate) 
Number of cycles 
Initial 
Denaturation 
94 2 min 1 
Denaturation 94 30 sec 
25 – 35 
As per protocol 
Annealing of 
Primers 
As per protocol 30 sec 1 
Extension 72 As per protocol 1 
Final Extension 72 As per protocol  
Hold Cycle 4 ∞  
 
 
2.11.3 PCR Equipment, Reagents and Conditions 
All reactions were carried out in either 20 or 25 µl volumes in dome-capped 0.2 mL thin 
walled PCR tubes (Greiner Bio-One Ltd. Gloucester, UK). Primers were obtained from 
Invitrogen (Paisley, UK), and Sigma (Dorset, England) and DreamTaq Green 
MasterMix (Fermentas) was used for each PCR. A DNA molecular size marker for use 
in electrophoresis (Norgen 100bp LowRanger purchased from Geneflow Ltd, 
Staffordshire, England) was included on every agarose gel. Amplification took place in 
a Sprint Thermal Cycler (Thermo Scientific) or PX2 Thermal Cycler (Thermo Scientific). 
Positive and negative controls were included in each PCR run.  
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2.11.4 Agarose Gel Electrophoresis 
Following PCR the amplimer products were subjected to electrophoresis on 1 – 2% 
(w/v) agarose gels using 1X tris-borate-EDTA buffer (TBE). Single-loci PCR’s were run 
at 100 V for approximately 30 minutes and genotyping PCR gels were run at 90V for 2 
hours 30 minutes with ethidium bromide incorporated into the gel. The PCR products 
were then visualised using UV light (312 nm) from a transilluminator and gel 
documentation software (UVIPhotoMW, UVITec Ltd, Cambridge). 
 
2.12 PCR Assay for Identification of Pseudomonas aeruginosa 
2.12.1 Genus- and Species-Specific PCR 
Extracted DNA from known culture collection type strains and isolates collected from 
the hospital and patients were subjected to Pseudomonas genus specific (PA-GS) and 
Pseudomonas aeruginosa species-specific (PA-SS) PCR using primer pairs PA-GS 
forward and reverse and PA-SS forward and reverse respectively (Spilker et al., 2004). 
Primer pairs PA-GS and PA-SS are both 16s rDNA signature sequences. The expected 
amplicon sizes for P-GS and PA-SS are 618 bp and 956 bp respectively (see Table 
20). PCR products were separated using agarose gel electrophoresis in a 1.2% gel and 
visualised using the gel documentation system. 
 
Specificity and sensitivity of these primer sequences were checked by a preliminary 
optimisation PCR using control strains of P. aeruginosa, S. maltophilia and B. cepacia. 
Both S. maltophilia and B. cepacia formerly belonged to the Pseudomonas genus and   
 114 
were chosen to ensure that the primers did not give a positive PCR reaction for these 
closely related species. 
Table 20: Pseudomonas spp. and Pseudomonas aeruginosa PCR Assay Conditions 
 
Pseudomonas Genus and Pseudomonas aeruginosa specific PCR conditions as 
described by Spilker et al (2004). 
 
2.12.2 Multiplex PCR of Pa-GS & Pa-SS Protocol 
A multiplex PCR protocol was developed and optimised using the primers from the 
Pseudomonas Genus-Specific PCR and P. aeruginosa Species-Specific protocols for 
simultaneous amplification of both loci according to “Multiplex PCR: Critical Parameters 
and Step-by-Step Protocol” (Henegariu et al., 1997). These modifications to the existing   
PCR Assay Primer 
Sequence 
5’-3’ 
Conditions 
No. of 
Cycles 
Product 
Size (bp) 
Pseudomonas 
Genus 
Specific 
PA-GS 
PA-GS-F –
GACGGGTGAGTAA
TGCCTA 
 
PA-GS-R – 
CACTGGTGTTCCTT
CCTATA 
Initial Denaturation (95
o
C, 
2 min) 
 
Denaturation (94
o
C, 20 
sec) 
Annealing (54
o
C, 20 sec) 
Extension (72
o
C, 40 sec) 
Final Extension (72
o
C, 1 
min) 
Hold (4
o
C, ∞) 
1 
 
All at 25 
cycles 
1 
1 
618 
Pseudomonas 
aeruginosa 
species-
specific 
PA-SS 
PA-SS-F - 
GGGGGATCTTCGG
ACCTCA 
 
PA-SS-R - 
TCCTTCGAGTGCC
CACCG 
Initial Denaturation (95
o
C, 
2 min) 
 
Denaturation (94
o
C, 20 
sec) 
Annealing (58
o
C, 20 sec) 
Extension (72
o
C, 40 sec) 
Final Extension (72
o
C, 1 
min) 
Hold (4
o
C, ∞) 
1 
 
All at 25 
cycles 
1 
1 
956 
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Spilker (2004) protocol included addition of DMSO at 2% and 5% and also a reduction 
of primer concentrations. 
 
2.12.3 PCR Assay for Stenotrophomonas maltophilia 
Species specific PCR of Stenotrophomonas maltophilia was performed using 23S 
rRNA-directed PCR as described by Whitby et al (2000), using the primers SM1 and 
SM4 (Whitby et al., 2000) (see Table 21 for details). This sequence was designed using 
regions of 23S rRNA specific to S. maltophilia in comparison to the 23S rRNA 
sequence of Burkholderia cepacia published by Hopfl et al (1989). In preliminary work 
using this primer sequence, strains from the type collection of S. maltophilia and 
B. cepacia were used for control purposes. 
 
Amplification of this region produces a 531 bp product. PCR products were separated 
using agarose gel electrophoresis in a 1.5% gel and visualised using the gel 
documentation system.  
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Table 21: PCR Conditions for species-specific Stenotrophomonas maltophilia PCR 
Assay 
 
PCR Assay Primer 
Sequence 
5’-3’ 
Conditions 
Number 
of 
Cycles 
Product 
Size 
(bp) 
S. 
maltophilia  
Species- 
Specific 
SM1  
&  
SM4 
 SM1  
CAGCCTGCGAAAAG
TA 
 
SM4     
TTAAGCTTGCCACG
AACAG 
Initial Denaturation (95
o
C,  
5 min) 
 
Denaturation (95
o
C, 10 sec) 
Annealing (58
o
C, 10 sec) 
Extension (72
o
C, 1 min) 
 
Final Extension (72
o
C, 2 min) 
Hold (4
o
C, ∞) 
1 
 
All at 30 
cycles 
 
 
1 
1 
531 
 
Stenotrophomonas maltophilia specific PCR conditions as described by Whitby et al 
(2000). 
 
2.13 PCR-based Typing of Study Isolates  
Two separate repetitive sequence-based PCR (rep-PCR) DNA fingerprinting 
techniques were used to examine the genetic relatedness of a selection of the target 
species isolated during the study. The methods selected were REP-PCR first described 
by Versalovic et al., (1991), and BOX-PCR as described by Koeuth et al.,(1995). The 
two sets of rep-PCR cycling conditions were chosen in accordance with Lin et al., 
(2008) (Table 22). Seven investigations were undertaken to compare a selection of the 
isolates from outlet swabs, water samples or patient specimens and are outlined in 
more detail in Table 36. 
 
Initial work used the conditions given in Table 22, but in order to optimize the two PCR 
techniques, a number of variables were examined including primer concentration,   
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DMSO incorporation, alterations to the annealing temperature and reproducibility 
check. 
 
Table 22.  Conditions for PCR-based Typing (Lin et al., 2008) 
 
PCR 
Assay 
Primer Sequence 
5’-3’ 
Conditions 
Number of 
Cycles 
BOX-
PCR 
5’-
CTACGGCAAGGCGACGCTGAC
G-3’ 
Initial denaturation: 95
o
C  7mins 
 
Denaturation: 94
 o
C 1 min, 
Annealing : 52
 o
C 1 min, 
Extension : 65
 o
C 8 min 
Final extension : 65
 o
C 16 min 
 
Hold 4
o
C, ∞ 
1 
 
 
All at 30 
cycles 
 
 
 
1 
REP-
PCR 
5’-IIIICGICGICATCIGGC-3’ 
5’-ICGICTTATCIGGCCTAC-3’ 
Initial denaturation: 95
o
C  2mins 
 
Denaturation : 92
 o
C 30 secs,  
Annealing : 40
 o
C 1 min, 
Extension : 65
 o
C 8 min 
Final extension : 65
 o
C 16 mins 
 
Hold 4
o
C, ∞ 
1 
 
 
All at 35 
cycles 
 
 
 
1 
 
 
2.14 Cluster Analysis of Genotyping Results 
Comparison of the resulting electrophoresis DNA fingerprint patterns of isolates was 
done using GelCompar II (version 6.5) software, (Bionumerics, Applied Maths, 
Belgium) to generate dendograms and similarity matrices. All electrophoresis gels were 
entered into and processed in Gelcompar. Gels were processed through the 
successive steps including defining lanes; assigning a reference system; normalisation   
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and band searching. Cluster analysis was done using DICE similarity coefficient and 
UPGMA. 
 
Both PCR techniques were first examined with GelCompar to assess reproducibility. A 
single isolate was repeatedly investigated by PCR and the similarity level identified 
using scaled optimisation and band tolerance functions. Instructions from GelCompar II 
Section 5.3.4 Optimisation of Similarity Coefficient Parameters were followed.  
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3. Results 
3.1 Bacterial Growth on R2A and Differential and Selective Media 
The following results were from different types of media: water recovery, general 
purpose and selective/differential media. 
 
3.1.1 Growth of Bacteria on R2A Media Following Membrane Filtration 
All colonies on the filter membranes were examined and average colony counts noted 
from each 100 mL water sample, after 48 hours incubation at 37oC. If <300 colonies, 
these were counted and the number recorded (Figure 21A). However, the majority of 
colonies were uncountable or the colonies were of a mucoid nature. When this 
happened, membranes were scored as semi-confluent or confluent growth (Figures 
21B & 21C). Representative colonies (two of each when discrete colonies were seen) 
were picked, using toothpicks, and patched onto the selective and differential media.  
  
Fig. 18a 
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Figure 21 A, B & C.  Water Filtration Membranes on R2A agar following 48 hours incubation at 
37oC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 21C: Confluent  
Confluent growth and 
specks of silt also 
collected from the water 
sample. 
Figure 21A: Countable 
(i.e. <300) 
From this membrane a 
number of morphotypes 
can be seen. Two 
colonies representative of 
each morphotype were 
then selected for further 
investigation on selective 
plates. 
Figure 21B: Too many to 
count  
Growth observed during 
the study as too many to 
count. Two morphotypes 
can be seen: 1). <1mm 
dark yellow colonies, 2). 
4-5mm mucoid yellow 
colonies.  
A 
C 
B 
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3.1.2 Growth of Bacterial Species on MacConkey Agar 
This medium was used as an aid to select Gram negative bacteria and differentiate 
between lactose and non-lactose fermenting phenotypes associated with the study 
target species (TS). 
 
This medium was particularly useful for the isolation of TS from swabs of water outlets 
and patients. On occasion, P. aeruginosa was not isolated from the swab plated on Ps-
Cet agar but a single colony could be found on the MacConkey agar. This was then 
sub-cultured onto Ps-Cet where growth was strong and of the morphology typical of 
P. aeruginosa. 
 
Also, when a non-lactose fermenting colony was evident on MacConkey agar it was 
sub-cultured onto both VIA and LAM. On occasion this would also lead to the isolation 
of a potential target species following characteristic growth on the respective media. 
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3.1.3 Pseudomonas species on Pseudomonas Cetrimide (Ps-Cet) Agar 
Growth of putative P. aeruginosa isolates on this medium was frequent from water 
samples and outlet swabs. It was also used to isolate the species from patients. The 
appearance of bacterial growth on this media was varied, colonies showed a range of 
green pigmentation from a lime green to a deep turquoise, which, on further 
investigation (species-specific PCR) were identified as P. aeruginosa. On rare 
occasions discrete, small, circular white colonies were also seen. Identification of these 
colonies using API 20 NE strips, revealed P. putida or P. fluorescens. Colonies of this 
type were not processed further. Pigment producing colonies were selected and 
subcultured onto TSA and stored at -70oC for examination later. 
 
Figure 22. Pseudomonas aeruginosa on Pseudomonas Cetrimide Agar 
 
 
 
 
 
 
 
P. aeruginosa grown on Pseudomonas Cetrimide agar showing a colour change in the 
medium as a result of pyocyanin production. 
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3.1.4 Stenotrophomonas maltophilia on Vancomycin-Imipenem-Amphotericin B 
(VIA) Agar 
 
VIA was designed as a selective and differential media for S. maltophilia (Kerr et al, 
1996) and throughout this study gave consistent results. It was observed that the 
colonial appearance of S. maltophilia can vary, but most often the colonies were 
colourless/pale blue in appearance and approximately 1-2 mm in diameter. Other 
appearances included a more yellow colour or colourless/pale blue with a dot in the 
centre. Regardless of appearance, all of these morphologies were confirmed as 
S. maltophilia using species-specific PCR as described by Whitby et al; (2001), see 
section 2.12.3. 
 
Figure 23.  Stenotrophomonas maltophilia on VIA agar 
 
 
 
 
 
 
 
S. maltophilia grown on VIA agar showing a colour change indicative of growth of the 
species  
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3.1.5 Acinetobacter baumannii on Leeds Acinetobacter Media (LAM) 
LAM was designed as a selective and differential medium for the detection of 
A. baumannii, but does allow the growth of some other bacteria. As reported by Jawad 
et al; (1994) other bacteria such as S. maltophilia and B. cepacia also give the same 
appearance and colour change as A. baumannii. This observation was also made 
during the current study with numerous morphologies seen. The more frequently 
observed morphotype had a yellow/orange colouration but the characteristic 
pink/mauve of A. baumannii was also seen. However, further analysis showed that 
A. baumannii was not recovered from any source. Identification of the other isolates 
from LAM is described in section 3.1.5.1. 
 
Figure 24. Acinetobacter baumannii on LAM agar 
 
 
 
 
 
 
 
The distinctive colour change in the medium can be seen from the uninoculated plate 
(left) in contrast to the plate with A. baumannii growth (right). 
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3.1.5.1 Investigation of Isolates from LAM  
During the study many isolates had the appearance of A. baumannii on LAM and were 
stored for further analysis as presumptive A. baumannii. Other colony types were also 
observed: a number of bacteria caused no colour change to the media and had varied 
colony appearances, including yellow, white and orange (further described in Table 23). 
A wide variety of bacterial genera and species were identified using the API 20 NE 
system, the success of the identifications were variable, with results ranging from 
“unacceptable profile”, “low discrimination” to “excellent identification”. Overall, the 
results confirmed that no A. baumannii had been recovered from the water and swab 
samples. 
 
Table 23. Examples of Colony Characteristics of Bacterial Growth on LAM  
 
Colony and media 
appearance on LAM 
Sample Isolated 
from 
Oxidase 
reaction 
Identification by 
API 20 NE 
Pink colonies with mauve media 
Change 
Water Negative 
Stenotrophomonas 
maltophilia 
Pink colonies with mauve media 
Change 
Throat swab Positive Burkholderia cepacia 
Yellow colonies, no colour 
change 
Water 
 
Swabs of outlets 
Positive 
Chryseobacterium 
indologenes 
Flavimonas oryzihabitans 
White colonies, occasional 
colour change 
Throat Swabs Negative 
Vibrio parahaemolyticus 
Chryseomonas luteola 
Orange colonies, no colour 
change 
Swabs of outlets Positive 
Chryseobacterium 
indologenes 
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3.1.6 Function of Gridded Plates 
The use of gridded plates enabled many colonies from water sample filter membranes 
to be processed at one time, making this method very efficient for this study. Each 
square of the gridded plate was used for one colony or a small area of a confluent plate 
and could be referenced back to the original water sample. When a streak on a gridded 
plate gave a TS morphology and representative media change, a second subculture 
was made for single colonies for storage and further investigation. 
 
Figure 25. Patching of colonies from R2A onto a gridded plate  
 
 
 
 
 
 
 
Gridded plate of Pseudomonas Cetrimide agar following incubation. Squares with no 
growth show how effectively the agar suppresses growth of other species. Squares with 
pigmented growth were then subcultured for single colonies on a second Ps-Cet plate. 
  
 127 
3.2 Alterations to Outlets of Ward 7 
The planned start and completion dates for the alterations to be made to the outlets of 
the Annette Fox Haematology Unit were 19th November 2007 – 5th December 2007. 
Unfortunately this was significantly delayed by a number of events. The first delay 
occurred due to an outbreak of norovirus on the ward which made the start of 
refurbishment impossible. Work finally commenced on 7th January 2008, however, 
several difficulties were encountered. 
 
As a decant facility was not available, the alterations could only be carried out one 
room at a time when not occupied by a patient. The availability of rooms was 
dependent on the in-patient activity of the ward and the need for urgent admissions and 
planned chemotherapy treatments which restricted the work program on occasion. 
Once the work had been completed, further procedures involving mechanical and 
electrical contractors, deep clean teams and infection control members were required 
before the room could be reopened for patient occupancy. 
 
Further delays were caused by the new tap outlets in the patient rooms were felt to be 
unsuitable as they were too high and caused considerable splashing around the sink 
area. As a result these taps were replaced with more appropriate ones, sited at a lower 
level.  
 
The bath outlet for Room 1 was never altered and so throughout the study the old tap 
remained and was not able to have filters attached. A further refurbishment problem   
 128 
occurred with the sink taps in the kitchen. The old outlets (individual hot and cold taps) 
were replaced with a mixer tap, this proved unsuitable for the ward as the temperature 
could not be properly controlled and cold water was unavailable for patient drinking 
water. Therefore, the original taps were reinstated (prior to commencement of the 
study) and replaced at a later date [week 12 of Phase 1] with new, separate hot and 
cold taps. 
 
3.3 Water Sampling on Ward 7 
Following plumbing alterations, there was a 7 week period of water sampling to 
establish the baseline numbers of bacteria and to allow for the establishment of a 
workable water sampling protocol for the 37 ward outlets (Figure 13). 
 
The main water sampling study period was June 2008 - April 2010 and alternated 
between unfiltered water samples and point-of-use filtration (Pall AquasafeTM filters). 
Phases 1 and 2 both lasted for 6 months while phases 3 and 4 were reduced to 4 
months each, meaning that there were fewer samples taken in the last two phases 
(Table 24). 
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Table 24: Dates of Study Phases 
 
 Alterations 
to ward 
plumbing 
Baseline Phase 1 Phase 2 Phase 3 Phase 4 
Filtration 
status 
Unfiltered Unfiltered Unfiltered Filtered Unfiltered Filtered 
Dates 
 
January - 
April 2008 
 
April - 
June 2008 
 
June 2008 - 
January 
2009 
 
January - 
June 2009 
 
July - 
November 
2009 
 
November 
2009 – April 
2010 
Time span 3 months 7 weeks 6 months 6 months 4 months 4 months 
No. of 
water 
samples 
0 188 786 629 610 613 
 
 
3.3.1 Establishment of Baseline Microbial Load and Operational Protocol 
 
A total of 188 water samples (95 proximal, 93 distal) were collected with 185 (98.4%) 
yielding bacterial growth. The membranes with bacterial growth had on average, too 
many colonies to count or were confluent. 
 
Before taking water samples, swabs of the outlets were collected. In total, 95 swabs 
were taken and 80 (84.2%) of these yielded growth on MacConkey agar with the 
remaining 15 swabs yielding no growth. Ten separate samples yielded presumptive 
P. aeruginosa on Ps-Cet agar.  
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From the investigation to establish baseline numbers from water samples and outlet 
swabs it was anticipated that very high numbers of future water samples would be 
positive for bacterial growth with a high density of bacterial numbers. It was also 
anticipated that there would be high recovery of bacteria from outlet swabs. 
 
From this it was possible to put procedures in place for the operational protocol of the 
study. It was decided that the kitchen outlets would be sampled weekly, and half of the 
patient rooms would be sampled every other week on rotation. Water samples were 
collected from 0900 on Mondays and Tuesdays and taken immediately for processing 
at the University laboratories. 
 
A total of 1395 swabs (tap and shower) were collected along with 2826 water samples 
These comprised a sample collected on immediate opening of the outlet (proximal 
water sample) plus a second sample collected following a 2 – 3 minute flush (distal 
water sample). 
 
Sporadic issues surrounding the collection of samples to strict study protocol included: 
no access to a scheduled room (e.g. due to treatment being given) or an outlet already 
being used (therefore no proximal sample available). On other occasions no distal 
sample was collected if patients, visitors or ward staff requested the room to be 
vacated.  
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3.3.2 Phase 1 & 3 - Unfiltered Water Samples 
Phase 1 began on 16th June 2008 as the first six month unfiltered phase. A total of 
1396 water samples (proximal and distal) were collected during Phases 1 & 3. In total, 
1379 samples yielded bacterial growth (98.8%) and >90% of membranes had too many 
colonies to count. Of the three target species only P. aeruginosa and S. maltophilia 
were identified. Presumptive A. baumannii were examined further but were found to be 
other species (see 3.1.5.1). The remaining two target species were isolated individually 
from 300 (21.5%) of the water samples. However, on a further 11 occasions, 
P. aeruginosa and S. maltophilia were isolated from the same water sample meaning 
that the total isolation occasions was 322 (23.1%) with P. aeruginosa isolated 190 times 
and S. maltophilia 132 times (Table 25, Figure 26). 
 
The overall recovery of these two species was notably different between the two 
unfiltered phases; Phase 1 saw the one or both target species recovered on a total of 
222 (28.3%) occasions compared with recovery in Phase 3 of only 100 (16.4%). A 
significant difference between the two phases was the isolation of P. aeruginosa from 
water samples; Phase 1 yielded P. aeruginosa from 18% of water samples in contrast 
to only 8.2% from Phase 3. Isolation of S. maltophilia was also seen to drop in Phase 3 
with 10.7% of samples in Phase 1 positive for the target species but only 8.2% in 
Phase 3 (Table 25).  
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Table 25.  Recovery of Target Species during Unfiltered Phases of Study  
 
Phase 
Total Water 
Samples 
(proximal & distal) 
Total 
Positive 
Growth 
Total water 
samples positive 
for 
P. aeruginosa 
Total water 
samples positive 
for 
S. maltophilia 
1 
(six months) 
786 
776 
(98.7%) 
140 
(18%) 
82 
(10.7%) 
3 
(four months) 
610 
603 
(98.9%) 
50 
(8.2%) 
50 
(8.2%) 
Total 1396 
1379 
(98.8%) 
190 
(13.6%) 
132 
(9.5%) 
 
 
Using the Fishers Exact Test there was a significant association between Phases 1 & 3 
and a sample yielding P. aeruginosa (P= <0.001) and therefore the reduction in 
recovery seen in Phase 3 was significant. This is contrast to the recovery of 
S. maltophilia (P= 0.167) shows that the reduced recovery seen in Phase 3 was not 
significantly different from Phase 1. 
 
Overall, the isolation of P. aeruginosa from water samples was more frequent than 
isolation of S. maltophilia by sampling occasion (not sub-divided in this instance into 
proximal and distal isolation). P. aeruginosa was isolated 158 times in contrast to 
S. maltophilia which was isolated 110 times. Several outlets were consistently negative 
for both species.  
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3.3.3 Isolation of Target Species from Outlet Swabs During Unfiltered Phases 
 
A total of 720 swabs were taken from the outlets immediately before collection of water 
samples. Of these, a total of 444 (61.7%) yielded bacterial growth and 70 (9.7%) were 
positive for a target species. On four occasions a single swab yielded P. aeruginosa 
and S. maltophilia taking the total of target species recovery to 74 (Table 26). Recovery 
of target species by outlet swab is shown in Figure 26. 
 
Isolation of a target species from an outlet swab was often indicative that this outlet was 
also a “hotzone” for this species. For both P. aeruginosa and S. maltophilia, isolation by 
swab, without isolation from the water sample, was frequently from an outlet that was a 
regular source of that species. On only 13 (S. maltophilia) and 9 (P. aeruginosa) 
occasions, were these bacteria isolated from swabs but not the concomitant water 
sample (Figures 27 and 28). 
 
Table 26.  Collection of Outlet Swabs and Isolation of Target Species   
 
Phase 
Total 
outlet 
swabs 
Total 
positive 
for 
growth 
Total 
swabs 
positive for 
P. 
aeruginosa 
Total 
swabs 
positive for 
S. 
maltophilia 
Total 
isolation 
of TS 
Isolation of 
TS from 
swab only 
Isolation of 
TS from 
swab and 
water 
1 
 (six 
months) 
406 
313 
(77.1%) 
19 
(4.7%) 
23 
(5.7%) 
42 
15 
(3.7%) 
27 
(6.7%) 
3 
 (four 
months) 
314 
131 
(41.7%) 
16 
(5.1%) 
16 
(5.1%) 
32 
7 
(2.2%) 
25 
(8%) 
Total 
 
720 
444 
(61.7%) 
35 
(4.9%) 
39 
(5.4%) 
74 
22 
(3.1%) 
52 
(7.2%) 
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Key to Outlet Types for Figures 26, 27 and 28 
Outlet A: (e.g. 2A) = Handwash station inside a patient room 
Outlet B: (e.g. 2B) = Wash basin outlet of an en suite patient bathroom 
Outlet C: (e.g. 2C) = Shower of an en suite patient bathroom 
HWS: = Handwash station of kitchen or handwash station located in the central corridor 
outside Room 5 [HWS(5)] 
NS: = Nurses station handwash sink located centrally on Ward 7 
Drug Prep: = Outlet located inside the drug preparation clinic  
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Figure 26. Isolation of target species from the outlets of Ward 7 during Phase 1 and Phase 3 
Phase 2 
6  
months
Phase 4 
4 
months
Outlet/Week No. 1 2 3 4 5 7 8 10 12 13 14 15 17 18 19 20 21 22 23 25 26 30 1 2 4 6 7 8 9 10 11 12 15 16 17 18 19 20
Kitchen Hot
Kitchen Cold S S
HWS S
Drug Prep
NS
1A
1 B
1 Bath
2A S
2 B S
 2 C S S S S S S S S S S
3A S S
3 B S S S S
3 C S S S
4A S S S S
4 B S
4 C S
5 B
HWS (5)
6A S S S
6 B
6 C S S S
7A S S S
7 B
7 C S S S S S S S S S
8A
8 B S
 8 C S S S
9A
9 B S
9 C
10A
10 B
10 C S S S S S
11A S S
11 B S
11 C S S
12A S S
12 B S
12 C
Phase 1 Phase 3
Graph 6. Frequency of Isolation of both target organisms, alone or together, from the Outlets of Ward 7 during Phase 1 and  
Phase 3 
    
= Sample taken, 
    no TS 
= P. aeruginosa 
isolated alone 
= S. maltophilia 
isolated alone 
= Both TS isolated   S = One or both TS 
isolated from an 
outlet swab 
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3.3.4 Isolation of Individual Target Species and Location of “Hotzones” 
During the unfiltered phases it became apparent that patterns were emerging, i.e. some 
outlets were more persistently associated with either species than others; these outlets 
are referred to as “hotzones”. For example, the shower of Room 7 was a persistent 
source of S. maltophilia and the handwash station in the kitchen was a persistent 
source of P. aeruginosa during phase 1 (Figures 27 and 28). 
 
Figure 27 shows that S. maltophilia was isolated from numerous outlets during the 
course of the two unfiltered water sampling phases. Certain outlets were consistently 
negative for S. maltophilia and whilst others were “hotzones”. The shower outlet of 
Room 2 was a persistent source in both phases as were the two tap outlets (outlets A & 
B) of Room 7. The shower of Room 7 and outlet B of Room 9 were persistent sources 
during Phase 1 but not in Phase 3. Neither of the handwash stations located in the 
kitchen and corridor yielded S. maltophilia along with the outlets of Room 8. It should 
also be noted that the showers of Ward 7 were often the source of S. maltophilia. 
 
From a total of 1396 (proximal plus distal) water samples taken during the unfiltered 
phases, S. maltophilia was isolated from 132 (9.5%). The samples from Room 7 
(outlets 7A, 7B and 7C) provided 49 of these positive results, accounting for 37.1% of 
all S. maltophilia isolations, on this basis Room 7 was designated as a S. maltophilia 
“hotzone”. The shower of Room 2 (outlet 2C) provided another 15 positive samples, 
accounting for a further 11.4% of the overall recoveries. In total these four outlets from 
two rooms gave 48.5% of all the positive samples.  
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Stenotrophomonas maltophilia was isolated by outlet swabbing on 39 occasions, 26 of 
these were collected with concomitant isolation from water samples and on 13 
occasions S. maltophilia was isolated from a swab with no isolation from the 
corresponding water sample. While the majority of these lone swab isolates were from 
outlets where S. maltophilia recovery had been observed at other times, three were 
collected from an outlet or, indeed, the room itself, where water isolation was not 
observed at any time (outlet 2A and 8B from Phase 1 and outlet 4C from Phase 3). Of 
all the S. maltophilia isolates recovered by outlet swabbing, 77% were collected from 
shower outlets. 
 
Figure 28 shows that P. aeruginosa was isolated from numerous outlets during the 
course of the two unfiltered water sampling phases. As with S. maltophilia, a number of 
outlets were a persistent source of P. aeruginosa while others were persistently 
negative. Outlets considered to be “hotzones” for P. aeruginosa isolation included the 
handwash station in the kitchen during Phase 1 (but not in Phase 3) and outlet A of 
Room 4. 
 
Pseudomonas aeruginosa was isolated from 190 samples (13.6%). A further 35 
P. aeruginosa were isolated from outlet swabs. This was similar to the isolation of 
S. maltophilia from outlet swabs with the larger proportion then also positive for 
recovery from the concomitant water sample. Only nine were isolated from swabs alone 
without isolation from the concomitant water sample, three of which came from an outlet   
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(and room) where P. aeruginosa was not isolated (Outlets 4B and 6C during Phase 1 
and 12B in Phase 3), see Figure 28.  
 
In contrast to S. maltophilia, P. aeruginosa isolates recovered from outlet swabs were 
collected from showers on 37.1% of occasions (in comparison to 77% of S. maltophilia) 
this figure was the same for outlet type A. Recovery by swabbing from outlet type B was 
20%.
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Figure 27. Isolation and Location of S. maltophilia from the Outlets of Ward 7 during unfiltered Phases  
Phase 2 
6 months
Phase 4 
4 months
Outlet/Week No. 1 2 3 4 5 7 8 10 12 13 14 15 17 18 19 20 21 22 23 25 26 30
% Positive 
(Water 
samples)
1 2 4 6 7 8 9 10 11 12 15 16 17 18 19 20
% Positive 
(Water 
samples)
Kitchen Hot 0 0
Kitchen Cold 0 s 6
HWS 0 0
Drug Prep 0
NS 0
1A 18 25
1 B 0 0
1 Bath 9 0
2A S 0 0
2 B 18 s 25
 2 C S S S 54 s s s s s s 63
3A 0 0
3 B 0 0
3 C 36 s s 50
4A 0 13
4 B 0 0
4 C 20 s 0
5 B 11 17
HWS (5) 0 0
6A 9 0
6 B 27 33
6 C S S 36 0
7A S S S 67 71
7 B S 75 71
7 C S S S S S S S S S 75 29
8A 0 0
8 B S 0 0
 8 C 0 0
9A 33 0
9 B S 63 17
9 C 43 s s s 50
10A 0 0
10 B 0 17
10 C 27 s s 33
11A 22 0
11 B S 11 0
11 C S 22 14
12A 0 0
12 B 0 0
12 C 0 29
Phase 1 Phase 3 
= Water sample negative for 
S. maltophilia 
= S. maltophilia isolated S = S. maltophilia 
recovered from outlet swab 
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Figure 28. Isolation and location of P. aeruginosa from the Outlets of Ward 7 during unfiltered Phases 
Phase 2 
6  months
Phase 4 
4 months
Outlet/Week No. 1 2 3 4 5 7 8 10 12 13 14 15 17 18 19 20 21 22 23 25 26 30
% Positive 
(Water 
samples)
1 2 4 6 7 8 9 10 11 12 15 16 17 18 19 20
% Positive 
(Water 
samples)
Kitchen Hot 0 0
Kitchen Cold 14 S 13
HWS 68 S 12
Drug Prep 0
NS 0
1A 36 13
1 B 0 0
1 Bath 9 0
2A 0 0
2 B 9 13
 2 C S 18 S S S 25
3A 20 S S 25
3 B S S S S 80 38
3 C S 13 13
4A 60 S S S S 63
4 B S 0 0
4 C 10 0
5 B 22 17
HWS (5) 56 0
6A 36 S S S 50
6 B 73 67
6 C S 0 0
7A 33 14
7 B 17 0
7 C 0 0
8A 58 29
8 B 0 0
 8 C S S S 17 20
9A 44 0
9 B 50 67
9 C 0 17
10A 18 0
10 B 82 50
10 C S S S 18 0
11A S S 89 33
11 B S 11 0
11 C S 11 0
12A S 63 S 29
12 B 0 S 0
12 C 0 0
Phase 1 Phase 3
= Water sample negative 
for P. aeruginosa 
= P. aeruginosa isolated S = P. aeruginosa recovered 
from outlet swab 
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3.3.5 Isolation of Target Species from Water Sample by Outlet Type  
During the study it became apparent that particular target species were more frequently 
isolated from a certain type of water outlet. P. aeruginosa was associated with isolation 
from the handwash stations located in the kitchen, central corridor (identified in the 
following graphs collectively as ‘HWS’) or patient rooms (Outlet type A) on 40% and 
34% of occasions respectively in contrast to S. maltophilia isolation from these outlets 
at 0% and 13% respectively, (Figure 29). 
 
Isolation of S. maltophilia was more often from patient rooms with no recovery of the 
species from the kitchen handwash stations in the kitchen and corridor. Recovery from 
the kitchen tap outlets and bath in Room 1 occurred only once from each. Patient room 
outlets yielded: Outlet type A (13%); Outlet type B (16%) and the showers (outlet type 
C) 31%. The high frequency of recovery of S. maltophilia from showers is in contrast to 
frequency of isolation of P. aeruginosa which was much lower at only 9%. 
  
  
 
142 
Figure 29.  Isolation of target species from water by outlet type during the unfiltered phases 
 
 
 
 
3.3.6 Isolation of target species from proximal versus distal water samples during 
unfiltered phases 
 
On the occasions where a target species was isolated from a single water sample (i.e. 
proximal or distal), isolation was more commonly from the proximal samples, 56% of 
isolations came from this type of water sample alone. This was the same for both 
P. aeruginosa and S. maltophilia and was in contrast to isolation from distal samples   
(1.5%) 
(7.7%) 
(40%) 
(0%) (5.3%) 
(5.3%) 
(12.6%) 
(33.7%) 
(16.1%) 
(24.9%) (30.7%) 
(9.0%) 
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alone, which only provided 6% of samples positive for recovery of target species. 
However, target species were isolated from both the proximal and distal samples on a 
further 38% of occasions suggesting that colonisation of the water outlet was not limited 
only to the final section of distribution system before the outlet but also further back in to 
the distribution system (Figure 30). 
 
Figure 30. Distribution of TS from Proximal, Distal or both types of water sample 
 
 
 
  
Proximal only: 
56% 
Distal  
6% 
Both 
38% 
Proximal only: 
182 
 
Distal only: 
18 
 
Both: 
122 
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3.4 Phases 2 & 4 – Filtered Water Samples 
During Phases 2 and 4; Pall AquasafeTM filters were placed on almost all the outlets of 
ward 7 and water samples and swabs were collected in the same manner as for 
Phases 1 and 3. Three outlets were not able to have filters installed. Firstly, the bath 
outlet of Room 1 was never altered as suitable fittings were not available. A further two 
outlets were added to the study on request of the nursing staff. A hand-wash station 
situated behind the nurses’ station which was unused was added on week 5 of Phase 
2. The drug preparation clinic was also added to the study at the start of Phase 3. In 
effect these outlets operated as controls during Phases 2 & 4 and showed that high 
bacterial numbers were still present in the water distribution system during the filtered 
phases (see section 3.4.2). It is also of note that on arrival on Ward 7 at the beginning 
of Week 24, Phase 2, the filtered shower heads in Rooms 6 – 12 had been replaced by 
BRI Estates before the agreed dates. However, the tap outlets of those rooms had not 
been removed. 
 
3.4.1. Bacterial Growth from Filtered Samples  
From 1242 filtered water samples (690 proximal, 683 distal), 278 (22.38%) were 
positive for bacterial growth. There was a substantial reduction in numbers of positive 
water samples and also in the average CFU/100 mL. Only 22% of water samples 
yielded bacterial growth in the filtered phases in contrast to 98% from Phases 1 & 3. 
Average colony counts were reduced from uncountable numbers to 4.6 CFU/100 mL 
with a median CFU count of 1 and a range of 1 - 150.  
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A total of 20 water samples from filtered outlets produced colonies which were too 
numerous to count. On one occasion both proximal and distal water samples (Outlet B 
of Room 7, week 1, Phase 2) yielded bacterial growth with colonies too many to count. 
Seven of the 20 produced colonies which were too numerous to count from the 
proximal water sample and a positive result from the concomitant distal sample. 
However, from the distal samples the colony counts were significantly lower (1 – 11 
CFU/100 mL). The remaining 11 samples yielded colonies which were too numerous to 
count from one of the water samples but yielded no growth from the concomitant 
sample. 
 
S. maltophilia was the only target species isolated during these two phases and this 
occurred in week 24 of Phase 2 from the water sample of the hand-wash station in the 
kitchen (Table 27). There was no recovery of P. aeruginosa from any sample during 
Phases 2 & 4. 
 
Table 27. Collection of Water Samples during Filtered Phases, Bacterial Growth and 
Isolation of Target Species 
 
Phase 
Total 
water 
samples 
(proximal 
& 
distal) 
Total 
positive 
for 
growth 
Number of 
membranes 
with 
uncountable 
growth 
Average 
colony 
count on 
countable 
membranes 
Total water 
samples +ve 
for P. 
aeruginosa 
Total water 
samples +ve 
for S. 
maltophilia 
2  
(6 months) 
629 
127 
(20%) 
13 6.26 0 
1  
(0.16%) 
4 
(4 months) 
613 
151 
(25%) 
7 2.76 0 0 
Total 1242 
278 
(22%) 
20 4.6 0 
1 
(0.08%) 
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On twelve occasions bacteria from water samples grew on the selective media VIA, 
LAM or Pseudomonas Cetrimide agar, but only one of these was a target species 
(S. maltophilia), see Table 28. 
 
Swabs of the filter housing were collected before the collection of water samples and 
580 swabs were collected in the filtered phases. Of these, 141 (24.3%) yielded growth 
on MacConkey agar but only two produced growth on selective media, neither of these 
was a target species (Table 28). 
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Table 28. Growth on selective media from filtered outlets during Phases 2 & 4 
 
Phase Source 
Description of 
growth 
Further Identification 
2 
Week 3 
Room 11, Outlet B, 
Proximal sample 
Yellow on LAM 
API – Flavimonas oryzihabitans 
(99.8%) 
Week 4 
Room 2, Outlet B, 
Proximal sample 
Pink on LAM API – Ralstonia pickettii (99.7%) 
Week 13, Swab of hot tap, 
Kitchen, 
VIA 
API – Sphingomonas 
paucimobilis (81.1%) 
Week 11, 
Room 7, Outlet C, 
Proximal sample 
Pseudomonas 
Cetrimide 
Negative for P. aeruginosa by 
species-specific PCR.  
API – P. putida (99.6%) 
Week 14, 
Room 4, Outlet C, 
Proximal sample 
Pink on LAM 
API – Comamonas acidovorans 
(99.3%) 
Week 24 
HWS, Proximal sample 
VIA 
Positive for S. maltophilia by 
species-specific PCR 
4 
Week 7, 
Room 10, Outlet B, 
Proximal sample 
Colourless 
mucoid on LAM 
API – Doubtful profile 
Week 15, Swab of Room 9, 
outlet C  
White on LAM API – Unacceptable Profile 
Week 15, 
Room 6, Outlet A, 
Proximal sample 
Yellow on LAM 
API – Chryseobacterium 
indologenes (95.1%) 
Week 16, 
Room 3, Outlet A, 
Proximal sample 
White on LAM Gram positive 
Week 18, 
Room 11, Outlet B, 
Distal sample 
Yellow on LAM Gram positive 
Week 20, 
Room 12, Outlet C, 
Proximal sample 
Orange on LAM Gram positive 
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3.4.2 Isolation of Target Species from Filtered Outlets during Phases 2 & 4 
 
From unfiltered outlets, S. maltophilia was the only target species recovered from an 
outlet swab or water sample. The bacterium was isolated from the unfiltered proximal 
water samples of the bath in Room 1 in weeks 4, 7 (also the outlet swab) and 15; the 
proximal water sample from the shower in Room 12 and the swab of the shower in 
Room 9. All these occurred in Phase 2, no target species were isolated during Phase 4 
(Figure 32). 
 
 
  
 
149 
          Figure 31. Isolation and location of Target Species during the Filtered Phases 
 
 
Phase 1 Phase 3
Outlet/Week No.
6 
months 1 2 3 4 5 7 8 11 12 13 14 15 16 17 18 20 22 23 24 25
4 
months 1 2 3 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Kitchen Hot
Kitchen Cold
HWS
Drug Prep (unfiltered)
NS (unfiltered)
1A
1B
1C (unfiltered)
2A
2B
2C
3A
3B
3C
4A
4B
4C
5B
HWS (5)
6A
6B
6C
7A
7B
7C
8A
8B
8C
9A
9B
9C
10A
10B
10C
11A
11B
11C
12A
12B
12C
Phase 2 Phase 4
 = Filtered Sample, no TS    = Filtered Sample S. maltophilia isolated  
  
 
150 
   Figure 32. Recovery of Target Species from Unfiltered Outlets during Filtered Phases 
Phase 1 Phase 3
Outlet/Week No. 6 months 1 2 3 4 5 7 8 11 12 13 14 15 16 17 18 20 22 23 24 25 4 months 1 2 3 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Kitchen Hot
Kitchen Cold
HWS
Drug Prep (unfiltered)
NS (unfiltered)
1A
1 B
1 Bath (unfiltered) S
2A
2 B
 2 C
3A
3 B
3 C
4A
4 B
4 C
5 B
HWS (5)
6A
6 B
6 C
7A
7 B
7 C
8A
8 B
 8 C
9A
9 B
9 C S
10A
10 B
10 C
11A
11 B
11 C
12A
12 B
12 C
Phase 2 Phase 4
 = unfiltered Sample, no TS   = S. maltophilia from 
unfiltered Sample, 
 S. maltophilia 
isolated  
S = Isolation of S. maltophilia 
from outlet swabs 
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3.4.3 Bacterial Growth from Proximal versus Distal Water Samples from Filtered 
Outlets 
 
The recovery of bacteria from filtered outlets came from 51% of proximal water sample 
with no recovery from the concomitant distal sample. This is in contrast to recovery from 
the distal sample alone (22%) without recovery from the accompanying proximal 
sample. A further 27% of positive samples came from the proximal and distal sample 
from an outlet (Figure 33). 
 
Figure 33. Bacterial Isolation from proximal and distal water samples from filtered outlets 
during Phase 2 & 4 
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3.5 Patient Recruitment on Ward 7  
The first patient (Patient P.001) consented to join the study and the first samples were 
taken on 14th June 2008. After this, a further 19 patients gave their consent (Table 29). 
Patient recruitment for the study proved more difficult than anticipated with many 
patients declining the invitation to join. One particular area of concern was the provision 
of faecal samples with many patients feeling “too embarrassed” to give these. In this 
circumstance, it was agreed that the patient could give just the throat and axillae 
samples if it would ensure their consent to join the study. 
 
Patients, whenever possible, consented to samples being taken upon admission and 
weekly thereafter, while resident on Ward 7. Some patients were recruited to the study 
after their initial admission and so the first sample collected after this. Faecal samples 
were very infrequent (see Appendix 4 for details of individual patient sample data). 
Whenever possible patient room occupancy was recorded to allow correlation with tap 
and water isolates. Only three patients (P.004; P.013 and P.014) became colonised or 
infected with a target species during the study. These isolates were then subjected to 
further analysis. 
 
The average age of study patients was 50 (range of 29 – 71). The ratio of males: 
females was even (10 of each). Table 29 gives details of the patients, three of whom 
were of further interest are discussed in sections 3.5.1 - 3.5.3. 
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Table 29. Summary of Patients recruited into the study 
 
Patient 
Age 
(years) 
Sex Dates in study 
No. of 
sampling 
occasions 
Recovery of 
Target Species 
P.001 48 M 
June - December 
2008 
13 None 
P.002 38 F 
July 2008 – 
February 2009 
12 None 
P.003 30 M 
September - 
November 2008 
8 None 
P.004 58 M 
September - 
October 2008 
8 P. aeruginosa 
P.005 62 M 
October 2008 – 
March 2009 
8 None 
P.006 58 F 
November 2008 – 
May 2010 
20 None 
P.007 Unknown F February 2009 1 None 
P.008 69 F 
February - March 
2009 
4 None 
P.009 66 M 
March - June 
2009 
8 None 
P.010 59 M June 2009 2 None 
P.011 51 F 
June - September 
2009 
8 None 
P.012 71 F August 2009 2 None 
P.013 51 F 
September - 
December 2009 
8 S. maltophilia 
P.014 60 F September 2009 2 S. maltophilia 
P.015 62 M 
October 2009 – 
June 2010 
23 None 
P.016 58 M 
November 2009 – 
June 2010 
8 None 
P.017 48 M March 2010 1 None 
P.018 47 M April - June 2010 6 None 
P.019 45 F April - June 2010 8 None 
P.020 29 F April - June 2010 5 None 
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3.5.1 Patient P.004 
Patient P. 004 was a 58 year old male with a diagnosis of acute myeloid leukaemia 
(AML). His first admission to Ward 7 was 11th August 2008 and discharge was on 28th 
October 2008. The first samples were collected on 4th September 2008 (Week 12 of 
Phase 1). However, this patient’s treatment had already commenced and he was in 
receipt of antibiotics (meropenem and gentamicin from 30th August – 8th September 
2008). This patient was reported as bacteraemic with P. aeruginosa on 28th September 
2008 (week 15). 
 
Pseudomonas aeruginosa was isolated from P.004 from the first samples taken for the 
study (throat swab and faeces sample). All isolates collected from this patient from this 
point were confirmed by species-specific PCR and tested for antibiotic susceptibilities. 
Faecal isolate (N. 425); throat isolate (N. 426), recovered on week 12 (4th September 
2008), and the blood culture isolate supplied by the BRI (sample taken on 2nd October) 
all displayed intermediate resistance to imipenem. Only one isolate displayed 
resistance to any of the antibiotics tested: a throat isolate N. 509 (recovered week 14, 
18th September 2008) which was resistant to imipenem and also exhibited intermediate 
resistance to aztreonam. Further isolates were recovered from this patient on weeks 
15, 17, 19 and 20 (all throat) but displayed only intermediate resistance to aztreonam 
and were susceptible to imipenem. However, the antibiotic susceptibilities of the blood 
culture isolate N.637 (sample collected week 16) was reported by the BRI microbiology 
laboratory as resistant to meropenem and imipenem and intermediately-resistant to 
imipenem when tested by disc diffusion (Table 30 and 33). 
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The antibiotic treatment history of the patient is summarised here: 
 
30.08. 2008 – 08.09.2008 meropenem, gentamicin 
28.09.2008  piperacillin/tazobactam, gentamicin (one day, changed to 
meropenem) 
02.10.–06.10.2008  meropenem changed to ceftazidime, gentamicin, 
metronidazole 
06.10.2008 piperacillin/tazobactam, amphotericin B (ceftazidime and 
gentamicin continued) 
14.10.2008     teicoplainin added 
24.10.2008     all antibiotics stopped 
(All antibiotic histories kindly supplied by Ms V. Drew, Research nurse, BRI). 
 
Table 30. Blood Culture Results of Patient P.004 
 
Date Sample Collected and 
Sample Type 
Species Cultured 
Antibiotic Susceptibilities of Target 
Species Only 
28.09.2008 
Venous blood 
 
E. coli 
 
P. aeruginosa 
Not reported 
 
Meropenem                       
Piperacillin/tazobactam 
Ceftazidime  
Gentamicin   
 
 
R                       
S                       
S 
S 
29.09.2008 
Not specified 
P. aeruginosa Meropenem                       
Piperacillin/tazobactam 
Ceftazidime  
Gentamicin   
Imipenem 
R 
S 
S 
S 
R 
30.09.2008 
Peripheral blood 
P. aeruginosa Meropenem                       
Piperacillin/tazobactam 
Ceftazidime  
Gentamicin   
R 
S 
S 
S 
2.10.2008 
Peripheral blood 
P. aeruginosa Meropenem                       
Piperacillin/tazobactam 
Ceftazidime  
Gentamicin   
R 
S 
S 
S 
4.10.2008 
Hickman Line 
Coagulase-negative 
staphylococci 
None reported  
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3.5.2 Patient P.013 
Patient P.013 was a 51 year-old female with a diagnosis of AML. Her first admission 
was 20th August 2009, the patient was then repeatedly discharged and re-admitted to 
the ward, before final discharge on 8th December 2009. The first samples were 
collected on 26th August 2009; this was the patients 3rd admission to the ward and 
during week 8 of Phase 3. The antibiotic history of the patient is described here: 
 
28.8.2009  Neutropenic sepsis: continuing piperacillin/tazobactam and 
gentamicin, started clarithromycin 
30.08.2009  Antibiotics changed to meropenem – for 7 days (blood cultures 
and faeces sent, no growth from either – unknown source of 
infection) 
13/14.09.2009  Flucloxacillin 
19.11.2009  Spiked temperature – ciprofloxacin, (gentamicin x1 dose only), 
vancomycin, meropenem, all stopped 08.12.09 
01.12 – 08.12.2009  Caspofungin 
01.12.2009  Groin/ vulval swab = Pseudomonas (susceptible to piperacillin/ 
tazobactam, meropenem, ciprofloxacin, gentamicin) 
07.12.2009  Blood cultures positive mixed coagulase-negative staphylococci  
 
Stenotrophomonas maltophilia was recovered from a throat swab taken on 8th 
September 2009. This occurred in the same week as recovery of the same species 
from Patient P.014 (section 3.5.3). The isolate displayed resistance to the 
aminoglycosides amikacin and gentamicin and also exhibited intermediate resistance to 
ciprofloxacin, aztreonam and piperacillin/tazobactam.  
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3.5.3 Patient P.014 
Patient P.014 was a 60 year-old female with a diagnosis of AML. First admission was 
15th August 2009 and first samples collected on 4th September 2009 (week nine of 
Phase 3). Second (final) samples were collected on 8th September 2009. Following this 
the patient was transferred to a high dependency unit from 18th and 23rd September. 
The patient returned to Ward 7 but was too ill for any further samples to be collected 
and she sadly died on 26th September 2009. The antibiotic history of the patient is: 
 
09.09.09-  Piperacillin/tazobactam and gentamicin, changed to meropenem 
and vancomycin   
14.09.09   Changed to ceftazidime, metronidazole and linezolid  
22.09.09       Stopped 
 
Only one blood culture sample (Hickman line white lumen) was positive for this patient 
(14/9/2009), coagulase-negative staphylococci cultured from the aerobic culture bottle 
after three days’ incubation. 
 
Both throat swabs yielded S. maltophilia, antibiotic susceptibilities indicated resistance 
to amikacin and gentamicin, one isolate also exhibited resistance to aztreonam while 
the other exhibited only intermediate resistance. Intermediate resistance was also seen 
against piperacillin/tazobactam. 
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3.6 Blood Culture Isolates from Ward 7 
Data supplied by the Bradford Royal Infirmary Microbiology Laboratory for all blood 
culture isolates from June 2008 - March 2010 was examined to determine the 
proportion of isolates which were Gram negative and also whether any of these 
belonged to the target species. Bacteraemia data for June 2004 - March 2006 were 
also reviewed to give a historical perspective. 
 
3.6.1 Historical Bacteraemia Cases: June 2004 - March 2006 
 
Brief details regarding positive blood culture information was supplied by the BRI for the 
period for Ward 7. From June 2004 - March 2006, 19/91 (20.9%) positive blood cultures 
were associated with Gram negative bacteria three of which were Pseudomonas spp. 
(Table 31). 
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Table 31. Bacteria isolated from blood cultures of patients on Ward 7, June 2004 – 
March 2006 
 
Gram Negative Bacteria 
P. aeruginosa 
(Ps. spp) 
E. coli 
 
Klebsiella spp. 
 
B. fragilis 
Enterobacter 
spp. 
2 (1) 9 4 1 2 
Gram Positive Bacteria 
S. aureus 
Coagulase-
negative 
staphylococci 
Micrococcus 
sp. 
Streptococcus 
spp. 
“Diphtheroids”  
8 (4 MRSA) 42 1 10 8 
 
Also present in the results for bacteraemia during this period were three incidences of 
fungal bacteraemia caused by Candida albicans. 
 
3.6.2 Ward 7 Blood Culture Results June 2008 – March 2010 
From June 2008 to March 2010, the microbiology laboratory received a total of 1354 
blood cultures from Ward 7 patients of which 197 were reported as positive which when 
justified to avoid duplication of the same sample showed 145 (10.7%) episodes of 
bacteraemia. Of these 93 (64.1%) were caused by Gram positive bacteria with 
coagulase-negative staphylococci the most common. Gram negative bacteria were 
responsible for 62 (42.8%) episodes with Klebsiella spp. and E. coli recovered most 
frequently. There was one episode of Candida albicans fungaemia and on one occasion 
unspecified “coliforms” were reported (Table 32).  
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With regard to the target species, no blood cultures with either S. maltophilia or 
A. baumannii were reported during this period. P. aeruginosa was isolated on ten 
occasions during the study (Table 33). 
 
Table 32. Bacteria Isolated from blood cultures of patients on Ward 7, June 2008 – 
March 2010 
 
Gram Negative Bacteria 
P. aeruginosa E. coli 
Klebsiella  
spp. 
Proteus 
mirabilis 
Enterobacter 
sp. 
Neisseria 
sp. 
8 23 26 2 2 1 
Gram Positive Bacteria 
S. aureus 
(+ MRSA) 
Coagulase-
negative 
staphylococci 
“Diphtheroids” 
Streptococcus 
spp.  
Enterococcus 
spp.  
Others 
2  (2) 54 6 8 19 4 
 
Table 33. P. aeruginosa isolated from blood cultures of patients on Ward 7 and Study 
Phase 
 
P. aeruginosa 
isolated 
No. Date 
DOB of 
patient 
Phase Week 
Study 
Patient 
Other 
species 
P. aeruginosa  1 04/08/2008 Mar-49 1 
 
No 
 
 
2 29/09/2008 Oct-50 1 15 P.004 
 
 
3 30/09/2008 Oct-50 1 15 P.004 
 
 
4 02/10/2008 Oct-50 1 16 P.004 
 
 
5 22/02/2010 Apr-39 4 
 
No 
 
P. aeruginosa - 
Polymicrobial 
6 22/08/2008 Jul-64 1 14 No CNS 
 
7 28/09/2008 Oct-50 1 15 P.004 E. coli 
 
8 21/01/2009 Apr-42 2 1 No 
Clostridium 
spp. 
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3.7 PCR-based identification of Presumptive Target Species 
Species-specific PCR’s were performed on presumptive P. aeruginosa and 
S. maltophilia isolates to confirm their identities. A multiplex PCR for genus-specific 
identification of Pseudomonas spp. plus species-specific identification of P. aeruginosa 
was attempted. 
 
3.7.1 Genus-Specific PCR for Pseudomonas spp. 
Preliminary experiments were conducted to confirm that the genus-specific PCR 
described by Spilker et al, (2004) was specific for the genus Pseudomonas and would 
not give false positives for other pseudomonads such as S. maltophilia, B. cepacia and 
also A. baumannii. Strains of these non-Pseudomonas bacteria from the reference 
collection (see section 2.3) were used to optimise the assay. The expected product size 
was 618 base pairs. 
 
The method was shown to be specific for the genus Pseudomonas according to results 
obtained with reference collection of P. aeruginosa strains and all other non-
Pseudomonas reference collection strains were negative (See Figure 34, lanes 10 – 
15). All the study isolates presumptively identified as Pseudomonas spp. were positive 
in genus-specific PCR assay (lanes 1-4 and 6-8) and the presumptive S. maltophilia 
negative (lanes 5, 10 & 11). 
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Figure 34. PCR results using the Pseudomonas genus specific assay  
 
 
 
 
 
 
 
 
 
 
 
 
 
Lanes 1 – 4 & 6 - 8: study isolates of presumptive Pseudomonas spp., Lane 5: study 
isolate S. maltophilia; Lane 9: DNA negative control; Lanes 10 - 11: S. maltophilia 
NCIMB 9203 and 9204; Lane 12: B. cepacia NCIMB 9085; Lane 13: A. baumannii 
NCTC 12156; Lane 14 & 15: P. aeruginosa NCTC 10662 and NCTC 12934; Lane 16: 
DNA Ladder.  
 
 
3.8.2 Species-Specific PCR for Pseudomonas aeruginosa  
This assay was used to determine if the isolates presumptively identified as 
Pseudomonas spp. could be confirmed as P. aeruginosa. The figure below (Figure 35) 
shows the results for the same isolates as the previous assay (genus-specific PCR, 
Figure 34) and shows which isolates were confirmed as P. aeruginosa. The expected 
product size was 956 base pairs.  
1        2        3       4        5        6        7        8       9       10      11      12     13      14      15     16 
 618bp 
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This species-specific assay showed that the isolate in lane 1 was not confirmed as 
P. aeruginosa. This isolate was recovered on Pseudomonas Cetrimide agar but grew 
without pigmentation or any characteristic of typical P. aeruginosa growth on 
Pseudomonas cetrimide agar. This isolate was cream, smooth and approximately 2mm 
in diameter in appearance. All other isolates tested in this assay grew with green 
pigmentation and were confirmed as P. aeruginosa in the species-specific 
P. aeruginosa assay (lanes 2-4 and 6-8). 
 
Figure 35. PCR Results using P. aeruginosa Species-Specific assay 
 
 
 
 
 
 
 
 
 
 
 
Lane 1 
– 4 & 6 - 8: Test isolate: presumptive Pseudomonas spp., Lane 5: Test isolate S. 
maltophilia; Lane 9: DNA negative control; Lane 10 - 11: S. maltophilia NCIMB 9203 
and 9204, Lane 12: B. cepacia NCIMB 9085; Lane 13: A. baumannii NCTC 12156; 
Lane 14 & 15: P. aeruginosa NCTC 10662 and NCTC 12934; Lane 16: DNA Ladder.  
 
  
    1        2       3       4        5        6       7        8       9       10     11      12     13     14      15     16 
 956bp 
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3.8.3 Multiplex PCR for Pseudomonas Genus and P. aeruginosa identification  
 
Attempts were made to combine the primers for the genus-specific and species-specific 
PCR’s from the Spilker et al (2004) protocol, in order to identify both at the same time. 
Optimisation steps included primer titration (Figure 36), altering annealing temperature, 
inclusion of DMSO, increasing the concentration of dNTP’s and increasing the number 
of cycles. These modifications proved unsuccessful with the apparent loss of the 956bp 
species-specific PCR product. 
 
Figure 36. Gel Electrophoresis of One Optimisation Step (Primer Titration) for Pseudomonas 
Multiplex PCR 
 
In isolation both the GS- and SS-PCR primers give clear bands of distinct sizes, but 
addition of both primers into a single reaction produced ill defined bands.  
Genus-Specific                                                                                                                             
Primers Only 
Species-Specific
Primers Only  
Both primers
@ 0.1 pmol 
Both primers 
@ 0.2pmol 
Both Primers 
@ 0.3pmol 
G-S Primers @ 0.1pmol 
S-S Primers @ 0.2pmol 
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3.8.4 PCR Assay for the identification of Stenotrophomonas maltophilia 
A species-specific assay was used for the confirmation of S. maltophilia as described 
by Whitby et al (2000). Optimisation was performed to ensure that the assay did not 
give false positive results with other closely related species. The expected PCR product 
was 531 base pairs (see Figure 37). 
 
This optimisation assay showed specificity for S. maltophilia (lanes 1 -2 and 7 – 8) with 
negative results for all other genera (lanes 3 - 6). 
Figure 37. PCR results from the test S. maltophilia assay 
 
 
 
 
 
 
 
 
 
Lane 1: DNA Ladder, Lane 2 - 3: S. maltophilia NCIMB 9203 & 9204; Lane 4 - 5: 
P. aeruginosa NCTC 10662 and NCTC 12934; Lane 6: DNA negative control; Lane 7 – 
8: Test isolates S. maltophilia.   
 531 bp 
    1           2           3           4          5          6          7          8        
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3.9 Antibiotic Susceptibility Testing of Stenotrophomonas maltophilia 
Isolates 
 
The antibiotic susceptibilities of S. maltophilia isolates were determined using the Kirby 
Bauer disc diffusion assay. The antibiotics levofloxacin and minocycline were selected 
from CLSI M100-S16 “Table 2B-4. Zone Diameter Interpretive Standards and 
Equivalent Minimal Inhibitory Concentration (MIC) Breakpoints for Stenotrophomonas 
maltophilia” and a further eight antimicrobials selected from BSAC version 9.1 “Table 8. 
MIC and zone diameter breakpoints for Pseudomonas spp.” A total of 263 isolates from 
outlet swabs, water samples and patient P.013 and P.014 isolates were tested. The 
average number of antimicrobials to which the isolates were resistant or intermediately-
resistant was 3.6. Four of the isolates were resistant to six antimicrobials. Three of 
these highly resistant isolates came from Rm 2, shower and the en-suite wash basin in 
weeks 19 and 21 of Phase 1, and the fourth from the handwash station of Room 7 in 
week 17 of Phase 3. None were fully susceptible. 
 
Stenotrophomonas maltophilia isolates were most frequently resistant to the 
aminoglycosides (amikacin and gentamicin 92.8 and 96.2%, respectively and a further 
4.9% intermediately resistant to amikacin). Resistance was also seen to ciprofloxacin 
(16.6% resistant, 20.4% intermediate), piperacillin/tazobactam (2.3% resistant) 
ceftazidime (2.3% resistant), co-trimoxazole (1.8% resistant). Intermediate resistance to 
aztreonam was very high (82.3%) with an additional 6% of isolates resistant. None of 
the isolates were resistant to colistin, levofloxacin or minocycline (Table 34).  
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The three isolates of S. maltophilia recovered from patients P.013 and P.014 were 
included in these results. The single isolate recovered from patient P.013 (throat swab) 
was resistant to amikacin and gentamicin and also exhibited intermediate resistance to 
ciprofloxacin, aztreonam and piperacillin/tazobactam. The two isolates recovered from 
patient P.014 (throat swabs) were also resistant to amikacin and gentamicin. Isolate 
N.1119 was resistant to aztreonam while isolate N.1127 exhibited only intermediate 
resistance. Intermediate resistance was also seen to piperacillin/tazobactam. The 
patient isolates were either resistant or intermediately resistant to five antimicrobials 
compared with the overall average of 3.6 from water isolates.  
 
A further 58 isolates which had zone diameters defined by BSAC as “sensitive” 
showing that a further 22% of isolates could have been classified as either 
intermediately resistant (where appropriate) or resistant had the zone of inhibition been 
recorded as 1 mm smaller (Table 34). 
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Table 34.  Antibiotic susceptibilities of S. maltophilia isolates and number of isolates 
meeting the minimum sensitive breakpoint defined by CLSI (M100-S16) and BSAC 
(V9.1) 
 
Antibiotic 
(disc content) 
No. of isolates/263 (%) Sensitive 
breakpoint 
(mm) defined 
by BSAC/CLSI 
No. isolates 
recorded as 
min value for 
“sensitive”  S I R 
Ciprofloxacin (5 µg) 165 (62.7) 54 (20.5) 44 (16.7) ≥30 30 
Amikacin (30 µg) 6 (2.3) 13 (4.9) 244 (92.8) ≥19 1 
Gentamicin (10 µg) 10 (3.8) - 253 (96.2) ≥18 1 
Aztreonam (30 µg) 16 (6.1) 216 (82.1) 31 (11.8) ≥36 8 
Ceftazidime (30 µg) 259 (97.7) - 6 (2.3) ≥30 7 
Colistin (25 µg) 263 (100) - 0 (0) ≥14 3 
Piperacilin/ 
tazobactam (75/10 µg) 
257 (97.7) - 6 (2.3) ≥22 6 
Co-trimoxazole 
(1.25/23.75 µg)  
258 (98.1) - 5 (1.9) ≥20 2 
Levofloxacin (5 µg) 263 (100) 0 (0) 0 (0) ≥17 0 
Minocycline (30 µg) 263 (100) 0 (0) 0 (0) ≥19 0 
S = Sensitive; I = Intermediate resistance; R = Resistant 
 
 
3.10 Antibiotic Disc Diffusion Assay of Pseudomonas aeruginosa 
The antimicrobial susceptibilities of P. aeruginosa isolates were determined using the 
Kirby Bauer disc diffusion assay. Eight agents were selected from BSAC version 9.1 
“Table 8. MIC and zone diameter breakpoints for Pseudomonas spp.” A total of 256 
isolates recovered from water, outlet swab and patient P.004 were tested. Overall, 
resistance in these isolates was very low with the maximum resistance observed to two 
antimicrobials. This occurred in eight isolates; four were resistant to ciprofloxacin and 
aztreonam (all intermediate) and the other four resistant to imipenem (three 
intermediate, one resistant) and aztreonam (intermediate). All isolates resistant to   
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imipenem were recovered from patient P.004. Isolates that were intermediately 
resistant to ciprofloxacin were from four separate water samples. Of the 256 isolates 
tested, 248 (97%) displayed intermediate resistance to aztreonam; the eight that were 
not resistant to aztreonam were not resistant to any other antibiotic (Table 35). 
 
However, 14 isolates had the minimum zone diameters defined by BSAC as “sensitive” 
showing that a further 5.5% of isolates could have been classified as either 
intermediately resistant (where appropriate) or resistant had the zone of inhibition been 
recorded as 1mm smaller (Table 35). 
Table 35.  Antibiotic susceptibilities of P. aeruginosa isolates and number of isolates 
meeting the minimum sensitive breakpoint defined by BSAC (V9.1) 
 
Antibiotic  
(disc content) 
No. of isolates/256 (%) 
Sensitive 
breakpoint 
(mm) defined 
by BSAC/CLSI 
No. isolates 
recorded as 
min value for 
“sensitive” 
S I R 
Ciprofloxacin (5 µg) 252 (98.4) 4 (1.6) 0 (0) ≥30 6 
Gentamicin (10 µg) 256 (0) - 0 (0) ≥18 0 
Aztreonam (30 µg) 8 (3.1) 248 (96.9) 0 (0) ≥36 6 
Ceftazidime (30 µg) 256 (0) - 0 (0) ≥24 0 
Colistin (25 µg) 256 (0) - 0 (0) ≥14 1 
Piperacilin/ 
tazobactam (75/10 µg) 
256 (0) - 0 (0) ≥22 0 
Imipenem (10 µg) 252 (98.4) 3 (1.2) 1 (0.4)) ≥23 0 
Levofloxacin (5 µg) 256 (0) 0 (0) 0 (0) ≥22 1 
S = Sensitive; I = Intermediate resistance; R = Resistant 
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3.11 Typing of Study Isolates 
From the isolates collected throughout the study, seven subgroups of S. maltophilia and 
P. aeruginosa were selected for further investigation using the PCR-based typing 
methods BOX- and REP-PCR. The rationale for each analysis that was done to 
compare strains is summarised in Table 36. 
Table 36. Summary of typing studies for S. maltophilia and P. aeruginosa study 
isolates 
 
Study Overview Rationale 
1 
Comparison of S. maltophilia 
isolates from patients P.013 & 
P.014 and the rooms they 
occupied (4 & 9). 
To investigate all isolates recovered from 
rooms 4 & 9 throughout Phase 3 for evidence 
of possible transmission from water to patient 
or patient to water.  
2 
Comparison of all 
S. maltophilia isolates from 
week 10 of Phase 3 
To establish whether any isolates genetically 
related to those from patients could be 
identified elsewhere on the ward on the week 
that two patients became colonised. 
3 
Comparison of the Room 7 
"Hotzone" of S. maltophilia, 
from the end of Phase 1 and 
the start of Phase 3 
To investigate whether one strain of S. 
maltophilia was present in all three outlets of 
Room 7, and whether the strain was still 
detectable following the six month intervention 
with filters.  
4 
Comparison of S. maltophilia 
isolates from the "Hotzone" 
shower in Room 2. 
To establish whether one or several strains 
colonised a shower from Phase 1 to Phase 3 
despite the changing of shower heads by BRI 
Estates and the presence of filters for six 
months. 
5 
Comparison of isolates 
recovered sporadically from 
the shower of Room 11 
To determine if different strains could be 
recovered from an outlet that only produced 
sporadic recovery throughout the study. 
6 
Comparison of all S. 
maltophilia isolates recovered 
during Phase 2 (filtered) 
To investigate whether the isolate recovered 
from a filtered outlet during Phase 2 matched 
any other S. maltophilia isolates recovered 
from unfiltered outlets, as this might indicate 
cross-contamination. 
7 
Investigation of all isolates of 
P. aeruginosa from the onset 
of colonisation of patient P.004 
to discharge 
To establish a possible relationship between 
isolates recovered from patient P.004 from 
whom P. aeruginosa was isolated (throat and 
faecal samples and blood cultures) and water 
isolates. 
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3.11.1 Optimisation of PCR-based Typing Methods 
The initial PCR cycle conditions were taken from Lin et al., (2008) and step-wise 
alterations made to find the optimal conditions for typing of S. maltophilia and 
P. aeruginosa. These included primer titrations, DMSO incorporation, alterations to the 
annealing temperature and reproducibility checks to ensure fidelity of the technique. All 
PCR’s were performed using crude cell lysates to facilitate high-throughput. 
 
3.11.2 Optimisation of BOX-PCR 
Figures 38a – e, show the effects of several optimisation steps for typing S. maltophilia 
and P. aeruginosa using BOX-PCR. Addition of DMSO at concentrations of 0, 5 and 
10% (v/v), were investigated with 5% DMSO chosen as the optimal concentration to be 
used (Figure 38a). The annealing temperature of 52OC (Lin et al., 2008) was retained 
as band resolution was lost at higher temperatures (Figure 38b). Investigations to 
determine the optimal amount of primer for BOX-PCR concluded that 100 pmol would 
be adopted throughout the study for typing of S. maltophilia and 80 pmol/reaction for 
P. aeruginosa (Figures 38c & 38d). It was noted that although additional bands were 
generated with P. aeruginosa if the amount of primer used was higher, these amplimers 
were of a similar size, and difficult to resolve or reproduce. Figure 38e shows the 
reproducibility of typing profiles of S. maltophilia isolates with optimised BOX-PCR 
conditions. 
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Figure 38 (a, b, c, d & e ). Effect of DMSO incorporation on BOX-PCR 
 
 
 
 
 
 
 
 
 
Figure 38a: Using two S. maltophilia isolates (K279a & N.967), each section shows the 
different concentrations of DMSO. The isolates are duplicated in each section.  
 
Figure 38b. Effect of Increasing Annealing Temperature of BOX-PCR 
 
 
 
 
 
 
Figure 38b: Using four S. maltophilia isolates (K279a; N.967, N.1049 & N.1050 in 
duplicate) the effects of increasing annealing temperature were investigated. Gel No.2 
shows the effect of increasing the temperature to 54OC, band resolution is 
compromised. 
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Figure 38c. Investigation of Optimal Amount of Primer for BOX-PCR for S. maltophilia isolates 
 
 
 
 
 
 
 
Figure 38c: Two isolates of S. maltophilia (N.222 & N.250) were used to establish 
optimal primer amount. 100 pmol/reaction was selected for BOX-PCR, based on the 
number and clarity of bands generated in each profile. 
 
Figure 38d. Investigation of Optimal Amount of Primer for BOX-PCR for P. aeruginosa isolates 
 
 
 
 
 
 
 
 
 
Figure 38d: One P. aeruginosa isolate (N.426) was used to establish optimal primer 
amount. 80 pmol/reaction was selected for BOX-PCR.  
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Figure 38e. Reproducibility of BOX-PCR assays 
 
 
 
 
 
 
 
Figure 38e: Five S. maltophilia isolates (N.222; N.250; N.1229; N.1271 and N.1312, 
each in triplicate) were used to check the reproducibility under optimised PCR 
conditions of 5% DMSO, 52OC annealing temperature and 100 pmol/reaction of primer. 
Good reproducibility of profiles for each isolate can be seen. 
 
The optimal conditions for BOX-PCR of S. maltophilia and P. aeruginosa were 
determined to be: 
 Cycling conditions of: 1 cycle of 95OC for 5 minutes, 30 amplification cycles 
consisting of 94OC for 1 minute, 52OC for 1 minute, 65OC 8 for minutes and a 
final single cycle of 65OC for 16 minutes  
  Inclusion of 5% (v/v) DMSO in the reaction mixture 
 Use of 100 pmol of primer per reaction for S. maltophilia and 80 pmol per 
reaction for P. aeruginosa 
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3.11.3 Optimisation of REP-PCR 
The same optimisation processes used for BOX-PCR were used to optimise REP-PCR 
for typing S. maltophilia and P. aeruginosa. 
 
The optimal conditions for REP-PCR typing of S. maltophilia and P. aeruginosa were 
determined to be: 
 Cycling conditions of: 1 cycle of 95OC for 2 minutes, 35 amplification cycles 
consisting of 92OC for 30 seconds, 40OC 1 minute, 65OC for 8 minutes and a 
final single cycle of 65OC for 16 minutes. 
 Inclusion of 5% DMSO in the reaction mixture 
 Use of 80 pmol of each primer per reaction for both S. maltophilia and 
P. aeruginosa. 
 
 
3.11.4 Banding Patterns using REP- and BOX-PCR Typing methods 
The two different typing methods produced different band patterns with each species. 
Both techniques produced many bands with S. maltophilia isolates (Figure 39 a&b). 
However, BOX-PCR produced few bands with P. aeruginosa isolates compared with 
REP-PCR, and some of these amplimers were common to all isolates, thus reducing 
overall strain-discrimination of the technique (Figure 40 a&b). 
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Figure 39 (a&b). Comparison of BOX-PCR and REP-PCR Profiles of S. maltophilia 
 
 
Figures 39 a&b: Electrophoresis gels for 17 S. maltophilia isolates (in the same order on each gel) using BOX primers (Fig. A) and 
REP primers (Fig. B) respectively.   
Fig. A Fig. B 
1     2    3     4     5     6    7    8     9    10  11  12  13  14   15  16  17  18   19 20   
20 20 
1     2    3    4     5    6    7    8     9   10  11   12 13  14  15  16  17  18   19 20   
20 20 
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Figure 40 (a&b). Comparison of BOX-PCR and REP-PCR Band Patterns of P. aeruginosa 
 
Figures 40 a&b: Electrophoresis gels for 17 P. aeruginosa isolates (in the same order on each gel) using BOX-PCR (Fig A) and REP-
PCR (Fig B). BOX-PCR results in a reduced number of bands, and less variation in profiles between isolates in comparison with 
REP-PCR.  
Fig A Fig B 
1     2    3     4     5    6    7     8    9   10   11  12   13  14   15  16  17  18   19  20   
20 20 
1     2    3    4     5   6    7    8    9   10 11  12  13 14  15  16 17  18 19  20 
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3.11.5 Optimisation of Similarity Parameters using the GelCompar Software 
 
Multiple runs of the same isolates of S. maltophilia (N.222, nine runs) and 
P.  aeruginosa (N.426, six runs) were done using both PCR methods. By entering 
the profiles into the GelCompar database, to allow comparison, it was possible to 
establish the reproducibility of the technique using crude cell lysates. The average 
similarity generated a cut-off value for which isolate profiles would be considered 
‘indistinguishable’. Within the cluster analysis function, two parameters (optimisation 
and position tolerance) affect the similarity value. Optimisation is the shift allowed 
between any two patterns within which the software attempts to identify the best 
possible matching. Position tolerance is the maximal shift allowed between two 
bands on different profiles, for the software to still consider them as matching in 
size. A range of values for these parameters were applied to the repeat 
S. maltophilia and P. aeruginosa profiles, and the effect on clustering and matching 
of the profiles was assessed. Cut-off values (for defining ‘match’ and ‘non-match’) 
were then established from the similarity average generated from comparing these 
profiles (section 3.11.5.1). 
 
3.11.5.1 Stenotrophomonas maltophilia BOX- and REP-PCR Similarity Values 
 
After due consideration of the data from nine replicate profiles for strain N.222 
(Table 37), the similarity parameters selected for REP-PCR typing analysis using 
the Gelcompar software were optimisation = 1% and position tolerance = 1.5%. On 
the basis of the average similarities, cut-off values were established where profiles 
were considered to be indistinguishable, or not matching. REP-PCR of 
S. maltophilia gave much more variable results for reproducibility of profiles. Using   
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the above listed parameters, a range of similarity between profiles was observed 
between 33.34 – 100% giving an average of only 66.67%. It was not desirable to 
raise the values of the parameters any higher as this would risk losing the ability to 
discriminate between profiles (Table 37). The cut-off values where profiles were 
considered to be the same for BOX- and REP-PCR were set at 88 and 67% 
respectively (Table 37). 
Table 37. Effect of varying Optimisation and Position tolerance parameters to 
establish cut-off values for S. maltophilia 
 
S. maltophilia BOX-PCR 
Range 
Optimisation 
0%, 
Position 
tolerance 0% 
Optimisation 1% 
Position 
tolerance 1% 
Optimisation 
1% 
Position 
tolerance 1.5% 
Optimisation 2% 
Position 
tolerance 2% 
Range of 
similarity values 
of profiles 
54.77 – 100% 75.47-100% 76.70 – 100% 76.70 – 100% 
Average 
similarity/cut-off 
value 
77.39% 87.74% 88.35% 88.35% 
S. maltophilia REP-PCR 
Range of 
similarity values 
of profiles 
0% 25.5 – 100% 33.91 – 100% 43.71% 
Average 
similarity/cut-off 
value 
0% 62.75% 66.96% 71.86% 
Table 37: Data from nine replicate profiles for strain N.222. Area shaded in red 
shows parameters selected for cluster analysis per typing technique and the cut-off 
value where profiles are considered to match.  
 
3.11.5.2 Pseudomonas aeruginosa BOX and REP-PCR Similarity Cut-off values 
 
After due consideration of the data from six replicate profiles for strain N.426 (Table 
38), the similarity parameters were selected. BOX- and REP-PCR methods for 
typing P. aeruginosa isolates gave good results for profile reproducibility. However,   
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BOX-PCR produced only a small number of bands, giving doubts regarding its 
effectiveness to discriminate adequately between isolate profiles. Similarity 
parameters were more stringent for BOX-PCR when setting optimisation = 1% and 
position tolerance = 1%. REP-PCR generated more bands in isolate profiles and 
parameters were set at optimisation = 1% and position tolerance = 1.5% to give 
optimal results for establishing similarity between isolate profiles. The cut-off value 
where profiles were considered to match, was set at 93% for both BOX- and REP-
PCR (Table 38). 
 
Table 38. Effect of varying Optimisation and Position tolerance Parameters to 
establish cut-off values for P. aeruginosa  
 
P. aeruginosa BOX-PCR 
Range 
Optimisation 
0%, 
Position 
tolerance 0% 
Optimisation 
1% 
Position  
tolerance 1% 
Optimisation 
1% 
Position 
tolerance 1.5% 
Optimisation 2% 
position 
tolerance 2% 
Range of 
similarity values 
of profiles 
0% 85.70 – 100% 85.72 – 100% 85.70 – 100% 
Average 
similarity/cut-off 
value 
0% 92.85% 92.86% 92.85% 
P. aeruginosa REP-PCR 
Range of 
similarity values 
of profiles 
0% 79.18 – 100% 85.01 – 100% 90.07- 100% 
Average 
similarity/cut-off 
value 
0% 89.59 92.5% 95.04% 
Table 38: Data from six replicate profiles for strain N.426. Area shaded in red shows 
parameters selected for cluster analysis per typing technique and the cut-off value 
where profiles are considered to match.  
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3.11.6 Strain Typing Study 1 - Comparison of S. maltophilia isolates recovered 
from Patients P.013 and P.014 and water isolates from the outlets of Rooms 4 
and 9 during Phase 3 
 
In week 10 of Phase 3, S. maltophilia was cultured from throat swabs of two patients 
(P.013 and P.014). Isolate N.1124 was obtained from the former and isolates 
(N.1119 and N.1127) from two different swabs from the latter. Patients P.013 and 
P.014 were resident in rooms 9 and 4 respectively. Study 1 investigated strain 
relatedness using BOX- and REP-PCR primers between the patient isolates and all 
other S. maltophilia isolates cultured from outlet swabs or water samples from any 
outlet of Rooms 4 and 9 during Phase 3. This was to establish if patient isolates and 
water isolates before or after patient colonisation were related. Analysis of BOX- and 
REP-PCR profiles created two different dendrograms showing some grouping 
similarities between the two techniques but also, occasionally clustering different 
isolates. 
 
BOX-PCR indicated similarity below the cut-off value between two patient P.014 
isolate profiles and two water isolate profiles (both from the distal sample from 
Room 4, Outlet A on week 18 of Phase 3) and a single swab isolate profile from the 
shower of Room 4 in week 20. The patient was resident in this room in Week 4 and 
died soon after, therefore not in the room in the intervening weeks. The similarity 
values for the two patient isolates to the water/swab isolates (at 59 and 63%) are 
below the cut-off value (88%) which would make these profiles the same (Figure 41, 
BOX-PCR). The antibiotic susceptibility profiles show that all five isolates were 
resistant to amikacin and gentamicin. One of the patient isolates (N.1127) was 
resistant to aztreonam and the other patient isolate and the water source isolates 
were intermediately-resistant. Both patient isolates are intermediately-resistant to   
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ciprofloxacin but not those isolated from water sources. Thus, the overall conclusion 
was the patient and water isolates were unrelated. 
 
BOX-PCR revealed no relationship between the isolates from patients P.013 and 
P.014 but REP-PCR clustered one isolate from patient P.014 (N.1119) with that 
from patient P.013 (N.1124) at a similarity of 67%, the same as the cut-off value and 
the two isolates can be considered indistinguishable. Antibiotic susceptibilities for 
these isolates were the same with the exception of aztreonam, (N.1119 resistant 
and N.1124 intermediately-resistant). These are also clustered with shower isolates 
from Room 9 from weeks 4 and 7 at a similarity of 57% and with less similarity 
(55%) with the cluster of Room 4 isolates (Figure 41, REP-PCR). 
 
Other similarities include the three isolates taken from Room 4 in weeks 18 and 20 
(N.1296, N.1297 and N.1323). BOX-PCR showed a 100% match between the two 
profiles generated from the distal water sample isolates from Outlet A, which also 
clustered together (87%) with the swab isolate taken from the shower. REP-PCR 
also revealed a 100% match between the two water sample profiles and a similarity 
of 92% with the shower isolate of Room 4 making these three isolate profiles 
indistinguishable using this technique. This is consistent with antibiotic susceptibility 
data which showed the same profile for all three isolates (Figure 41). 
 
However, there are some differences between the results from REP- and BOX-PCR. 
REP-PCR did not cluster the two isolates recovered from patient P.014 but on 
examination of isolate N.1127 it has significantly fewer bands in its profile than any   
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other isolate. This could be explained by an amplification error possibly due to the 
crude genomic extraction. 
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Figure 41. Dendrogram of all Study 1 isolates (S. maltophilia) using BOX-PCR (left) and REP-PCR (right) 
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3.11.7 Strain typing Study 2 – Investigation of S. maltophilia patient isolates 
cultured from any water source during Week 10 of Phase 3 
 
Further isolates were compared with the isolates of strain typing Study 1 to 
investigate whether any of the strains had been isolated elsewhere during week 10, 
which could indicate cross-contamination or a point-source. These were recovered 
from Outlet B of Room 6 (two isolates both from the distal water sample, N.1152 & 
N. 1154) and the shower of Room 2 (three isolates, one swab [N.1115] and two from 
the proximal water sample [N.1140 & N.1141]). 
 
BOX-PCR clustered all three Room 2 isolates recovered in Week 10 with the 
isolates from Room 4 recovered in weeks 18 and 20 (similarity ranging from 88 - 
100%) indicating that these can be considered as the same strain. This is supported 
by antibiotic susceptibility profiles. These seven profiles are clustered with the 
profiles of the two patient P.014 isolates but are below the cut-off value. From the 
Ward schematic (Figure 13) it can be seen that these two rooms (2 & 4) are next to 
each other on the same side of the corridor and so it is possible that the same strain 
colonised this leg of the distribution system. REP-PCR also clusters the Room 2 
isolates with those of Room 4 but not with the patient isolates (Figure 42). 
 
Profiles generated from the isolates from Room 6 using BOX-PCR also clustered at 
a low value (52%) with the Room 2 & 4 profiles but were not clustered together 
using REP-PCR (Figure 42).  
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Figure 42. Dendrogram of all Study 2 isolates (S. maltophilia) using BOX-PCR (left) and REP-PCR (right) 
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3.11.8 Strain Typing Study 3 - Investigation of S. maltophilia from the Room 7 
"Hotzone" from the end of Phase 1 and the start of Phase 3 
 
All isolates of S. maltophilia cultured from the end of Phase 1 (weeks 26 and 30) 
and the beginning of Phase 3 (weeks 1 and 6) were compared using BOX- and 
REP-PCR to establish whether outlets that had been consistently associated with 
S. maltophilia was colonised with related strains or whether there was a change in 
the strains present over time (Figure 43). 
 
Both BOX- and REP-PCR clustered many isolates together. There was a distinct 
difference between isolates from the three different outlet types (i.e. outlet types A & 
B and shower) with separate clusters being formed for each outlet type, isolates 
recovered from the individual outlets are clustered closely (Figure 43). On only one 
occasion did an isolate (N.739) from Outlet B belong to a cluster from a different 
outlet (outlet A), both BOX- and REP-PCR results place this isolate as more closely 
related to the isolates from outlet A rather than the others recovered from outlet B 
(Figure 42). All isolates were resistant to amikacin and gentamicin and 
intermediately-resistant to aztreonam. With the exception of N.740 which also 
exhibited intermediate-resistance to ciprofloxacin, the isolates from outlets A and B 
were not resistant to any other antimicrobial. However, all isolates in this strain 
typing study recovered from the shower of Room 7 were resistant to ciprofloxacin, 
confirming the distinct clustering of isolates from this outlet. 
 
Room 7 isolates were either indistinguishable or very closely related between 
Phases 1 & 3. The range of similarity for BOX-PCR profile clusters was 85 – 100% 
showing very closely related and indistinguishable strains (cut-off value 88%). REP-
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PCR showed a range of 80 – 100%, above the cut-off value. This shows that the 
same strain of S. maltophilia can colonise outlets over a prolonged period of time, 
and return after a period when filters were used. 
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Figure 43. Dendrogram of all Study 3 Isolates (S. maltophilia) using BOX-PCR left and REP-PCR (right) 
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3.11.9 Strain Typing Study 4 - Investigation of S. maltophilia from "Hotzone" 
outlet 2C from the beginning of Phase 1 through to the end of Phase 3 
 
Study 4 also investigated a “hotzone”, namely the shower of Room 2. All isolates 
from Phase 1 and Phase 3 were compared to establish if the same strain persisted 
throughout the two phases (Figure 44). 
 
BOX-PCR delineated four distinct clusters, the first consists of 6 isolates (N.222 – 
N.302, reading from top to bottom) recovered from swabs and proximal and distal 
water samples in weeks 3, 5 and 10 of Phase 1. This cluster has three patterns 
within it, grouped at a similarity range of 67 – 100%. These isolates were all isolated 
from this outlet in Phase 1 on weeks 3, 5 or 10. 
 
The second cluster consists of 15 isolates (N.650 – N.1140) with a similarity ranging 
from 90 – 100% and therefore can be considered indistinguishable. These isolates 
are a mixture of those recovered from both Phases, the earliest recovered in week 
10 of Phase 1 (August 2008) and the latest 14 months later in week 15 of Phase 3 
(October 2009). This cluster shows, as with strain typing study 3, that strains can 
persist in an outlet for a long period. 
 
The third cluster consists of only four isolates (N.430 – N.587) recovered in weeks 
12 and 19 of Phase 1. Finally the fourth cluster, which is distinct from the others, 
consists of seven isolates (N.1236 – N.1235) all recovered in weeks 15, 17 and 19 
in Phase 3. 
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Study 4, like Study 3, shows that particular strains can persist in an outlet over a 
long period of time, however, Study 4 also shows there can be many different 
strains colonising one outlet (Figure 44). 
 
REP-PCR created a dendrogram with many differences to that of BOX-PCR, some 
isolates are clustered together, for example, N.222, N.230 and N.303 while others 
have become members of a different group or clustered with a very low similarity 
level. However, the trend is the same with clusters of strains being formed 
containing the profiles of isolates recovered from both phases.  
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Figure 44. Dendrogram of Study 4 Isolates (S. maltophilia) using BOX-PCR (left) and REP-PCR (right)  
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3.11.10 Strain Typing Study 5 - Investigation of sporadic isolation of S. 
maltophilia from the shower of Room11 
 
In contrast to Strain Typing Studies 1-4 this study examined sporadic isolation of 
S. maltophilia from the shower of Room 11 in Phases 1 & 3. Recovery occurred in 
weeks 4 (outlet swab), 13 and 20 (water samples) in Phase 1 and from the water 
sample in week 19, Phase 3. The isolates in this strain typing study are in pairs with 
two isolates included per water sample. Study 5 investigated the relationship 
between isolates cultured from this outlet (Figure 45). 
 
With the exception of isolates N.250 and N.251, the other paired isolates all show 
indistinguishable profiles with both BOX- and REP-PCR. The isolates N.250 and 
N.251 were not matched by either PCR technique. 
 
Both BOX- and REP-PCR showed a match between the isolates recovered from this 
shower on week 20 of Phase 1 (October 2008) and 13 months later on week 19 of 
Phase 3 (November 2009) at 92% (BOX-PCR) and 76% (REP-PCR) similarity and 
therefore can be considered indistinguishable. This shows that although recovery 
was only sporadic from this outlet the same strain persisted over long periods of 
(Figure 45). 
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Figure 45. Dendrogram of Study 5 isolates (S. maltophilia) using BOX-PCR (left) and REP-PCR (right)  
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3.11.11 Strain Typing Study 6 - Investigation of S. maltophilia isolates from Phase 
2 (filtered) 
 
During Phase 2 S. maltophilia was isolated from proximal water sample from one 
filtered outlet (the hand-wash station in the kitchen) in week 24. Three unfiltered 
outlets (the bath in Room 1 and showers of Rooms 9 and 12) also yielded the 
bacterium during Phase 2. Study 6 investigated whether any of these isolates were 
related. 
 
Both PCR techniques showed four different strains recovered during Phase 2 
(Figure 45). The profiles of the two isolates from the handwash station do not match 
profiles from any other location in this analysis. Both methods show 100% match of 
the isolate profiles from the bath of Room 1 recovered on weeks four, seven and 15, 
again showing the longitudinal persistence of a strain in colonising outlets. The 
profiles of the two isolates recovered from the shower of Room 12 in week 24 were 
the same with both methods and the profile of the isolate from the shower in room 9 
was different from any other profile (Figure 46). 
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Figure 46. Dendrogram of Study 6 isolates (S. maltophilia) using BOX-PCR (right) and REP-PCR (left) 
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3.11.12 Strain Typing Study 7 - Investigation of all isolates of P. aeruginosa from 
first detection of colonisation by patient P.004 to patients discharge 
 
On week 12 of Phase 1, patient P.004 was positive for P. aeruginosa from both 
throat and faecal samples and developed P. aeruginosa bacteraemia in week 15. 
The aim of study 7 was to investigate all P. aeruginosa isolates recovered from 
patient, water and outlet swabs from week 12 through to the patients discharge in 
week 22, to establish whether a match existed between the patient isolates and 
water isolates. 
 
The number of isolates used in this study do not permit the dendrograms to be 
displayed on a single page and these are therefore spread over two. Key areas 
have been highlighted and enlarged on successive figures (Figures 47 to 50).   
Key Area 1 (REP-PCR)  Red  
Key Area 2 (BOX-PCR)  Blue (split over two pages) 
Key Area 3 (BOX-PCR)  Green 
Key Area 4 (BOX-PCR)  Black 
 
The cut-off value for P. aeruginosa profile matching using BOX- and REP-PCR is 
93% (Table 38) at which the isolates are considered to be indistinguishable. 
However, it is important to note that the profiles generated using BOX-PCR were 
not as discriminating as those generated using REP-PCR. Very few bands are 
present on BOX-PCR profiles, and some of these maybe species-specific making it 
difficult to discriminate between strains.  
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Figure 47 a&b shows the profiles generated using REP-PCR. Many clusters are 
apparent, but the main area of interest is highlighted as Key Area 1 (Figure 48). This 
area clusters profiles of P. aeruginosa isolates recovered from patient P.004 and 
from water samples taken from the cold tap in the kitchen and from Outlet B (plus 
outlet swab) of Room 3 plus one isolate from a swab of the shower of Room 3. 
 
Patient P.004 was recruited in week 12 and occupied Room 3. The patient is 
believed to have occupied this room until week 17. From samples taken on this 
week P. aeruginosa was isolated from a throat swab (N.426) and faecal sample 
(N.425). The profile of N.426 matches (100%), with another throat isolate (N.558) 
from this patient taken on week 16 while still occupying Room 3. These three 
profiles are clustered at a level below the cut-off value (80%) with another group of 
three throat isolates plus a blood culture isolate (blood sample taken week 20). 
These two groups are clustered, but at a very low level (71.3%), with the profiles of 
isolates recovered from outlet B plus the shower of Room 3 all recovered on week 
20 when the patient no longer occupied this room (Figure 48, Key Area 1). 
 
Patient isolate N.509 from a throat sample taken on week 14 was also clustered at a 
value below the cut-off level (86%) with two water sample isolates from outlet B of 
Room 3 recovered on week 15. This group is clustered at a still lower value (76%) 
with isolates recovered from the cold tap of the kitchen in weeks 13, 15 and 17 
(Figure 48, Key Area 1). 
 
While REP-PCR clusters groups of patient and water source isolates, the values are 
below those which would allow these isolates to be considered a match and so,   
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REP-PCR was unable to establish a link between isolates from patient P.004 and 
those from the water distribution system. 
 
The results using BOX-PCR (Figure 49) were far less discriminatory than REP-
PCR, and generated fewer bands in isolate profiles. The results of BOX-PCR can 
be seen in Figures 49a&b with greater detail shown in Key Areas 2, 3 and 4 (Figure 
50). 
 
Key Area 2 shows a cluster of isolates that includes patient P.004 and a number of 
isolates from the kitchen (cold tap and handwash station), Room 3, Room 7 and 
also a blood culture isolate supplied by the BRI microbiology laboratory. Within this 
cluster there are three further groups. The first contains three kitchen water sample 
isolates, two collected in week 13 (N.449, N.450) and one in week 15 (N.525), 
which show a 100% match to a throat isolate (N.509) collected from the patient in 
week 14. These isolates show the next closest relationship to another patient 
isolate, a throat isolate collected in week 20 at 88% and therefore just below the cut-
off value (Figure 50, Key Area 2). 
 
These isolates are clustered (83%) with a second group containing 14 more isolates 
which are indistinguishable (100% match) and comprise one faecal isolate (N.425 
recovered week 12) and two throat isolates (N.426 recovered week 12 and N.558 
week 16) with ten isolates recovered from the cold tap of the kitchen sink outlet 
recovered in weeks 13, 15 and 17. The final isolate in this cluster level is the blood 
culture isolate supplied by the BRI (N.637) and with a value of 95% is a match with 
all other profiles from this group. These two groups are finally clustered with the   
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third group at only 78% similarity which contains profiles from isolates recovered 
from Room 3, Room 7 and the handwash station of the kitchen. 
 
Key area 3 shows a 100% match between throat isolate (N.596) recovered in week 
19 and two swabs isolated from outlet B and the shower both recovered in week 20 
from Room 3. This patient was resident in Room 3 in weeks 12 (possibly 13 and 14 
but this cannot be confirmed), 15 and 16 but then moved to other rooms and was no 
longer resident in this location at the time of recovery of these isolates (Figure 50, 
Key Area 3). 
 
Finally, BOX-PCR reveals one more cluster (Key Area 4) between patient and water 
samples. However, these show only a weak connection; the two patient isolates 
recovered in week 15 (N.555 & 556) have a value of 76% and N.556 and the profile 
of isolate outlet B of Room 10 in week 13 show a value of 86% (Figure 50, Key Area 
4). 
 
Using BOX-PCR, a match was found between patient and water. However, due to 
the low discriminatory powers of this technique in this instance, the results from 
REP-PCR are more likely to be more reliable, i.e. that the strains were different. 
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Figure 47(a). Strain Typing Study 7. Dendrogram of all P. aeruginosa isolates using REP-PCR (section 1)  
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Figure 47(b). Strain Typing Study 7. Dendrogram of all P. aeruginosa isolates using REP-PCR (section 2)  
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Figure 48. Key area 1, REP-PCR of P. aeruginosa isolates 
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Figure 49(a). Strain Typing Study 7. Dendrogram of all P. aeruginosa isolates using BOX-PCR (section 1)  
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 Figure 49(b). Strain Typing Study 7. Dendrogram of all P. aeruginosa isolates using BOX-PCR (section 2) 
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Figure 50. Key Area 2 (left), Key Area 3 (top right) and Key Area 4 (bottom right), BOX-PCR of P. aeruginosa isolates
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4 Discussion 
The hospital environment is under ever increasing scrutiny for its role as a reservoir 
of nosocomial pathogens. The water distribution system of hospitals became a 
particular focus of attention in 2010 when the UK Director of Health Protection 
issued a “Dear Colleague” letter highlighting hospital water sources and the 
potential for infection from taps and sinks. It stated that incidents of infection with 
pseudomonads occurring in augmented care units had identified hand washing 
facilities as the source (Department of Health Gateway ref. 14720). This was 
expanded on in February 2012 with a further “Dear Colleague” letter that included: 
“Best Practice for hand wash stations to minimise the risk of Pseudomonas 
aeruginosa contamination” (Department of Health Gateway ref. 17216) (DH, 2010, 
2012a). This was in response to a recent outbreak of P. aeruginosa in neonates 
resulting in three deaths in Northern Ireland. A tap on the neonatal unit was thought 
to be the likely source of the outbreak (Wise, 2012). 
 
Increasingly important Gram negative opportunistic pathogens, with either known or 
suspected environmental reservoirs, such as P. aeruginosa, S. maltophilia and 
A. baumannii have not thus far been subject to mandatory surveillance in healthcare 
facilities. However, following the January 2012 P. aeruginosa outbreak and deaths 
of three babies in the Royal Jubilee Maternity Hospital in Belfast; P. aeruginosa has 
now been identified as a pathogen requiring surveillance. This includes 
environmental monitoring and implementation of control measures should it be 
found in healthcare water distribution systems. On 30th March 2012 the Department 
of Health issued advice for augmented care units regarding water sources and 
potential P. aeruginosa contamination of taps and water distribution systems. The   
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document contains details concerning risk assessment and practicalities of 
monitoring water supplies (Discussed in more detail later). 
 
Evidence of the high bacterial numbers and the broad range of species found in 
hospital water has come from a number of studies including an investigation in 
Lublin province, Eastern Poland, which examined the presence of bacteria in the 
water distribution network. Sixty-seven tap and shower water samples from six 
different hospitals were tested for Legionella and Gram negative bacteria from the 
Enterobacteriaceae and Non-Enterobacteriaceae families. No Enterobacteriaceae 
were isolated but 20 other Gram negative species were found including 
Acinetobacter haemolyticus and A. lwoffii; Aeromonas hydrophila; P. aeruginosa 
and other Pseudomonas spp., B. cepacia; Ralstonia spp; Sphingomonas 
paucimobilis, and S. maltophilia. Non-Enterobacteriaceae were isolated from all 
water samples from four of the hospitals and 79.1% of the water samples taken 
from the other two (Stojek et al., 2008). 
 
Other studies have investigated relationships between waterborne bacteria and 
infections in hospitalised patients. Wang et al., (2009) recovered non-fermentative 
Gram negative bacilli from 33% of seven different ICU water outlets. These included 
S. paucimobilis; P. aeruginosa; Chryseobacterium meningosepticum, B. cepacia 
and S. maltophilia. Using PFGE a strong correlation was found between bacteria 
recovered from water samples and those isolated from patients on the ICU, 
particularly C. meningosepticum. The study recommended water surveillance in 
instances of infections with C. meningosepticum and outbreak investigations and 
concluded that sterile water should be used in ICU’s (Wang et al., 2009).  
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Hospital water has been shown to be an important source of nosocomial infection 
caused by both P. aeruginosa and S. maltophilia (Abbassi et al., 2009; Blanc et al., 
2004; Reuter et al., 2002; Rogues et al., 2007; Sakhnini et al., 2002; Trautmann et 
al., 2001; Weber et al., 1999). A connection between water isolates and patient 
colonisation/infection was demonstrated by Trautmann et al., who reported that 
isolates of P. aeruginosa recovered from tap outlets and colonised/infected patients 
on an ICU were indistinguishable when typed using RAPD-PCR (Trautmann et al., 
2006). 
 
The current study did not attempt to identify every isolate recovered from water 
samples to species level but targeted three species: P. aeruginosa, S. maltophilia 
and A. baumannii. These were selected because of a) their clinical significance as 
opportunistic pathogens in immunocompromised patients; b) their ability to act as a 
potential reservoir for multi-drug resistance genes and c) published evidence which 
links patient infection and colonisation with strains from a water source. The study 
investigated the possibility that these nosocomial pathogens have a reservoir in the 
water distribution system supplying drinking and bathing water to 
immunocompromised patients on the Annette Fox Haematology Unit (Ward 7) at 
Bradford Royal Infirmary. A longitudinal study of water and a small subgroup of 
patients on the unit, found that both P. aeruginosa and S. maltophilia were endemic 
to the water supply, however, A. baumannii was not recovered. Analysis of reports 
from the microbiology laboratory revealed that P. aeruginosa had been isolated from 
blood cultures in several patients but none caused by S. maltophilia or 
A. baumannii.  
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The hospital-based part of the study was divided into four phases; Phases 1 and 3 
examined the microbiological quality of water supplies in the absence of point-of-
use filtration and Phases 2 & 4 examined water after installation of Pall AquasafeTM 
14 day water filters (tap and shower) in all patient room outlets and also the 
handwash stations (kitchen and central corridor) and kitchen taps. 
 
To facilitate the study it was necessary to make significant alterations to the 
plumbing in the patients’ rooms to be able to accommodate the new taps. It was 
anticipated that the correct fixtures and fittings would be in place by the end of 2007 
but it was April 2008 before all the work had been completed and the study could 
open to recruitment. 
 
The current fittings were incompatible with the point of use filters and required 
removal followed by installation appropriate fittings which were able to 
accommodate the filters. It was not possible to transfer patients to a decant ward to 
facilitate this. As a result changes were carried out piecemeal as and when the 
rooms became vacant. The majority of patients occupying rooms on the 
haematology ward are profoundly neutropenic and as a result significantly 
immunocompromised. To minimise the risk of infection to the remaining patients the 
rooms in which the work was taking place required sealing off during this time and a 
deep clean subsequently. This was a lengthy process and furthermore the hospital 
infection control team then had to complete appropriate checks before the room 
could be reopened to patient admission. The progress of the work was further 
delayed as a result of an outbreak of norovirus.  
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Incorrect fittings were installed on the ward and had to be removed and exchanged 
for the correct ones. Also, the separate hot and cold taps in the kitchen were initially 
changed to an unsuitable mixer tap which was unable to meet the domestic staff 
requirements for patients and the original fittings, which were incompatible with the 
Pall filters, had to be reinstalled temporarily. This was not rectified until August 2008 
(week 12 of Phase 1). 
 
Unfortunately patient recruitment into the study was significantly lower than 
anticipated. In total, only twenty patients gave their consent, considerably less than 
the 24 per year that were expected. This meant that there were only a small number 
of patients in the study present on the unit at any one time and so, few clinical 
samples were taken. Many patients that were approached for the study declined the 
invitation for several reasons. Patients were often fatigued and anxious as a result 
of their new diagnosis of cancer and did not feel well enough to want to be involved 
in the study. Others felt it was too much to take on as they had already entered 
complex national clinical trials for treatment of their underlying condition and were 
overloaded with information. A significant number of patients were embarrassed by 
the requirement for stool samples. In this situation it was agreed that if patients 
otherwise were happy to be recruited then only samples from the throat and axillae 
would be taken as a compromise. 
 
A further difficulty was inconsistencies in samples provided. The unit is very busy 
with many acute admissions and extremely ill patients receiving complex 
chemotherapy regimens. As a result sometimes, despite the nursing staffs best 
efforts, samples from study patients were forgotten. On occasion, incorrect samples 
were provided, for example nasal swabs were taken instead of throat swabs which   
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were unsuitable for the study and destroyed. This reduced the likelihood of 
detecting the onset of colonisation or infection with the target species. Eventually, 
after a review of procedures and discussion with staff, the haematology research 
nurses assumed responsibility for collecting patient samples, but only after 19th April 
2009 a significant way through into Phase 2 of the study. 
 
Following completion of the plumbing alterations the first samples were collected 
from April - June 2008. The aim of this pilot study was to establish working practices 
and bacterial presence and numbers from outlet swabs and water samples. It was 
confirmed that a range of bacteria, represented by varied colony morphologies on 
filter membranes and selective media, were present in large numbers in the water 
distribution system. The colonies on these first filter membranes (100 mL water 
sample) were often too many to count or had confluent growth making enumeration 
impossible. It was decided that this method would be used throughout the study as 
it was unknown if a reduction in bacterial numbers would occur following the settling 
period of the new plumbing and throughout the next four phases. Therefore, while it 
was considered that numbers might remain high throughout the study, this could not 
be confirmed at the beginning of the study. 
 
The sampling methodology adhered to the principles outlined by the HPA’s General 
Technique for the Detection and Enumeration of Bacteria by Negative-pressure 
Membrane Filtration (2007) and Enumeration of Pseudomonas aeruginosa by 
membrane filtration (2007) which advises collection of water in 100 mL samples. 
Both methods are based on that described in the Microbiology of Drinking Water 
2002 document (Environmental Agency, 2002). If the volume of water filtered had   
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been reduced, then the sensitivity with which small sub-populations of species of 
interest could be detected would also have been reduced. 
 
A decision was also made not to use sodium thiosulfate in the sample collection 
procedure as per HPA methodology for neutralising chlorine. Nor is the inclusion of 
this compound mentioned in the methods of sample collection in outbreak 
investigations that were key references consulted when developing the working 
water sampling protocol. As the BRI was not using any water treatment methods 
incorporating chlorine and as all samples were taken to the laboratory for immediate 
processing it was felt that its use was unnecessary. 
 
Following membrane filtration and incubation on R2A agar, preliminary isolation of 
target species from samples was done using selective/differential media. 
Pseudomonas cetrimide agar was chosen due to its selectivity for the species 
(Lowbury and Collins, 1955). On occasion, P. putida grew on this medium but 
colonies were easily distinguishable from those of P. aeruginosa due to the 
characteristic morphotype of P. aeruginosa contrasting with that of P. putida which 
was smaller; circular and cream in appearance. Pseudomonas cetrimide agar was 
also used for many other studies investigating P. aeruginosa in water (Bert et al., 
1998; Blanc et al., 2004; Ferroni et al., 1998; Rogues et al., 2007). 
 
Isolation of S. maltophilia was performed with VIA agar, as used to isolate this 
species from bottled water, salads and clinical and environmental samples (Pinot et 
al., 2011; Qureshi et al., 2005; Wilkinson and Kerr, 1998). VIA, with its high 
selectivity, only allows the growth of S. maltophilia or Enterococcus faecium.  
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Separation of these was enabled through the bromothymol blue indicator system 
which generates a blue halo around S. maltophilia. E. faecium was not isolated from 
outlet swabs or water samples throughout the study. The only occasion where it 
was seen was from patient P. 015 where presumptive E. faecium was recovered 
from throat swabs (yellow colouration of media and Gram positive). 
 
To aid the detection of A. baumannii, Leeds Acinetobacter medium was used. Many 
of the isolates which displayed the growth characteristics of Acinetobacter spp. on 
the agar proved to be either S. maltophilia or B. cepacia on further identification 
(see Table 23). While the hospital environment remains a potential reservoir of 
A. baumannii, it was not isolated from the water supply of Ward 7. The identity of 
isolates with typical colonial morphology was confirmed using API 20 NE. Putative 
isolates selected by Pseudomonas cetrimide agar and VIA were all confirmed as 
being the expected species, however, Final species confirmation was performed 
using species-specific PCR for P. aeruginosa and S. maltophilia as described by 
Spilker et al., (2004) and Whitby et al., (2000). 
 
It was decided that two water samples per outlet would be collected on each 
sampling occasion and this was completed whenever possible. The scheduled time 
of sample collection for the study was 9:00am; i.e. before most patients used their 
water facilities. However, it was not possible to ensure that the first sample taken 
represented first use of that outlet that day. If a patient had required care earlier, a 
nurse would have been in to attend to their needs and have used the handwash 
station. On other occasions, early rising patients (the less seriously ill) may have 
already used the en-suite facilities. It was also not possible to collect a first-use   
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sample from a kitchen outlet due to the frequency of use throughout the night and 
early morning. 
 
Recovery of Target Species during the Study  
 
Phase 1, the first unfiltered phase of the study, lasted six months from 16th June 
2008 – January 2009 and Phase 3 spanned another four months from 6th July – 30th 
November 2009. These phases both yielded results similar to the initial data from 
the baseline study of April – June 2008, in that the TVC’s from the water supplies 
were very high. During these phases it was possible to recover opportunistic 
pathogens from potable water and water for bathing facilities on the ward. The 
proportion of water samples or outlet swabs positive for bacterial growth in Phase 1 
was very high at 98.7% and 77.1% respectively. Water samples yielding bacterial 
growth were equally as high in Phase 3 (98.9%) but the number of contaminated 
outlet swabs dropped markedly to only 41.7%. 
 
It is possible that the reduction in swabs yielding bacterial growth could be related to 
the fixing of the filters to the outlet for the previous six months. When the study was 
first conceived, it was envisaged that ‘dummy’ filter units would be attached to all 
outlets in Phases 1 and 3, as appropriate controls for when the genuine POU filters 
were in place. Unfortunately, as the units are CE marked medical devices, it was not 
possible for the manufacturers to supply non-functional ones due to regulatory 
requirements. By having the device fixed to the end of outlets in Phase 2, a number 
of variables could have influenced that environment such as the terminal point of the 
taps could no longer be touched by patients, staff, visitors or cleaners (and their 
cleaning materials) thereby reducing external contamination of the outlet. Splash-  
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back from outlet use could also no longer cross-contaminate the outlet itself; the 
adaptor for the filter and the filter device provided an extension of the tap taking 
water-borne organisms further away from the outlet terminus. All these factors could 
have had a residual effect which contributed to the reduction in positive outlet swabs 
seen in Phase 3. 
 
Pseudomonas aeruginosa was the most frequently recovered target species from 
water samples (13.6%) followed by S. maltophilia (9.5%) during unfiltered periods. 
Recovery of the latter was much lower than that for the former. During Phase 1, 
18% of samples were positive for P. aeruginosa compared with 10.7% yielding 
S. maltophilia. However, recovery of P. aeruginosa in Phase 3 decreased 
significantly to only 8.2% with recovery of S. maltophilia slightly lower also at 8.2%. 
Statistical analysis showed the reduction to be significant for P. aeruginosa but not 
for S. maltophilia. The overall prevalence in unfiltered water samples of these target 
species was 21.5%  
 
Proximal (pre-flush) samples were taken on first opening of the outlet with the 
collection bottle in place to obtain water held in the section of pipe closest to the end 
of the outlet, and represents water a person would be exposed to on opening the 
outlet. The distal (post-flush) sample was more representative of the circulating 
water in the distribution system. Of the 322 isolates that were recovered from the 
water samples, 182 (56.5%) were recovered from the proximal sample with no 
additional recovery from the distal sample, suggesting that these bacteria were 
either not present or present in very low numbers throughout the distribution 
system, and that they may be more highly concentrated in biofilms in taps or 
proximal pipework. In the case of the former this may have arisen following initial   
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colonisation as a result of direct contact made by human hands or cleaning 
materials. 
 
Only 18 isolates were recovered from the distal samples without recovery from the 
concomitant proximal sample. These instances could be indicative of contamination 
extending through the distribution system or planktonic bacteria travelling through 
the circulating water. The recent Department of Health Guidelines (Gateway Ref: 
17734) for P. aeruginosa Contamination of Taps and Water Systems, states that 
while biofilms will be present on the materials that comprise the water distribution 
system, P. aeruginosa is often concentrated within the final 2 metres from the point 
of use (DH, 2012b). Therefore, recovery of the bacterium from the distal sample 
could still represent seeding from this final section of the water system. However, 
without the removal of the piping and examining of biofilm for target species, it is not 
possible to say whether contamination of the pipes is located near to the point of 
use and that this is where the target species were harboured. 
 
Of 720 outlet swabs taken during unfiltered phases, 444 (62%) were positive for 
bacterial growth but only 70 (9.7%) yielded target species; in contrast with 21.5% of 
water samples from which these species were recovered. A total of 74 target 
isolates were recovered by swab and 63 of these came from outlets already 
associated with that species either intermittently or as a persistent ‘hotzone’ (i.e. an 
outlet with 50% or more recovery of target species). In 70% of instances where 
there was recovery from the outlet swab, recovery of the same species occurred in 
the concomitant water sample. This shows that surveillance of a water distribution 
system must include water sampling and not rely on swabbing alone. In the current 
study the use of outlet swabs was a useful aid to the recovery of the bacteria of   
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interest as, on occasion, recovery was made solely by this method. However, 
examination of the water revealed far more information about outlet colonisation. 
Had swabs been the only surveillance method, then much smaller numbers of 
positive samples would have been detected. 
 
Regarding isolation of S. maltophilia from swabs, 15/23 were recovered from 
showers in Phase 1 and 15/16 were recovered from showers during Phase 3. The 
single non-shower isolation event in Phase 3 was from Outlet B (the bathroom 
washbasin) of Room 2 which was an outlet with only occasional isolation of 
S. maltophilia but never from an outlet swab. However, during Phase 3, the shower 
of Room 2 was a persistent source of S. maltophilia with 63% of water samples and 
75% of outlet swabs positive. Therefore while it is certainly possible that on this 
occasion Outlet 2B itself was the source of the contamination, it is also possible that 
there had been a cross-contamination from the shower, transferred via people or 
splashing. As these outlets are served by the same leg of distribution system, it 
could suggest that S. maltophilia has a higher affinity for the materials of showers 
heads than of taps (recovery of S. maltophilia from shower water samples was 31%, 
much higher than all other outlet types) and that the bacterium was residing in the 
shower but not in the water supply to that room. 
 
It was noted throughout the unfiltered phases that one target species was often 
more likely to be recovered from an outlet than the other. Five outlets met this 
criterion to be designated as a hotzone with respect to S. maltophilia. These were: 
outlets 2C, 7A, 7B, 7C, and 9B. Of these, outlets 7C and 9B displayed lower 
recovery rates following the return to unfiltered samples in Phase 3 with recovery   
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from water samples decreasing  from 75 - 29% from Outlet 7C and from 63 - 17% 
from 9B. 
 
Frequently S. maltophilia was recovered from showers despite routine shower-head 
changes made by the BRI Estates. This was done on a six monthly basis as part of 
the L. pneumophila control strategy, including week 7 of Phase 1. Showers are an 
important source of waterborne microbes either through inhalation of aerosols (as in 
the case of L. pneumophila) or direct contact between water and breaches in the 
skin, e.g. wound and catheter exit sites (Feazel et al., 2009; Perkins et al., 2009). 
 
When the routine change of the shower-heads on week 7 is analysed (Figure 27), it 
can be seen that the shower of Room 4, from that point forward in the study, was 
negative for S. maltophilia although the bacterium had been isolated on two earlier 
sampling occasions. This was also true for the shower of Room 9 (the next isolation 
of S. maltophilia was week 20 of Phase 1). At this time, the occupant of Room 2 
was in isolation because of tuberculosis and therefore the shower-head was not 
replaced as planned. No change was detected in the isolation of S. maltophilia from 
this shower and this outlet became a hotzone in Phase 1. Had this shower-head 
also been replaced then perhaps this reservoir would also have been eliminated as 
was the case for rooms 4 and 9. It is believed that all shower-heads were changed 
at this time. However, this action did not serve to interrupt the recovery of 
S. maltophilia from rooms 6 and 7 suggesting that the bacterium was present further 
back along the pipes or in the flexible hose.  
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The potential importance of changing shower heads as a control measure for 
pathogens such as S. maltophilia is evidenced again following the first filtered phase 
(Phase 2) when the switch was made from filtered shower heads back to 
conventional ones. In Phase 3 it was not until week 6 when S. maltophilia was 
isolated. The samples from the showers of Room 2 and Room 9 were positive on 
Week 4. However, the first samples taken from rooms 7 (a hotzone in Phase 1) and 
12 (previously never positive for S. maltophilia) on Week 1 of Phase 3 yielded 
S. maltophilia. This shows that showerhead replacements do not always eliminate 
species such as S. maltophilia. 
 
Interruption of recovery of P. aeruginosa was also seen following a change of 
shower heads (see Figure 28). The first two sampling occasions for the showers of 
Rooms 8 and 10 resulted in recovery of P. aeruginosa. Following shower-head 
changes on week 7, the species was not isolated again (see Figure 28). In the 
current study, P. aeruginosa was recovered less frequently from shower samples 
than S. maltophilia (9% versus 31%). A possible explanation could be that 
S. maltophilia is more adherent to the material from which the showers are 
constructed than P. aeruginosa. Feazal et al., (2009) showed in a study of 
showerheads taken from domestic homes, apartments and public buildings, across 
the USA, that in contrast to other waterborne bacteria such as Mycobacterium spp., 
Bacillus spp. and Sphingomonas spp., Pseudomonas spp. were more readily 
isolated from water samples from showers compared with the biofilm from showers 
(Feazel et al., 2009). 
 
Hotzones for P. aeruginosa included the handwash station located in the kitchen 
which was consistently colonised with P. aeruginosa during Phase 1 (but not Phase   
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3). Others were outlets 3B, 4A, 8A, 10B, 12A and the handwash station located on 
the corridor).From patient rooms, P. aeruginosa was more likely to be recovered 
from sink taps (outlets type A and B) in contrast to the association of S. maltophilia 
with showers. Sustained recovery of both species from an outlet was not observed, 
i.e. hotzones were associated with one species or the other. Recovery of the target 
species throughout the ward (Figure 13), did not follow a specific pattern, i.e. 
isolation was not associated with specific sections of the ward distribution network 
and recovery was dispersed throughout. 
 
Some types of materials used in the production of piping (e.g. plastic used in flexible 
hosing) and thermostatic mixing valves are associated with biofilm development and 
colonisation with P. aeruginosa (DH, 2010; Halabi et al., 2001; Rogers et al., 1994). 
Each component of a system can represent a new niche for biofilm establishment. 
In 1993 Ward 7 was converted from an open Nightingale-style ward to a unit with 
individual patient rooms. In comparison to many of the other wards in the hospital it 
has a relatively new distribution system. This consists of handwash stations 
incorporating thermostatic mixing valves (TMV’s), showers and wash basins 
operated by non-touch sensors. 
 
Pseudomonas aeruginosa colonisation was more frequently associated with sink 
outlets (types A and B) i.e. outlets incorporating TMV’s valves and/or non-touch 
sensors. TMV’s are difficult to maintain due to the complexity of the device and in 
terms of Legionella control, the guidelines are only applied to circulating water up to 
the TMV itself (Lee, http://www.hps.scot.nhs.uk/haiic/ic/presentations.aspx?id=55, 
presentation 2004). The section of distribution system following the TMV leading to 
the tap is subject to lower water temperatures than the circulating system, water   
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stasis and a reduced water flow if there is a water saving mechanism (such as a 
time-controlled non-touch sensor operated outlet). The high TVCs and recovery of 
target species observed in this study from the outlets of Ward 7 could be 
representative of these types of fixtures and fittings in general, but there are few 
comparative data relating to similar systems in other UK hospitals. If more time had 
been available, it would have been interesting to compare the microbiological quality 
of water samples from other wards in the same wing of the hospital, but which do 
not have TMVs. 
 
It has been suggested that TMV’s components could become contaminated with 
P. aeruginosa during testing and validation during the production and that this 
testing of the devices using non-sterile water could lead to devices which are 
already contaminated with P. aeruginosa being supplied to healthcare facilities 
(Kelsey M., Pall Masterclass 2012). 
 
Other components of water supply fixings which may become colonised with 
bacteria include flexible hoses connected to baths, handwash basins, ice machines, 
etc. In 2010 a communication from the Department of Health (Gateway Ref. 14265) 
stated that flexible hoses (excluding those running to showers) used in water 
systems should be identified and risk-assessed for the possibility of contamination 
with harmful microorganisms. This was in response to reports of high levels of 
Pseudomonas spp. and Legionella spp., in water samples fed by flexible hoses and 
associated with colonisation of their linings. The lining material identified as posing 
the greatest risk was ethylene propylene diene monomer (EPDM). This shows how 
the choice of materials used to manufacture devices can be an important factor in 
infection control.  
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Non-touch (“electronic eye”) taps have been fitted in many healthcare facilities as 
part of infection control measures and were placed in all the en-suite facilities on 
Ward 7. However, there is evidence that these fittings can be the source of bacteria 
including Legionella spp (Hargreaves et al., 2001; Leprat et al., 2003; Merrer et al., 
2005). Sydnor et al (2011) reported that of 20 manually-operated outlets and 20 
non-touch operated outlets they studied, 50% of water samples the former yielded 
Legionella spp. compared with only 15% from manual outlets. They also found that 
chlorine dioxide was not as effective in reducing Legionella from the non-touch 
outlets with 29% still contaminated following chlorine dioxide flushing compared with 
7% of the manual outlets. The authors speculated that the increased bacterial yield 
could be the result of contamination of the components that made up the outlet 
(Sydnor et al., 2012). 
 
Halabi et al., (2001) also reported increased bacterial numbers of both 
P. aeruginosa and Legionella spp. in 38 non-touch outlets (23 without and 15 with 
temperature control). 74% of the former and 7% of the latter were contaminated with 
P. aeruginosa. More detailed analysis showed that the magnetic valves and the 
outlets themselves were heavily contaminated. The study concluded that this 
localised contamination could have arisen because of the reduced amount of water 
flushing through the outlets along with low water pressure coupled with a standing 
temperature of around 35OC for the water remaining in this area providing nearly 
optimal growth conditions for P. aeruginosa (Halabi et al., 2001). 
 
The non-touch fittings in the patient rooms on Ward 7 (outlet type B), were all 
equipped with temperature control and were found to be colonised with 
P. aeruginosa on 24% of sampling occasions and S. maltophilia on 16%. For   
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P. aeruginosa this was lower than the handwash stations (outlet type A) in the 
patient rooms (with TMVs) which were positive on 33% of sampling occasions. In 
the current study it was not possible to dismantle any outlet fitting to investigate 
areas of contamination as this would have caused major disruption to the ward as 
the rooms would need to be vacated and sealed off to minimise risk of infection  
 
On Monday of week 12 (after samples had been collected), the kitchen taps were 
replaced for a type compatible with Pall filters. The next samples were collected on 
Monday of Week 13. On this occasion, P. aeruginosa was cultured from the cold 
outlet. There was no isolation the following week but the bacterium was recovered 
again in weeks 16 & 17. There was no further detection from this outlet in Phase 1. 
Also on week 12, patient P.004 gave consent to join the study and first samples 
were collected. These yielded P. aeruginosa from throat and faecal samples and the 
patient developed bacteraemia with this bacterium in week 15. Isolates recovered 
from patient P.004 and from water sources were characterised using antimicrobial 
susceptibility testing and strain typing to establish if they were related. 
 
Patient P.004 received meropenem and gentamicin 30th August and 8th September 
2008 (weeks 10 – 12). P. aeruginosa was recovered from samples taken on weeks 
12 (throat and faecal) and 14 (throat). These isolates were resistant/intermediately-
resistant to imipenem and intermediately-resistant to aztreonam. No further study 
isolates (patient or water) exhibited resistance/intermediate resistance to imipenem. 
The patient became bacteraemic in week 15 with P. aeruginosa and the BRI 
microbiology laboratory reported that these isolates were resistant to meropenem as 
do all successive reports until the final sample on 2nd October. A sample collected 
on 29th September was also resistant to imipenem (Table 29). One blood culture   
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isolate was made available for the study and was included in strain typing studies 
(section 3.11.12). 
 
Despite the reports of meropenem resistance, this agent was given from 28th 
September - 2nd October. It is possible that this was a result of earlier meropenem 
treatment. Unfortunately, because of the time the patient entered the study, it 
cannot be determined when resistance was acquired. It is unknown if the patient 
came into the hospital already colonised with the resistant strain of P. aeruginosa or 
if it was acquired following admission and subsequent antibiotic treatment as 
resistance to carbapenems in P.  aeruginosa is known to emerge during therapy 
(Carmeli et al., 1999). 
 
Antimicrobial susceptibility testing of P. aeruginosa isolates from water sources 
revealed very little resistance to the eight antimicrobials used. In total, 97% of 247 
water isolates were intermediately resistant to aztreonam only. The remaining eight 
were fully susceptible. Only four isolates recovered from water samples exhibited 
resistance to two antimicrobials (intermediate resistance to both aztreonam and 
ciprofloxacin). 
 
In the current study, the water distribution system did not harbour highly antibiotic 
resistant strains of P. aeruginosa. This is in contrast to other studies that have 
reported high levels of resistance in both clinical and environmental isolates. 
Deredjian et al., (2011) showed that isolates recovered from CF patients and the 
hospital environment were more resistant than isolates from the outdoor 
environment (Deredjian et al., 2011). Gad et al., (2007) reported resistance in   
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isolates from the hospital environment (patients’ beds, tables, ward sinks and 
surgical equipment) to be higher than in clinical ones (Gad et al., 2007). Another 
study found that 96% of isolates recovered from swimming pools and hot tubs in 
Ohio, USA, were multidrug-resistant (Lutz and Lee, 2011). Nevertheless, the water 
distribution system of Ward 7 harboured large numbers of the species and 
irrespective of the antimicrobial resistance phenotypes, these strains could still 
represent a potential threat to patients resident on the ward, or elsewhere in the 
hospital if transferred via staff. 
 
Typing of P. aeruginosa recovered from patient P.004 and water isolates was 
performed using the PCR-based typing techniques BOX- and REP-PCR. Pulsed-
field gel electrophoresis is often considered the method of choice for establishing 
genetic relatedness and while it has powerful resolution and discriminatory abilities 
it requires specialised equipment and many hours of processing for small batches of 
isolates. In contrast, repetitive sequence based-PCR (rep-PCR) facilitates a rapid, 
cost-effective and high-throughput typing method for large numbers of isolates (Lin 
et al., 2008; Nayak et al., 2011). 
 
In the current study, BOX and REP-PCR methods were used. BOX-PCR proved to 
be less discriminatory than REP-PCR for typing P. aeruginosa (Section 3.11.5.2), 
typically generating only three to four bands in each profile. This is in contrast to 
other studies which report this technique as suitable and highly discriminatory for 
the typing of isolates of P. aeruginosa of clinical and environmental origin (Mehri et 
al., 2011; Syrmis et al., 2004; Wolska et al., 2011). In the present study an 
annealing temperature of 52oC was necessary to ensure a reasonable degree of 
reproducibility. Mehri et al., (2011) and Wolska et al., (2011) used lower   
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temperatures (45 and 48oC respectively), presumably sacrificing profile 
reproducibility in favour of number of bands. The figures in the publication by Mehri 
et al., show very smeared banding patterns, which would not be suitable for 
computer analysis. Syrmis et al., (2004) used an annealing temperature of 53oC, 
which is very close to the one used in this work, and generally obtained more bands 
per strain profile. This could be a feature of the particular collection of isolates they 
analysed, or may have related to use of a different Taq polymerase. While the 
GelCompar software was able to define clusters amongst the very similar profiles 
obtained from the water isolates, in some cases this is more likely due to intra-
laboratory reproducibility and gel normalisation issues rather than true differences 
between profiles. Thus, more credence was given the REP-PCR results when 
analysing the data from the P. aeruginosa strain typing results. 
 
Strain typing study 7 (Section 3.11.12) compared water isolate profiles with those 
from patient P.004 throat, faecal and blood culture isolates from week 12 (first 
detection of P. aeruginosa from the patient), to week 22 on the patient’s discharge. 
Although the BOX-PCR showed patient and water isolate profiles to be 
indistinguishable, for the reasons outlined above, they were not deemed to match 
as REP-PCR clustered them below the cut-off level. 
 
Patient P.004 was the only study patient to have P. aeruginosa isolated from blood 
cultures (in 2008) as well as specimens collected for the purpose of the study. 
However, four other non-study patients on ward 7 also developed P. aeruginosa 
bacteraemia during the project. Three cases occurred during Phase 1: two in 
August (4th and 22nd) and another on 28th September 2008. There were no further 
cases until 21st January 2009 followed by a 12-month interval until February 2010.  
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However, these blood culture isolates were not available for typing, and thus it was 
not possible to investigate whether they may have been related. Given that the 
cases of bacteraemia occurred within a short time, there may have been cross-
transmission from patient-to-patient or contamination from a common source. 
 
The August/September 2008 cluster could also represent seasonality of blood-
stream infections with P. aeruginosa. Wilson et al., (2010) reported that certain 
Gram negative bacteria including E. coli, Klebsiella spp. and P. aeruginosa showed 
seasonal trends with peaks in summer (Wilson et al., 2011). Eber et al, 2011 also 
reported summer peaks and that imipenem-resistant P. aeruginosa blood culture 
isolates were 33.4% more frequent in summer compared with winter months (Eber 
et al., 2011). 
 
Throat swabs from two patients (P.013 & P.014) yielded S. maltophilia. Originally 
not regarded as being a particularly virulent organism (Crossman et al., 2008), it has 
become an important opportunistic pathogen with an attributable mortality rate of 
26.7% (Senol et al., 2002). It has also been shown to survive the water treatment 
processes and remain active within water distribution systems (Hoefel et al., 2005). 
The showers of Ward 7 acted as a reservoir for S. maltophilia and it is possible that 
the aerosolisation of the bacterium from this reservoir might have increased the risk 
of colonisation/infection of the patients’ respiratory tracts. The patient isolates were 
of immediate interest as they occurred in the same week (week 10, Phase 3) and 
colonisation with this bacterium had not been seen previously in other patients.  
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Patients P.013 and P.014 were both female and resident in rooms 9 and 4, 
respectively. Patient P.013 had one isolate recovered from a throat swab and 
S. maltophilia was recovered from two throat swabs from Patient P.014. The 
bacterium was not isolated from Room 4 throughout Phase 3 except for one 
occasion on Week 18 from outlet A. S. maltophilia was recovered from the shower 
in Room 9 on three occasions (weeks 4, 6 and 10), and outlet B on week 4 (see 
Figure 28). 
 
Comparison of antimicrobial susceptibilities revealed that all three clinical isolates 
were intermediately resistant to ciprofloxacin and piperacillin/tazobactam and 
resistant to amikacin and gentamicin. The first isolate from P.014 was also resistant 
to aztreonam. Both the second isolate from patient P.014 (N.1127) and the single 
isolate from patient P.013 (N.1124) were intermediately-resistant to aztreonam. 
 
Of the two rep-PCR methods used, REP-PCR was less reproducible than BOX-
PCR for typing S. maltophilia (Section 3.11.5) although Lin et al., (2008) reported 
the technique to be more discriminatory than BOX- and ERIC-PCR and to be 
reproducible (Lin et al., 2008). Based on the results presented in Section 3.11.5, 
BOX-PCR was deemed to be more useful. 
 
Although the antibiograms of isolates N.1127 and N.1124 were indistinguishable, 
both typing methods showed they were unrelated. However. REP-PCR matched 
patient P.013 isolate (N.1124) with the first P.014 isolate (N1119). Strain typing 
studies 1 and 2 attempted to establish a link between S. maltophilia patient and 
water isolates but neither method revealed a relationship. While studies 1 & 2 could   
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not identify a common source from the water from either of their rooms or connect 
them to any other S. maltophilia isolate recovered from water on week 10, it is still 
possible that these two patients were colonised from the same external source. 
 
Strain typing studies 3, 4 and 5 examined isolates from outlets which had either 
been identified as hotzones or yielded S. maltophilia sporadically. The aim of these 
studies was to discover whether the same strains were colonising outlets over time. 
Studies 3 and 4 identified strains that persisted in hotzone outlets from phase 1 - 
Phase 3 using both typing methods. 
 
Strain typing study 3 was also able to group the isolates on the basis of outlet of 
origin (Figure 43). On comparing profiles of isolates from all three outlet types in 
Room 7, three separate clusters were identifiable. Comparison of the antibiograms 
was not able to distinguish between isolates from outlets type A and B. Those from 
the shower were resistant to the same antimicrobials as those from A and B plus 
ciprofloxacin supporting the distinct clustering suggested by PCR. 
 
Isolates of S. maltophilia from the shower isolates from Room 2, (which was also a 
hotzone for S. maltophilia recovery), or those recovered sporadically from the 
shower of Room 11 were susceptible to ciprofloxacin in contrast to the isolates from 
the shower in Room 7. Ciprofloxacin resistance/intermediate resistance in shower 
isolates was 49% compared with 21% in those from taps. This may relate to the 
clonal grouping of the shower isolates. Alternatively, this could be explained by 
contamination of the showerhead by ciprofloxacin-resistant bacteria carried by 
patients.  
  
 
231 
All three clinical S. maltophilia isolates were resistant to five antimicrobials 
compared with an average of 3.6 (range 1 – 6) in those from water or water outlet. 
This suggests that the hospital water distribution system could act a reservoir for 
multiply-resistant S. maltophilia and also that patients resident on the ward were 
colonised with highly resistant strains. Berg et al., (1999), also investigated 
antimicrobial resistance in S. maltophilia isolates of clinical and environmental origin 
(unfortunately the environmental origin of these isolates are not listed in this 
reference) and reported that both can be multi-resistant, with two isolates from both 
environmental and clinical sources being resistant to 16 antimicrobials. They also 
found that many isolates were resistant to both amikacin and gentamicin 
(prevalence of 84% in environmental and 52 & 67% in clinical isolates respectively) 
and aztreonam (95% in clinical, 79% in environmental), a result very similar to the 
findings of the current study (Berg et al., 1999). Susceptibility testing of 
S. maltophilia is particularly difficult and the outcomes for both disc test and MIC’s 
can be affected by temperature and by growth medium (BSAC version 9.1). 
Aminoglycosides can be particularly affected by growth temperature, giving false 
susceptible results at 37OC. 
 
Rahmati-Bahram et al., (1997) studied the effect of temperature-induced changes 
on the chemical composition of LPS on susceptibility to aminoglycosides in 
S. maltophilia. The increased susceptibility to aminoglycosides at 37OC was 
deemed to be due to increased numbers of aminoglycoside binding sites (Rahmati-
Bahram et al., 1997). Nearly all the isolates in the current study were found to be 
resistant to amikacin and gentamicin when susceptibility tests were performed at 
30OC (93% and 97%, respectively). However it is important to note that the BSAC 
P. aeruginosa breakpoints were used to interpret zone diameters and they may not 
be entirely representative of clinical resistance in S. maltophilia. With this in mind,   
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incubation at 30OC as the standard for investigating S. maltophilia could have 
important clinical implications when considering antibiotic treatment. 
 
Co-trimoxazole, widely regarded as the drug of choice, is the only agent 
recommended by BSAC for susceptibility testing of S. maltophilia. Using the BSAC 
breakpoints, only five isolates recovered from water samples were resistant and all 
patient isolates were susceptible.  
 
Only single stool samples were collected from patients P. 013 and P.014 and these 
did not yield S. maltophilia. Indeed, S. maltophilia was not recovered from any of the 
19 stool samples from the patients recruited to the study. Although the number of 
specimens examined is too small to permit conclusions to be drawn, the absence of 
faecal carriage was reassuring. Kerr et al., (1991) showed high faecal carriage rates 
of S. maltophilia in adult haematological malignancy patients (Kerr et al., 1991). 
Apisarnthanarak et al., (2003) also reported faecal carriage of S. maltophilia with 
rates of 10.9% (14/128) of outpatients with diarrhoeal illness [or their contacts] and 
9.5% (4/41) of patients hospitalised in an oncology unit with diarrhoea respectively 
(Apisarnthanarak et al., 2003). A literature search found no other reports of faecal 
carriage in haematology malignancy patients. 
 
Acinetobacter baumannii can also colonise the digestive tract. Corbella et al., (1996) 
showed that this could be an important reservoir of the bacterium during an 
outbreak in which infections caused by MDR strains occurred more frequently in 
patients with faecal colonisation than those without (Corbella et al., 1996). As with 
S. maltophilia, there is a lack of studies which have investigated gastrointestinal   
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carriage of this bacterium and a possible relationship with subsequent infection in 
patients with haematological malignancy. Investigation of the samples from Ward 7 
patients, showed no evidence of colonisation by A. baumannii. However, the very 
small number of patients studied must be borne in mind when considering the 
significance of this result. 
 
The prognosis for a patient with a haematological malignancy has improved in 
recent years due to the availability of new treatments. However, more profound 
immunosuppression and the use of invasive therapeutic and diagnostic procedures 
have led to an increased risk of severe infections (Tumbarello et al., 2009). While 
long-term survival has improved infections, particularly those associated with 
bacteraemia, are one of the most significant complications of therapy and a 
significant cause of mortality and morbidity (Wisplinghoff et al., 2003). Some centres 
have reported a rise in Gram negative infections (Chen et al., 2004; Guven et al., 
2006; Velasco et al., 2006), which is of significance given higher mortality rates 
associated with Gram negative bacteraemia compared with those caused by Gram 
positive bacteria, especially when antibiotic resistance is a compounding factor 
(Anderson et al., 2006; Cosgrove, 2006; Tumbarello et al., 2007). 
 
Filtered Phases of the Study 
 
Phase 2, the first phase of the study in which filters were used, began in January 
2009. Domestic and nursing staff were instructed not to touch or clean the filters, 
and to pass the same information on to patients. Unfortunately it appears that this 
information was not always relayed to patients. It became apparent that some of the 
filters were almost certainly interfered with. On several occasions the devices were   
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removed by a patient as they were unaware that the tap operated as normal with a 
filter in situ. When this was brought to attention, the filter was replaced with a new 
one. Outlet swabs (swab of the filter-housing rim and immediate internal rim) and 
water samples were collected in the same way as in Phase 1. 
 
The proportion of water samples which yielded bacterial growth following the 
installation of Pall AqausafeTM filters decreased from 98.8% to 22.4% and overall 
bacterial counts were markedly reduced from too many to count to an average of 
4.6 CFU/100mL with a median of 1 CFU/100 mL, although 20 specimens yielded 
colony numbers which were too numerous to count. Only one target species 
(S. maltophilia) was recovered from a water sample during the two phases. This 
was from the handwash station located in the central corridor, an outlet consistently 
negative for S. maltophilia from swabs and water samples in both unfiltered phases. 
This suggests that the bacterium was unlikely to have originated from the water 
supply, and that the device may have been contaminated in situ although 
S. maltophilia was not recovered from the outlet swab taken before the water 
sample was obtained. 
 
Eleven out of 278 positive samples from filtered outlets yielded bacteria capable of 
growing on selective/differential media (Table 28). Three Gram positive bacteria and 
six Gram negatives grew on LAM including the species Ralstonia pickettii, a 
bacterium that has been shown, in a drug preparation solution, to be capable of 
growing with a reduced cell size, such that it can pass through even a 0.2 µm 
membrane (Sundaram et al., 1999). The species recovered from water samples 
were first incubated on R2A agar for 48 hours, potentially allowing stressed forms to 
revive before subculture onto media incorporating antibiotics. It is also theoretically   
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possible that if there was a large amount of particulate material in a water supply, 
the integrity of the pleated membranes could be compromised and allow bacteria to 
pass through. However, a site inspection performed at the start of the study 
determined the amount of particulates in the ward 7 supply was negligible, making it 
unlikely that damage to the filters was the cause of these rare isolations. 
 
It is worth noting a report that ultramicrocells of S. maltophilia, i.e. cells of reduced 
size associated with stress can also pass through 0.2 µm cellulose acetate and 0.1 
µm nylon filter membranes (Silbaq, 2009). However filtration in the Silbaq study was 
achieved using single layer membranes, in contrast to the much more complex 
pleated, double membrane construction of filters used in the current study. The 
ultramicrocells require incubation for 72 hours to grow on minimal media and hence 
would not be detected in most water sampling protocols. It is not known whether 
ultramicrocells are clinically significant, as there is no evidence to suggest that they 
are capable of colonising or infecting a susceptible host. 
 
The possibility that the membranes were contaminated during specimen processing 
cannot be excluded, for example, airborne bacteria could have been drawn into the 
membrane filtration funnel as the vacuum system drew the water through it. This 
could have been prevented by using sealed sterile membrane filtration units 
incorporating HEPA filters to ensure only sterile air comes through, as are used for 
sterility checks on pharmaceutical preparations. Overall, the use of POU filters 
seemed effective in reducing patient exposure to the target species endemic in the 
water supplied to Ward 7.  
  
 
236 
Stenotrophomonas maltophilia was isolated on several occasions from unfiltered 
outlets during Phase 2 showing it was still present in the water distribution system 
during this period (Figure 32). However, other than a single instance of recovery of 
S. maltophilia from the handwash station on week 24, the bacterium was not 
isolated from any filtered outlet during Phase 2 of the study.  
 
Vonberg et al., (2005) used Pall AQF1S and AQF2 filters as a control measure for 
nosocomial legionellosis in two German hospitals and reported similar findings to 
the current study. Tap and shower filters were used in this two centre study. A bone 
marrow transplant unit in one centre used non-impregnated filters whereas an ICU 
in the other employed silver-impregnated filters. 
 
In the transplant unit, 25% of unfiltered water samples were positive for Legionella 
spp. (median count, 2 CFU/mL). Following filter installation this decreased to 0.6% 
with (median count, 4 CFU/mL) after 3 – 4 days but increased to 2.8% (median 
count, 2 CFU/mL) after seven days. In the ICU 90% of unfiltered water samples 
yielded Legionella spp. (median, 9 CFU/mL): this reduced to 0.4% (median, 1 
CFU/mL) after seven days and increased to 2.2% (median, 3 CFU/mL) at 14 days. 
No data were given for total bacterial counts but the results show that POU filtration 
reduced but did not eliminate Legionella spp. in water samples (Vonberg et al., 
2005). 
 
A number of studies have examined the use of POU filters as an infection control 
intervention (Aumeran et al., 2007; Cervia et al., 2010; Engelhart et al., 2002; 
Holmes et al., 2010; Trautmann et al., 2008; van der Mee-Marquet et al., 2005; 
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Vianelli et al., 2006), see Table 10, and a number of authorities have now 
recommended their use. The Robert Koch Institute (Germany) and the CDC both 
recommend of POU filters use for endoscope reprocessing (Robert-Koch-Institute, 
2002; Sehulster and Chinn, 2003). The French Ministry of Health advised the use of 
0.2 μm filtration in at-risk areas (French-Ministry-of-Health, 2002). The World Health 
Organisation has recommended POU filters for control of Legionella when 
Legionella-free water cannot be guaranteed (WHO, 2007). Also in some German 
hospitals, POU filters are automatically installed on neonatal units, haematology-
oncology units and endoscopy suites (M. Trautmann, personal communication). In 
the UK, the Yorkshire Cancer Network (YCN) stated that POU filtered water is the 
most appropriate water source for immunocompromised cancer patients and also 
evaluated the cost of providing safe water for immunocompromised patients (Hall et 
al., 2004) (see Table 39). 
 
The cost of POU filters, or indeed any other control method is a concern especially 
in the NHS where resources are finite. In outbreak situations when the source is 
suspected to be waterborne, POU filtration can be applied to terminate the outbreak 
quickly (Vianelli et al., 2006). However in non-outbreak situations the cost of routine 
use needs to be justified. Trautmann et al., (2008) and Holmes et al., (2010) 
examined this. Both studies took place in a non-outbreak situation and Trautmann 
et al., (2008) sought to reduce endemic P. aeruginosa infections on a surgical ICU. 
 
Trautmann et al., (2008) reported that the mean monthly rate of 
infection/colonisation with P. aeruginosa decreased from 3.9 ± 2.4 in the pre-filter 
period to 0.8 ± 0.8 in the POU filter period. Pre-filtration 97% of water samples 
yielded P. aeruginosa compared with 0% when filters were used. They concluded   
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that 7.6 infections per 100 patients staying ≥3 days were prevented (23 cases/year), 
giving a saving of approximately US $64,000 (Trautmann et al., 2008). 
 
Holmes et al., (2010) also showed an overall cost saving with POU filtration. In an 
investigation of the efficacy and cost-effectiveness of POU filtration in a subacute 
care unit, the number of infections was reduced. The total patient care costs were 
reduced by US $248,136 against a cost $17,100 for filtration including materials, 
labour for filter changes, and surveillance of water samples pre- and post-filter. The 
net saving was $231,036 (Holmes et al., 2010). 
 
Other strategies to interrupt patient acquisition from water supplies have included 
use of bottled water or sterile-filtered bottled water (Petignat et al., 2006; Vianelli et 
al., 2006). The Yorkshire Cancer Network compared different water sources for 
microbiological and, organoleptic (taste and smell) quality as well as cost. Table 39 
shows the cost comparison that was issued in 2004. 
Table 39. Evaluation of the cost for the Provision of Water for 
Immunocompromised Patients by the Yorkshire Cancer Network (YCN 2004) 
Water Source 
Sterile water 
provided by 
pharmacy 
Carbonated 
Bottled Water 
Bottled Still 
Water (Non-
carbonated) 
Filtered (Pall 
Aquasafe) 
Cost 
£3.56 for 6X 1 
litre bottles 
£1.98 for 6X 1 
litre bottles 
£1.98 for 6X 1 
litre bottles 
£19.65 per 
filter (4-day 
filter life, 2 
required per 
week) 
Overall cost to 
ward per day 
£47.50 £26.40 £26.40 N/A 
Overall cost to 
ward per week 
£336 £184.80 £184.80 £39.30 
Microbiological 
Quality 
Acceptable Acceptable Acceptable Acceptable 
Organoleptic 
Acceptability 
Unacceptable Unacceptable Acceptable Acceptable 
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The overall conclusions of the report was that filtration is cost-effective and, if strict 
protocols are put in place to ensure that filters are changed in accordance with the 
manufacturers’ recommendations, filters are the preferred method for provision of 
potable water for immunocompromised cancer patients.(Hall et al, 2004). 
 
A further benefit of POU filters was reported by Tu et al., (2007) who demonstrated 
that filtration reduced the number of false-positive results from attributed to non-
tuberculosis Mycobacteria present in rinse water. Filters were associated with a 
reduction in the number of false-positives (1.2%) compared with samples treated 
with tap water and deionized water used during the staining procedure in the 
laboratories (10.7 and 8.7%, respectively). The cost of disposable filters was 
significantly offset by the reduced number of misdiagnosed cases of tuberculosis 
(Tu et al., 2007). 
 
During the current study, filters were kindly supplied by Pall Medical. At this time the 
cost of 14-day filters was £42 each and Ward 7 had 38 outlets being filtered at an 
approximate cost of £1596 every 14 days which is an overall cost of £41,496 
annually. However, Pall Medical have now introduced 31-day filters which retail at 
£35 each giving an approximate monthly price of £1330 and £15,960 annually 
making these devices more cost effective (cost of devices supplied by Ms B. 
Duncanson, Pall Medical, personal communication). However, the additional cost of 
alterations to outlets should they not be compatible with the devices and the 
adaptors required for fitting the filters should also be taken into consideration.  
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Pall AquasafeTM filters were associated with a reduction of P. aeruginosa and 
S. maltophilia in water samples at the point of use suggesting a role for these 
devices as an infection control measure. Aside from the acquisition costs of these 
filters, there are a number of factors that need to be addressed before any 
establishment chooses to use these devices. For long term use, appropriate water 
outlets must be in place, i.e. outlets with a screw thread that allows the filter 
adaptors to be fitted. This means it may be necessary for outlets to be altered. 
Sediment content of the water can reduce the length of time these filters are 
effective and water pressure can also have an effect. Care must be taken when 
fitting the devices to ensure that contamination does not occur and, in addition, they 
must be replaced on the correct date, with robust protocols implemented to ensure 
this occurs. Some filters have aids for this such as bar coding and PDA technology 
along with staff education presentations. It should be noted that not all POU filters 
incorporate the same filtration technologies, nor do they contain bacteriostatic 
additives. Levels of validation are not necessarily equal and they may or may not 
have CE and/or WRAS approval. 
 
Despite such measures, problems may still occur with the filters in-situ. A number of 
patients on Ward 7 were confused by the devices thinking that they needed to be 
removed before turning on the tap. This meant that the housing of the filters could 
be contaminated as a result of being handled, and also from being left on the side of 
the sink. This might explain why bacteria were recovered from water samples during 
phases when filters were operational. This was not observed with shower filters, 
possibly because they look similar to conventional shower heads. The issue of 
patients interfering with the devices could be remedied in part with pictorial 
instruction sheets now available from Pall Medical and appropriate instruction from 
nursing staff.  
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Finally, concerns have been raised that devices in place for prolonged periods could 
cause a build-up of biofilm behind the filter which could then be flushed from the 
outlet when the filter is removed contaminating the user or the environment although 
there is no published evidence to support this hypothesis. Indeed, it is noteworthy 
that in Phase 3 following removal of filters, recovery of target species was reduced 
in comparison with Phase 1. 
 
Of the target species only P. aeruginosa was identified as a cause of bacteraemia 
during the current study and the number of cases was very low. Data from the BRI 
microbiology laboratory identified only three cases 2004 – 2006 and five more 
during the study (Tables 32 & 33). Three cases occurred during Phase 1: two in 
August (4th and 22nd) and another on 28th September 2008. There were no further 
cases until 21st January 2009 which was the first week of the first filtered phase 
which suggests that colonisation and/or onset of infection may have occurred within 
the previous unfiltered phase. There were no further cases for 12-months until 
February 2010 during Phase 4. It can be speculated that that the use of POU filters 
in Phase 2 may have prevented patient acquisition of P. aeruginosa from water 
supplies on the ward and consequent absence of bacteraemias for over a year. 
However, in the absence of typing data from the other infected patients this is 
impossible to prove. Overall, there were small numbers of cases of P. aeruginosa 
bacteraemia in patients on Ward 7 before or during this study despite the bacterium 
being endemic to the water supplies.  
 
Patients on this ward were not routinely given antimicrobial prophylaxis against 
opportunistic pathogens so the general lack of infections with the target species 
may indicate that water isolates are not particularly pathogenic. In a study  
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investigating the virulence gene distribution in clinical, nosocomial and 
environmental isolates of P. aeruginosa from Tasmania, Australia, Bradbury et al 
(2010) found that many virulence genes were highly conserved with the exception of 
exoU, a gene involved with cytotoxic effects. This gene was found in much lower 
numbers in only 18% of 184 isolates. Further investigation revealed that isolates 
containing this, were more likely to be found from the environment (sinks and wash 
tub) of intensive care and neurosurgical units than from isolates recovered from 
elsewhere including CF patients, showing the environment of these units to be a 
potential reservoir for highly virulent strains (Bradbury et al., 2010). However, 
Fenner et al., (2006) compared the virulence of 81 P. aeruginosa isolates from the 
hospital water of four hospitals in France with 69 clinical isolates (52 from blood 
cultures, 17 from bronchoalveolar lavage). Using an amoebal virulence test the 
results showed that the clinical isolates were significantly more virulent than the 
environmental. (Fenner et al., 2006). 
 
Control methods 
 
The BRI is a large campus with a correspondingly large water distribution network, 
making water management, a complex issue. To maintain water at temperatures 
inhibitory to Legionella spp., hot water at the BRI leaves the boiler room at 62OC 
and returns at 55 - 56OC. During the study there was no chemical treatment of the 
water distribution system (Tim Overend, BRI Estates, personal communication). 
 
In the HSE’s ACoP-L8 guidelines for controlling Legionella spp, removal of 
irregularly used taps and showers is recommended. Where infrequently used 
showers and taps are not removed, Point 165 recommends these outlets should   
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undergo a weekly flushing regime lasting for “several minutes” in order to reduce the 
number of Legionella from the outlet. HTM-04-01 Part B recommends this be done 
more than once a week in healthcare facilities. In the current study, one of the most 
frequently used outlets, was the handwash station in the kitchen. Despite the 
frequent flushing, this outlet was consistently colonised with P. aeruginosa from 
weeks 1 – 23 of Phase 1. This demonstrates that colonisation by this bacterium may 
not always be controlled by flushing. 
 
Following an outbreak of P. aeruginosa and P. putida on a paediatric haematology-
oncology unit, Aumeran et al., (2007), used replacement of shower heads and 
hoses and disinfection of taps as initial control measures. Despite these, most of the 
outlets in the ward were still contaminated with Pseudomonas spp. and, there were 
three more cases of infection. Chlorination of the water system and installation of 
single-use disposable 7-day POU filters were then used as control measures and no 
further contamination with Pseudomonas spp. was observed. However, these 
control measures were not adopted permanently due to the damage caused to the 
water distribution system by enhanced chlorination and the cost of replacing the 
filters every seven days. Instead, a ‘water loop’ device that used lower levels of 
chlorine plus filtration was installed (Aumeran et al., 2007). 
 
Biofilms are present in most drinking water distribution systems and can shield the 
bacteria from disinfection processes (Henne et al., 2012; Stoodley et al., 2001; 
Williams and Braun-Howland, 2003). Henne et al., (2012) showed unique biofilm 
communities existed at different locations along a 20 year-old water distribution 
system and that, although certain materials did not support the growth of some 
bacterial species, the existing biofilm could be overgrown by others (Henne et al., 
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2012). Many systemic control methods have been developed for controlling 
pathogens in water but they can be challenged by the presence of biofilm (see 
Table 9). 
 
Chlorine dioxide has superior penetration of biofilm than chlorine and is a more 
effective barrier over a wider pH range than copper-silver ionisation (Lin et al., 2011) 
and has been shown to be effective in the control of Legionella spp. from hospital 
water systems (Srinivasan et al., 2003; Zhang et al., 2007). However, this can take 
a long time to be achieved (Sidari, 2004; Zhang et al., 2007). The protection 
afforded by biofilm means that species such as Legionella app. are able to resist 
chlorination (Cooper and Hanlon, 2010). Shrivastava et al., (2004) were able to 
show that suboptimal levels of chlorine in drinking water can also lead to selection 
of multi-drug resistant P. aeruginosa (Shrivastava et al., 2004). 
 
Hosein et al., (2005) described an outbreak of Legionnaires disease in a Welsh 
hospital despite compliance with the current UK standards for temperature and use 
of chlorine dioxide. Legionella remained present in significant numbers with only a 
slight reduction of positive sites. Chlorine dioxide dosing had been first used in 1983 
following an outbreak of Legionnaires’ disease affecting six patients over three 
months. The dose at that time point was 0.3 parts per million (ppm) and took three 
months to achieve. Following another case in 1999, the water system for the cardiac 
intensive care unit was isolated from the rest of the hospital and hyperchlorination 
undertaken. A two year monitoring programme was established with monthly 
monitoring for the first six months followed by quarterly thereafter.  
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Following chlorination, Legionella was eliminated from the unit but, after 11 days of 
treatment, the bacterium returned to levels close to those seen prior to treatment. 
Throughout the monitoring period, Legionella was isolated from both hot and cold 
water. While there was a reduction in maximum and average counts over the time 
period, there was no reduction in the proportion of sites positive for Legionella spp. 
The study found that while the chlorine dioxide dosing of the hot and cold water 
supplies cost the hospital £25,000 per year, there was only a minimal effect on the 
presence of Legionella. The hospital raised levels of chlorine dioxide to 0.5 ppm 
(maximum permissible in the UK) but results were still unsatisfactory. A study in the 
USA reported successful control of Legionella with 0.8 ppm of chlorine dioxide 
(Srinivasan et al., 2003) but Sydnor et al., recently found that this did not completely 
remove Legionella from outlets operated by non-touch sensors (Sydnor et al., 
2012). 
 
Other water control methods include copper-silver ionisation which in a review of 
Legionella control methods by Lin et al., (2011), was deemed the best technology 
to-date although it is expensive (Lin et al., 2011). This method has also been 
effective for reducing numbers of P. aeruginosa, S. maltophilia and A. baumannii, in 
an in vitro study, but further evaluation is needed in large-scale water distribution 
networks (Huang et al., 2008). 
 
A more recent development in systemic disinfection techniques is a product known 
as Ecasol (Trustwater, Ireland), a disinfectant generated by electrochemical 
activation of a dilute salt solution. In a five week pre-treatment survey of hot and 
cold water from 15 washbasin taps in a dental hospital, there was consistent and 
heavy contamination with a wide variety of species including P. aeruginosa;   
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P. fluorescens; Sphingomonas paucimobilis and Comamonas acidovorans. An initial 
manual cleaning and shock-dosing of the water tank and water network was 
performed. The tank was drained and network flushed with mains water then 
maintained at 2.5 ppm. The microbiological quality of water from five sentinel taps 
was then monitored weekly for 54 weeks. Samples were cultured for 10 days at 20 
– 22OC on R2A agar. Samples yielded no growth from 95.2% of cold water samples. 
The remainder yielded TVCs of <20 CFU/mL (12 samples) and 100 CFU/mL (one 
sample). The mean growth from hot water outlets was 2 CFU/mL. This is in contrast 
to a pre-treatment average of 5022 CFU/mL from cold water and 482.5 CFU/mL 
from hot (Boyle et al., 2012). Unfortunately, the researchers did not report which 
species were still being recovered from the water so it is not clear whether Ecasol 
eliminated P. aeruginosa. 
 
Water samples in the Ecasol study were collected after flushing taps for only one 
minute, meaning that detection of bacteria from the end of the distribution system 
(i.e. in water trapped in the tap area between uses) could have been missed, 
lowering the average counts. Smaller water samples were also collected (50 mL) 
than in the current study (100 mL) which could reduce overall sensitivity for 
detection of bacteria. Boyle et al., (2012), also compared of the relative costs of 
Ecasol treatment and POU filtration for their hospital. The initial cost of installing the 
Ecasol-generating equipment was approximately €35,000 with annual maintenance 
and running costs of €4000. The estimated annual cost of POU filters for washbasin 
taps in the study hospital was €12,000 (Boyle et al., 2012). Assuming similar pro-
rata increases in costs for each system over time, then the Ecasol would have to be 
used for at least nine years before financial benefit was seen relative to the cost of 
using filters. However, this analysis was done using costings for 14-day filters. In 
2010 Pall   
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Medical introduced CE-marked 31-day filters, which are less expensive than the 14-
day devices, and hence would lower costs further. 
 
All systemic control methods have advantages and disadvantages relating to cost, 
exposure to hazardous compounds, storage, maintenance and ease of 
installation/retro-fitting and consequently many of them have variable results for 
short- and long-term use (Ortolano et al., 2005). Main concerns are reliability; 
including the ability to remain effective long- term; biofilm penetration and/or 
sloughing; maintenance of active concentrations; activity at all areas of the 
distribution system; and the potential for bacteria (either planktonic or biofilm-
associated) to develop resistance to the biocide, (Lin et al., 2011; Ortolano et al., 
2005). Such whole-system approaches are rarely able to remove all bacteria from 
the water, without altering the organoleptic qualities. An advantage of POU filtration 
is that it is not systemic and provides a targeted physical barrier between water and 
user and does not affect water quality, apart from removal of some particulates. 
Also, POU filters can be placed in a small number of key locations within a hospital 
and on just sentinel outlets thus not incurring the cost of a hospital-wide systemic 
method. 
 
Increasing Surveillance and Controls for Waterborne Opportunistic 
Gram negative Pathogens 
 
The DH document of March 2012 Water Sources and Potential P. aeruginosa 
Contamination of Taps and Water; supplemented the advice provided in the CMO 
“Dear Colleague” letter of February 2012. The document gives best practice 
guidance and covers: a). how to assess the risk to patients if water systems become   
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contaminated with P. aeruginosa; b). what actions to take if water systems become 
contaminated with the bacterium; c). protocols for sampling, analysis and monitoring 
for P. aeruginosa in water, and d). development of water safety plans. The guidance 
is aimed at augmented care units (paediatric and adult critical care, neonatal, burns, 
renal, transplant and haematology-oncology) and acknowledges that the ecology of 
P. aeruginosa may be different to Legionella and therefore the testing regimes 
appropriate for Legionella may not be appropriate for P. aeruginosa. In view of this, 
an addendum to HTM 04-01 to cover P. aeruginosa and water quality in augmented 
care units is expected by the end of March 2013 (DH, 2012b). This may include 
other opportunistic Gram negative pathogens such as S. maltophilia, but at the time 
of writing this is unclear. 
 
The 2012 guidelines state that infection prevention and control teams should ensure 
best practice relating to use and location of handwash stations and monitor clinical 
isolations of P. aeruginosa to detect possible outbreaks. This includes not disposing 
of bodily fluids or environmental cleaning fluids in HWS; and not washing patient 
equipment or storing used equipment in them. It also stresses that when cleaning 
HWS, the tap should be cleaned first. Washing of patients should be done with 
water from outlets which have been determined by risk assessment to be safe. All 
infrequently used taps should be flushed (and this activity recorded) at least daily for 
one minute in the morning. It is also recommended to use pre-filled, single-use 
bottles for of alcohol-based hand gels or cleaning fluids. Risk assessments and 
management approaches must be undertaken to ensure appropriate sampling, 
monitoring and clinical surveillance with initial assessments to be completed by 
June 2012 in all augmented care units, with the appropriate water sampling 
performed by the end of that month. Risk assessments should consider the 
susceptibility of patient groups and engineering assessments of water systems.  
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Outlets to be sampled are those that supply water that has direct contact with 
patients, used to wash staff hands or clean patient equipment. The water sampling 
protocol (Annex 1 of the document) is similar to that used in the current study. 
Samples should be taken at times of no, or little, use to maximise recovery (early 
morning is recommended). Pre- and post-flush [2 minutes] samples should be taken 
but if water samples are not available then take an outlet swab can be obtained. 
Membrane filtration followed by incubation on CN agar, a selective/differential 
medium for P. aeruginosa which includes cetrimide and nalidixic acid, is 
recommended. The guidelines also recognise the importance of showers and gives 
methods for sampling them. Results are to be recorded as: 0 CFU/100 mL, 
“satisfactory; 1 – 10 CFU/100 mL, retest and refer back to person responsible for 
water safety plans and >10, investigate cause and put corrective actions in place. 
 
When a result is recorded as satisfactory the guidelines state that no further testing 
is required for another six months. However, if these interpretive criteria had been 
used for the current study and applied to the growth-negative samples taken from 
the HWS in the kitchen on week 3 of Phase 1, then this sentinel outlet would have 
been missed as a frequent source of P. aeruginosa. It would be better practice if 
outlets were tested on two separate occasions, several days to one week apart, 
before being classified as “satisfactory”. The document also interprets the numbers 
of P. aeruginosa recovered from water samples. High numbers from the pre-flush 
but low numbers from the post-flush sample are deemed to suggest a local outlet 
problem, whereas high counts from both samples suggest a systemic problem. 
 
It is also recommended that when investigations into clinical infections are 
underway then the laboratory should retain both clinical and water isolates for three   
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months so that they will be available for typing. When sending isolates for typing the 
number of taps tested is important. The document states that where many taps are 
positive for the bacterium then a single colony from each sample should be sent, 
whereas if only two or three taps are positive then two isolates can be sent from 
each one. From the strain typing analysis in the current work, it was seen that 
several strains can be present an outlet at the same time (Section 3.11.8), thus, by 
sending only one isolate it is possible that an epidemiological important strain could 
be overlooked. Also, at present, there are no there is no systematic collection of 
data of clones of P. aeruginosa as there is for surveillance of MRSA and C. difficile. 
While the Liverpool Epidemic Strain, is a clone that is well documented and studied 
(Al-Aloul et al., 2004; McCallum et al., 2002; Panagea et al., 2005), it is unknown 
whether particular clones are associated with hospital water which could act as a 
source for at-risk patients. If evidence collected as a result of the new DH guidelines 
suggests that there is a link between water sources and P. aeruginosa infections 
then a central water testing laboratory could be established to monitor key strains. 
 
In situations where outlets are found to be contaminated with the bacterium then 
risk reduction and preventative measures need to be considered. In regard to 
protecting the patient, strategies include use of water from an alternative outlet 
which has been validated as “safe”, use of single-use wipes for patient hygiene, 
supplementation of hand washing with alcohol rubs and a review of the cleaning of 
equipment such as incubators and nebulisers. It also adds that for bathing 
neonates, sterile or filtered water should be considered (DH, 2012b). 
 
Strategies for improvement of water quality include checking for underused outlets 
with consideration given to removing them (along with attached pipework so   
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avoiding dead legs), and assessing the system for flexible hoses, blind ends and 
dead legs. The new guidelines suggest the use of POU filtration as a temporary 
measure until a permanent, safe engineering solution is developed, however, it 
does state that long term use may be required. 
 
The guidelines note that although disinfection of the distribution system may be 
necessary, this may not be effective against biofilms. If this method is adopted then 
weekly sampling should be undertaken on augmented care units to ensure that the 
biofilm does not continue to seed the water or that the disinfection does not lead to 
increased numbers of bacteria by sloughing of biofilm. Alternatively, a POU filter 
could be placed on a small number of sentinel outlets with only these allowed for 
hand and patient washing. The document also suggests removal and replacement 
of contaminated outlets if other control measures fail, but notes that this may not be 
a long term solution. 
 
Concerns raised regarding the DH guidelines are that the routine sampling of water 
outlets (in the absence of clinical data to suggest a problem with P. aeruginosa), 
could be a time-consuming and potentially expensive waste of resources. 
 
Furthermore, without robust typing data allowing comparison of water-related and 
clinical isolates, the epidemiological significance of positive water samples may be 
difficult to determine. Although submission of isolates for typing is recommended in 
the guidance when there only one isolate from each outlet is to be sent. This could 
very easily yield misleading information. Moreover, it could be argued that a more 
effective approach is that the requirement for environmental sampling should be   
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undertaken only when enhanced patient surveillance indicates an increased 
incidence of colonisation/infection with this bacterium. 
 
Based on the findings of the current study, best practice for water sampling (pre- 
and post-flush), would be to obtain specimens on more than one occasion before an 
outlet could be considered as “satisfactory”. A DH recommendation is to take an 
outlet swab in place of a water sample (when early-use samples are unavailable) 
but this method has been shown in the current study to be inadequate for detecting 
water outlets positive for the bacterium and should not be relied upon to determine 
whether an outlet can regarded as “satisfactory”. 
 
In the risk assessment section, the DH guidance neglects to mention any action to 
be taken in augmented care units during periods of remedial plumbing work. 
Evidence from week 12, Phase 1 of this study shows the emergence of 
P. aeruginosa following removal and replacement of tap fittings (Figure 28). Risk 
assessment should consider whether water filters should be placed on sentinel taps 
for a period of time with all others left unused except for frequent flushing. Outlets 
should be proven by repeated tests to be free of the bacterium before filters are 
removed and unfiltered taps reinstated for use.  
 
Paragraph 17 of the DH document recommends flushing for infrequently used taps. 
However, as has been seen in the current study, the frequently used (thus 
frequently flushed), handwash station located in the kitchen was persistently 
positive for the bacterium. Flushing of infrequently used taps would not represent a 
robust control measure for P. aeruginosa (or S. maltophilia).  
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Whist there was no clear evidence that the high levels of P. aeruginosa in the Ward 
7 water supplies were associated with colonisation or infection, the relative risk 
would be different on units treating other types of patient. Using a four-step risk 
assessment approach, Mena and Gerba (2009) concluded that while the risk of 
colonisation from ingesting P. aeruginosa in water is low, it is slightly higher if a 
patient is taking an antibiotic that isolates are resistant to. This is probably a 
consequence of the antibiotic suppressing part of the normal gut flora, thereby 
facilitating colonisation by P. aeruginosa. Their analysis also found that the greatest 
source of variability/uncertainty in the risk assessment was the density distribution 
of exposure, rather than the dose-response or water consumption distributions. 
Overall, they concluded that the type of exposure to water contaminated with 
P.  aeruginosa that presented the greatest health risks were a) skin exposure in hot 
tubs and b) lung exposure from inhaling aerosols (Mena and Gerba, 2009). This 
could have implications for cystic fibrosis and burns patients and others receiving 
hydrotherapy treatment (Solomon, 1985; Tredget et al., 1992; Lutz and Lee, 2011). 
Neither of these factors are considered in the DH guidance. 
 
The recommendations from the current study are that, if costs prohibit use of POU 
filters on all outlets, then a minimum of one key tap on an augmented care unit 
should have a water filter in place at all times if there is evidence increased 
incidence of P. aeruginosa colonisation/infection. Dependent on the risk 
assessment of the patient population, the outlet(s) should supply bathing water (e.g. 
for neonates) and/or drinking water. By restricting the filters to a ward-by-ward 
usage, the amount of time spent replacing the devices and recording changes, 
would be reduced. Although this may only require a short amount of time for an 
individual filter, this can become time-consuming on a larger scale, e.g. for 
Legionella outbreaks. It also recommends a minimal number of unit-based staff   
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members should be designated as “responsible person(s)”. The number designated 
should allow for shift changes and annual leave, but the implication is that 
individuals trained for the needs and requirements of a specialised care ward are 
those best placed to take responsibility for this task. Correct handling of the device 
during replacement to avoid contamination must also be observed as is 
communication with ambulant patients regarding their use and operation. The 
introduction of 31-day filters (Pall Medical) will also reduce the time spent in 
changing these devices. Ideally the manufacturer should supply training aids to 
make this task as easy as possible e.g. bar codes and PDA technology, suitable 
labelling for change dates etc. 
 
The advantages of POU filtration include instantaneous protection from waterborne 
pathogens without the need for systemic treatment. In outbreak situations, universal 
adaptors can be fitted to outlets and the filters provide an instant barrier. In non-
outbreak situations, if outlets already have screw-thread taps then the fitting of filters 
is very quick. However, if outlets do not have screw-thread taps, long term use 
precludes universal adaptors and outlets need to be changed for those which are 
compatible. This requires plumbing alterations and disruption to hospital wards, 
however these may need to be done to replace non-touch taps or old fittings with 
excess biofilm build-up. 
 
In the current study, in the absence of POU filtration, water from taps/showers 
represented a persistent source of P. aeruginosa and S. maltophilia. POU filtration 
almost completely eliminated target species from water samples and outlet swabs. 
Although a reduction in P. aeruginosa bacteraemia was observed during the filtered 
phases, overall numbers were small and there were no typing data to permit   
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characterisation of these strains. Nevertheless, filtration merits further investigation 
as an intervention to prevent infection with water-associated bacteria in vulnerable 
patients. 
 
Further questions 
 
In this study, the target species were shown to be endemic to the water distribution 
system of Ward 7 but did not appear to be colonising/infecting patients on the ward. 
Only a small number of patients were recruited to the study, limiting the likelihood 
that colonisation could be detected, but data provided by the hospital microbiology 
laboratory showed that the incidence of bacteraemia caused by target species was 
low during all phases. Overall, the results of this study and reports from other 
investigators raise several key questions: 
 
 In non-outbreak situations, is mandatory surveillance of water necessary? 
 Should healthcare facilities adopt higher standards for water quality than 
normal point of use standards? 
 Should there be an attempt to establish whether there are key clones 
persisting in water, and if so, which molecular typing method should be 
adopted? 
 
On a broader level, other issues include: 
 Is there enough evidence to support removal of unnecessary TMV’s and 
non-touch operated taps 
 As in Germany, should units such as neonatal, haematology-oncology and 
endoscopy suites, automatically have POU filters fitted to all outlets?  
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Most of these points are not addressed in the new DH guidelines, but with the 
mandatory requirement for augmented care units to undertake risk assessments 
on water supplies, they are topics that urgently need to be debated within the 
UK, with input from microbiologists, NHS estates, ward staff and plumbing 
engineers, as well as relevant manufacturers. 
 
A further question concerns the microbiological quality of domestic water for 
immunocompromised individuals who are treated within their own homes. Von 
Baum et al., (2010) investigated the water supplies from the homes of 65 patients 
treated for haematological malignancy and discharged from hospital while 
neutropenic. Non-tuberculous Mycobacteria were cultured from 95% of households, 
Legionella spp. from 9% and P. aeruginosa from 11%. There were no cases of 
legionellosis but there was one instance of infection with M. chelonae and seven 
with P. aeruginosa. The study was unable to confirm patient acquisition from the 
domestic water supplies (von Baum et al., 2010). Nevertheless, the following 
questions arise. Should patients while still neutropenic be allowed to return home? 
Keeping in mind that preventing patients from returning home would not be a 
feasible option, many patients are neutropenic long-term and there is not the 
capacity to keep them as in-patients and there is additional risk of acquiring a HCAI. 
When neutropenic patients are at home, should POU water filters be fitted to their 
taps for drinking and bathing purposes? If filtration were recommended for home 
use, how should this be funded – by the patient (too costly for most) or the NHS? 
Finally, is there a sufficiently broad evidence base to suggest that 
immunocompromised individuals can become infected with waterborne pathogens 
while treated in the home?  
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Further Work 
 
Further work arising from this study could include additional investigation of the 
P. aeruginosa and S. maltophilia isolates, especially those recovered from water 
sources. Highly discriminatory techniques such as PFGE and MLST would allow 
more detailed characterisation of the relationship between these isolates. Data from 
these typing methods could contribute to a UK surveillance database for these 
species which could help define differences or similarities between clinical and 
water-associated strains. With the cost of whole-genome sequencing falling 
continuously it might then be possible to sequence strains persistently associated 
with the water supplies sequenced to identifying genetic attributes that enable them 
to colonise this niche. 
 
Although infections associated with the target species in patients on Ward 7 were 
not regarded as a specific clinical problem they were reported in patients on other 
wards. If time and resources had been available three further sub-studies could 
have run alongside the main study:  
a). An investigation on another ward identified as having higher rates of infections 
with these species comparing water and clinical isolates  
b). A sub-study of another large water distribution network (e.g. the university 
network) to compare the frequency of recovery of target species to establish 
whether the levels were unique to the hospital or typical of large systems (a pilot 
study of this was undertaken but time constraints meant that the work was not 
possible to complete).  
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c). A study to investigate the microbiological quality of domestic water supplies 
could be undertaken to compare the findings with the findings from large distribution 
networks. 
 
Following completion of the current study, BRI Estates commissioned a chlorine 
dioxide system for the hospital water distribution system. A further extension of the 
work would have been a six month investigation on ward 7 to compare recovery of 
the target species after introduction of chloride dioxide with data collected during the 
unfiltered and POU filtered phases. 
 
If more time had been available, it would have been interesting to compare the 
microbiological quality of water samples from other wards in the same wing of the 
hospital, but which do not have TMVs and also to dismantle a number of type A and 
Type B outlets to investigate their components for microbiological contamination 
(e.g. outlets associated with consistent recovery versus outlets with little or no 
recovery of target species) 
 
Concluding Remarks 
It is believed that this double cross-over study lasting nearly two years is the first to 
investigate the effect of POU filtration on the numbers of three clinically important 
Gram negative species in the water distribution system of a hospital ward with the 
relationship between patient and environmental isolates characterised using two 
molecular typing techniques. From this work it was established that the target 
species were endemic within the water supplies and could be controlled using POU 
filtration.  
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Overall, 22% of water samples yielded P. aeruginosa and/or S. maltophilia 
suggesting significant contamination of the distribution system supplying water to 
patients immunocompromised as a result of haematological malignancy at the point 
of use. These bacteria could also be recovered from around the rim of water outlets. 
There was no clear relationship between contamination and the actual location of 
outlets within the water distribution network of the ward. Repeated isolation of these 
opportunistic pathogens from water sources in rooms subsequently designated as 
“hot zones” indicated that patients occupying these rooms would have had 
prolonged exposure to these bacteria. Although this study was not able to establish 
a link between patient isolates and water supplies, the failure to do so could be 
explained by a number of factors including the particular isolates selected and the 
very small number of patients who consented to join the study. This should be taken 
into account when devising further studies on this topic.  
 
The study has given insight into the infection risk to patients from hospital water – a 
commodity which is widely regarded as safe. The findings are useful to those 
involved in the provision of safe water for immunocompromised patients as it has 
shown that, not only can bacteria be found in outlets over long periods, but also that 
recently issued national guidance which promotes assessment of water quality 
based on single samples from each outlet might provide falsely reassuring results 
Moreover, results from the study provide further evidence that point-of-use filtration 
represents a robust and practical method for the removal of the two target species 
from water supplied to patients, such as those with haematological malignancy, who 
are vulnerable to infections associated with theses waterborne bacteria.   
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Translational Summary 
 Some studies investigating hospital-associated infection have concluded 
that hospital water supplies were the source of the infecting bacteria. 
 This investigation examined whether three species of bacteria, 
Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Acinetobacter 
baumannii, which can cause infections in vulnerable patients, can be found 
in hospital water sources. 
 This study also investigated whether taps and showers fitted with point-of-
use water filters could reduce patient exposure to water-borne bacteria. 
 The setting was a specialist ward for patients with haematological disorders 
including leukaemias. Over two years, water samples were collected weekly 
from taps and showers in patient rooms and kitchen taps used for both 
patient drinking water and ward cleaning. 
 In four alternating phases, water samples were obtained from outlets with 
and without filters.  
 In-patients treated for blood cancers were asked to consent for samples 
(throat and skin swabs and faeces) to be taken during their stay. These were 
examined for the target bacterial species. 
 Target species grown from water sources or patient samples were 
compared using DNA fingerprinting to identify if there was a link between 
them. 
 P. aeruginosa and/or S. maltophilia were isolated from 22% of 1396 non-
filtered water samples. A. baumannii was not detected. With the filters in 
place, the recovery of P. aeruginosa and S. maltophilia dropped to 0.08% of 
1242 water samples. 
 Some outlets, “hotzones”, were persistently associated with P. aeruginosa 
or S. maltophilia. These species were associated with particular types of 
outlet: S. maltophilia with showers and P. aeruginosa with outlets that had 
thermostatic mixing valves or were operated by electronic non-touch 
sensors.  
 Only one patient became infected with P. aeruginosa. Two other patients 
developed throat colonisation with S. maltophilia. DNA fingerprinting was 
unable to show a link between the patient and water isolates.  
 Unfiltered water from taps/showers was a persistent source of P. 
aeruginosa and S. maltophilia. Filtration was associated with a reduction in 
isolation of both target species from water supplies. 
 Point-of-use filtration merits further investigation as a method of preventing 
infection or colonisation with water-borne bacteria in vulnerable patients.   
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Appendix 2. Patient Information Sheet 
  
  
  
 
 
Annette Fox Haematology Unit 
 
 
 
INFORMATION FOR PATIENTS AND INVITATION TO PARTICIPATE IN A 
RESEARCH STUDY 
 
 
Investigation of Hospital Water Supplies and the Epidemiology of 
Gram-negative Infections in Patients with Haematological Malignancy 
 
 
 
Background information 
The human body harbours a large number of bacteria, especially on the skin and in 
the gut. Normally, these do not cause us any problems and can actually be 
beneficial to us. However, if you receive chemotherapy and your white blood cell 
count falls, this increases your risk of infection. There can be an effect on the type of 
bacteria that live in your mouth, throat and intestines and one of the aims of the 
study is to see if this is the case. 
 
Bacteria can also be found in our water supplies including bottled water and are not 
usually harmful to us. If you have a very low white blood cell count (neutropenia) as 
a result of chemotherapy then it is possible that bacteria from water could cause 
infection. 
 
The taps and showers in the rooms and kitchen on ward 7 are being replaced to 
contain filters. Extensive studies have previously demonstrated that these types of 
filter are effective at removing bacteria from the water but we do not know if this 
reduces a patient’s chances of developing an infection when they are neutropenic 
after chemotherapy.  
 
 
Participation in the study 
You are being invited to take part in this study because we know that you will 
become neutropenic as a result of chemotherapy or your underlying blood/lymph 
gland disorder. 
If you agree to take part in the study then we would require weekly throat swabs and 
samples of your faeces. These may sometimes need to be taken as part of your 
normal care but some may be extra. We would also like you to continue providing 
samples when you attend the day case unit and outpatient clinics.  
The throat swabs will be taken by the nurses. This involves gently rubbing a swab 
which looks a bit like a cotton wool bud over your throat. It takes seconds to do and 
is not painful. Once you have opened your bowels a specimen of faeces will be 
  
 
III 
collected by the nurse. These are both routine procedures that the nurses regularly 
carry out. 
 
The samples will be sent to a laboratory, to see what types of bacteria they contain. 
The samples of faeces and swabs will then be destroyed but any bacteria grown will 
be stored at the University of Bradford for the duration of the study. 
 
In addition to collecting these specimens we would need to record information on 
any infections that you may develop by looking at laboratory results and your case 
notes.  All of this information will be recorded anonymously so that it cannot be 
linked to you in any way. 
 
Your participation in this study is entirely voluntary, and you would be free to 
withdraw from it at any time. This would not affect the care that you receive in any 
way. 
 
This study is part of a research collaboration between the Haematology Unit at 
Bradford Royal Infirmary, the University of Bradford, and Pall Europe Ltd, who make 
the filters. 
 
If you have any further questions please do not hesitate to contact us by telephone 
as below or ask the nursing staff on ward 7 who will contact us on your behalf: 
 
 
 
 
Dr Lisa Newton      Mrs. Debbie Burke 
Consultant Haematologist    Research Nurse 
01274 364367      01274 364168 
 
 
 
 
 
 
 
 
 
 
Author:  Dr L Newton 
Version: 1 
Date: 31.8.2007 
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Appendix 3.  Patient Consent Form 
   
 
 
 
Investigation of Hospital Water Supplies and the epidemiology of 
Gram –negative infections in patients with haematological malignancy 
 
CONSENT FORM 
 
1. I have read the attached Information Sheet 
 
2. I have had an opportunity to discuss this study and ask questions 
 
3. I have received enough information about the study and satisfactory             
answers to all of my questions 
 
4. I understand that I am free to withdraw from the study at any time, without 
having to give reasons and without affecting my future medical care 
 
5. I understand sections of my medical records relating to my participation in 
the study may be inspected by a Research Scientist from the University of 
Bradford. All personal details will be treated as STRICTLY CONFIDENTIAL. 
Any information recorded about my case will be done so anonymously. 
 
6. I understand that the samples of faeces and swabs will be destroyed once 
samples have been taken to grow bacteria and that any bacteria grown will 
be stored at the University of Bradford for the duration of the study 
 
7. I agree to participate in this study  
 
Patient’s Signature:________________________________________ 
 
Name in block letters:______________________________________ 
 
Date___________________________________________________ 
 
 
 
Doctor/Research Nurse’s signature:___________________________ 
 
Name in block letters:______________________________________ 
 
 Position:  _______________________________________________ 
 
 Date ___________________________________________________ 
 
Dr L J Newton 
Version 1: 31 August 2007 
  
 
V 
Appendix 4. Patient Raw Data 
 
  
D.O.B: 
03/01/1960
Age: 48 Male
Sample 
No.
Sample 
Taken
Sample 
Collected
Phase/
Week
Room 
Number
Location Mac LAM VIA Ps-Cet Notes
1 14-Jun-08 16-Jun-08  P1 W1 Throat 0 0 0 0 On 1st admission
Axilla 0 0 0 0
Stool Pink 0 0 0
2 24-Jun-08 30-Jun-08 P1 W3 Throat Pink 0 0 0 Readmission
Axilla Pink 0 0 0
Stool Pink White 0 0
3 09-Jul-08 P1 W5 Axilla Pink 0 0 0
Throat Pink 0 0 0
4 16-Jul-08 P1 W6 Axilla Pink 0 0 0
Throat Orange & pink 0 0 0
Stool Pink Yellow 0 0
5 22-Jul-08 P1 W7 Axilla 0 0 0 0
Throat 0 0 0 0
Stool 0 Cream 0
Cream, not 
considered 
to be P. 
aeruginosa 
6 31-Jul-08 P1 W7 Axilla 0 0 0 0
Throat 0 0 0 0
7 04-Aug-08 04-Aug-08 P1 W8 Axilla Pink 0 0 0
Throat Pink 0 0 0
8 03-Sep-08 05-Sep-08 P1 W12 Axilla 0 0 0 0
Throat 0 0 0 0
Stool Pink White 0 0
9 02-Oct-08 03-Oct-08 P1 W16 Axilla Pink 0 0 0
Throat Pink 0 0 0
10 11-Nov-08 11-Nov-08 P1 W22 Rm 1 Axilla Pink 0 0 0
Throat Pink 0 0 0
11 24-Nov-08 25-Nov-08 P1 W24 Rm 3 Axilla 0 0 0 0
Throat Pink 0 0 0
12 01-Dec-08 02-Dec-08 P1 W25 5 Axilla Pink 0 0 0
Throat Pink 0 0 0
Stool Pink white 0 0
13 09-Dec-08 09-Dec-08 P1 W26 5 Axilla Pink 0 0 0
Throat Pink 0 0 0
Patient P.001
Media Result/Colony Morphology
  
 
VI 
  
D.O.B: 
02/01/1971
Age: 38 Female
Sample 
No.
Sample 
Taken
Sample 
Collected
Phase/
Week Room Location Mac LAM VIA Ps-Cet Notes
1 31-Jul-08 P1 W7 Axilla Pink 0 0 0
Throat Pink White 0 0
2 06-Aug-08 P1 W8 Axilla 0 0 0 0
Throat Pink White 0 0
3 03-Sep-08 04-Sep-08 P1 W12 Axilla 0 0 0 0 Readmission
Throat Pink White 0 0
4 15-Sep-08 16-Sep-08 P1 W14 Rm 3 Axilla Pink 0 0 0
Throat Pink White 0 0
5 07-Oct-08 09-Oct-08 P1 W17 Rm 9 Axilla Pink 0 0 0 Both samples labelled axilla
Axilla Pink White 0 0
6 15-Oct 16-Oct-08 P1 W18 Rm 11 Axilla Pink 0 0 0
Throat Pink 0 0 0
7 21-Oct-08 23-Oct-08 P1 W19 Rm 11 Axilla Pink 0 0 0
Throat Pink White 0 0
8 30-Oct-08 31-Oct-08 P1 W20 Rm 11 Axilla Pink 0 0 0
Throat Pink White 0 0
9 03-Nov-08 04-Nov-08 P1 W21 Rm 11 Axilla 0 0 0 0
Throat Pink White 0 0
10 16-Dec-08 17-Dec-08 P1 W27 Rm 9 Axilla Pink 0 0 0
Throat 0 0 0 0
11 20-Feb-09 23-Feb-09 P2 W7 Rm 2 Axilla Pink 0 0 0
Throat White 0 0
12 24-Feb-09 24-Feb-09 P2 W8 Rm 2 Axilla 0 0 0 0
Throat 0 White 0 0
Patient P.002
Media Result/Colony Morphology
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D.O.B: 
17/01/1978
Age: 30 Male
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week Room Location Mac LAM VIA Ps-Cet Notes
1 04-Sep-08 05-Sep-08 P1 W12 Axilla (TMC) Pink 0 0 0 Treatment already started
Throat (1) Pink 0 0 0
2 06-Sep-08 07-Sep-08 P1 W13 Stool mucoid pink 0 0
Cream, not 
considered P. 
aeruginosa
3 23-Sep-08 25-Sep-08 P1 W15 Axilla 0 0 0 0
Throat Pink White 0 0
4 02-Oct-08 03-Oct-08 P1 W16 Rm 2 Axilla Pink 0 0 0
Throat Pink 0 0 0
5 08-Oct-08 09-Oct-08 P1 W17 Rm 2 Axilla Pink 0 0 0
Throat Orange White 0 0
6 21-Oct-08 23-Oct-08 P1 W19 Rm 4 Axilla Pink 0 0 0
Throat Pink 0 0 0
Stool Pink 0 0 0
7 30-Oct-08 31-Oct-08 P1 W20 rm 3 Axilla 0 0 0 0
Throat Pink White 0 0
8 04-Nov-08 04-Nov-08 P1 W21 Rm 3 Axilla Pink 0 0 0
Throat Pink White 0
White, not 
considered P. 
aeruginisa 
Transferred to LGI for 
further treatment
Patient P.003
Media Results/Colony Morphology
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D.O.B: 
11/10/1950
Age: 58 Male
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week Room Location Mac LAM VIA Ps-Cet Notes
1 04-Sep-08 05-Sep-08 P1 W12 Rm 3 Axilla Colourless & Pink 0 0 0 Treatment already started
Throat Green 0 0 Green SS-PCR +ve P. aeruginosa  (N.425)
Stool Pink & Green 0 0 Green SS-PCR +ve P. aeruginosa (N.426)
2 18-Sep-08 18-Sep-08 P1 W14 unconfirmed Axilla mixed pink 0 0 0
Throat Green Colourless 0 Green SS-PCR +ve P. aeruginosa (N.509)
3 23-Sep-08 25-Sep-08 P1 W15 Rm 3 Axilla 0 0 0 0
Throat Green 0 0 Cream & Green
SS-PCR +ve P. aeruginosa (N.555 - 
556)
4 02-Oct-08 03-Oct-08 P1 W16 Rm 3 Axilla Pink 0 0 0
Throat Green 0 0 Green SS-PCR +ve P. aeruginosa (N.558)
5 07-Oct-08 09-Oct-08 P1 W17 Rm 7 Axilla Pink 0 0 0
Throat Pink 0 0 0
Hickmann Pink 0 0 0
6 15-Oct-08 16-Oct-08 P1 W18 Rm 7 Axilla Pink 0 0 0
Nose Pink 0 0 0
7 21-Oct-08 23-Oct-08 P1 W19 Rm 12 Axilla 0 0 0 0
Throat Green White 0 Green SS-PCR +ve P. aeruginosa (N.596)
8 28-Oct-08 31-Oct-08 P1 W20 Rm 12 Axilla 0 0 0 0
Throat Mucoid pink White 0 Cream & Green SS-PCR +ve P. aeruginosa (N.608)
Patient P.004
Comments: Patient developed P. aeruginosa  bacteraemia during this sampling duration. Also have in 
sample collection blood culture isolate supplied by BRI Microbiology Dept.
Media Results/Colony Morphology
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D.O.B: 
06/01/1946
Age: 62 Male
Sample 
No.
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 30-Oct-08 31-Oct-08 P1 W20 Rm 2 Axilla 0 0 0 0
Throat Pink 0 0 0
Stool Pink White 0 0
2 03-Nov-08 04-Nov-08 P1 W21 Rm 2 Axilla Pink 0 0 0
Throat Pink 0 0 0
Stool Pink White 0 0
3 17-Nov-08 18-Nov-08 P1 W23 Rm 2 Axilla Pink 0 0 0
Throat 0 0 0 0
4 02-Dec-08 02-Dec-08 P1 W25 Rm 12 Axilla Pink 0 0 0
Throat colourless 0 0
5 09-Dec-08 09-Dec-08 P1 W26 Rm 12 Axilla 0 0 0 0
Throat Pink 0 0 0
6 16-Dec-08 17-Dec-08 P1 W27 Rm 4 Axilla Pink 0 0 0
Throat Pink 0 0 0
Stool Pink 0 0 0
7 20-Feb-09 20-Feb-09 P2 W7 Unkown Axilla 0 0 0 0
Throat White 0 0
8 18-Mar-09 19-Mar-09 P2 W10 Unkown Axilla Pink White 0 0
Throat 0 0 0 0
Patient P.005
Media results/Colony Morphology 
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D.O.B: 
18/11/1946
Age: 58 Female
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 03-Nov-08 04-Nov-08 P1 W21 Rm 9 Axilla Pink 0 0 0 Treatment Started
Throat Pink White 0 0
2 06-Nov-08 10-Nov-08 P1 W21 Rm 9 Stool Orange and Pink White 0 0
3 18-Nov-08 18-Nov-08 P1 W23 Rm 1 Axilla Pink 0 0 0
Throat Pink 0 0 0
4 24-Nov-08 25-Nov-08 P1 W24 Rm 1 Axilla Pink 0 0 0
Throat Colourless & Pink 0 0 0
5 25-Nov-08 01-Dec-08 P1 W25 Rm 1 Faecal Pink 5-6mm white 0 0
6 01-Dec-08 02-Dec-08 P1 W26 Rm 1 Axilla Pink 0 0 0
Throat Pink 0 0 0
Faecal Pink 0 0 0
7 09-Dec-09 09-Dec-09 P1 W26 Rm 1 Axilla Pink 0 0 0
Throat Pink 4 mm white 0 0
API result: 99.2% 
Chryseomonas luteola
8 Unknown 06-Jan-09 Rm 4 Faecal Pink 0 0 0
9 06-Jan-09 06-Jan-09 P1 W30 Rm 4 Axilla Pink 0 0 0
Throat Pink >5mm White 0 0
10 12-Jan-09 13-Jan-09 P2 W1 Rm 12 Axilla
Throat >5mm white
11 19-Jan-09 20-Jan-09 P2 W2 Rm 12 Axilla Pink 0 0 0
Throat Pink 2-4mm white 0 0 API: Chryseomonas luteola
12 Unknown 19-Jan-09 Rm 12 Faecal Pink
3-4mm white & 
1mm pink 0 1mm cream
13 Unknown 27-Jan-09 Rm 12 faecal Pink 2-3mm white 0 1-2mm White API:  C. luteola
14 16/03/2010 P4 W16 Rm 10 Axilla Pink 0 0 0 Readmission
Throat 0 0 0 0
15 23/03/2010 P4 W17 Rm 10 Axilla Pink 0 0 0
Throat
3x 1mm 
white/LAM: KOH 
Neg 0 0
16 30-Mar-10 30-Mar-10 P4 W18 Rm 10 Axilla Pink 0 0 0
Throat Pink 0 0 0
17 29-Apr-10 29-Apr-10 PW Rm 9 Axilla 0 0 0 0 PW = Post Water Sampling
Throat Pink white 0 0
18 04-May-10 05-May-10 PW Rm 9 Axilla 0 0 0 0
Throat Pink White 0 0
19 11-May-10 12-May-10 PW Rm 9 Axilla Pink 0 0 0
Throat 0 0 0 0
20 18-May-10 19-May-10 PW Rm 9 Axilla Pink 0 0 0
Throat Pink 0 0 0
Patient P.006
Media Results/Colony Morphology
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D.O.B: 
Unknown
Unknown Female
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 10-Feb-09 10-Feb-09 P2 W5 6 Axillae 0 0 0 0
Throat 0 0 0 0
Stool White
white, not 
considered 
to be Ps.
API result for Ps. Cetrimide agar: 
99.2% C. luteola
No longer wished to continue in 
study - 2nd samples not taken
Media Results/Colony Morphology
Patient P.007
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D.O.B: 
02/05/1939
Age: 69 Female
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 20-Feb-09 20-Feb-09 P2 W7 6 Axillae 0 0 0 0
Throat 0 0 0 0
2 24-Feb-09 24-Feb-09 P2 W8 6 Axillae 0 0 0 0
Throat pinkish 0 0
3 18-Mar-09 19-Mar-09 P2 W10 6 Axillae Pink 0 0 0
Throat Pink 0 0 0
4 24-Mar-09 30-Mar-09 P2 W11 6 Axillae 0 0 0 0
Throat
Yellow/LAM & 
colourless with 
yellow 
discolouration
API result for LAM colony: 
Required 48hrs, good ID, 
98.9% Vibrio parahaemolyticus
Media Results/Colony Morphology
Patient P.008
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D.O.B: 
03/01/1943
Age: 66 Male
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 24-Mar-09 30-Mar-09 P2 W11 Axillae 0 0 0 0
Throat White
White - not S. 
maltophilia 0
2 21-Apr-09 22-Apr-09 P2 W14 Axillae 0 0 0 0
Throat Colourless 0 0
3 28-Apr-09 28-Apr-09 P2 W15 Axillae 0 0 0 0
Throat 0 0 0 0
4 Unknown 05-May-09 Stool White 0 0
5 06-May-09 07-May-09 P2 W17 Axillae 0 0 0 0
Throat Pink 0 0
API result for LAM colony: 24 hr, 
acceptable ID: 94.4% B. 
cepacia , at 48hrs: unacceptable 
profile
6 11-May-09 12-May-09 P2 W18 Axillae 0 0 0 0
Throat White 0 0
API result for LAM colony: 
Required 48 hrs, unacceptable 
profile
7 09-Jun-09 11-Jun-09 P2 W22 8 Axillae 0 0 0 0
Throat White 0 0
8 15-Jun-09 16-Jun-09 P2 W23 8 Axillae 0 0 0 0
Throat White 0 0
Required 48hrs, acceptable ID, 
99.3% B. cepacia
Media Results/Colony Morphology
Patient P.009
  
 
XIV 
 
 
D.O.B: 
13/12/1950
Age: 59 Male
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 03-Jun-09 09-Jun-09 P2 W21 3 Axillae 0 0 0 0
Throat Pink White 0 0
Stool 
(undated) Pink White 0 0
2 09-Jun-09 11-Jun-09 P2 W22 3 Axillae 0 0 0 0
Throat Pink White 0 0 Too ill for further samples
Patient P.010
Media Results/Colony Morphology
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D.O.B: 
19/11/1958
Age: 51 Female
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 30-Jun-09 01-Jul-09 P2 W25 5 Axillae 0 0 0 0 Using shower in Rm 7
Throat 0 0 0 0
2 08-Jul-09 08-Jul-09 P3 W1 5 Axillae Pink 0 0 0
Throat 0 0 0 0
3 21-Jul-09 27-Jul-09 P3 W3 6 Axillae 0 0 0 0
Throat 0 0 0 0
4 27-Jul-09 29-Jul-09 P3 W4 5 Axillae 0 0 0 0
Throat 0 0 0 0
5 18-Aug-09 18-Aug-09 P3 W7 11 Axillae Pink 0 0 0
Throat Pink 0 0 0
6 25-Aug-09 25-Aug-09 P3 W8 5 Axillae 0 0 0 0
Removed consent for throat 
samples
7 04-Sep-09 07-Sep-09 P3 W9 5 Axillae 0 0 0 0
8 08-Sep-09 08-Sep-09 P3 W10 5 Axillae 0 0 0 0
Media Results/Colony Morphology
Patient P.011
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D.O.B: 
06/01/1938
Age: 71 Female
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 14-Aug-09 17-Aug-09 P3 W6 10 Axillae 0 0 0 0
Throat 0 0 0 0
2 25-Aug-09 25-Aug-09 P3 W8 11 Axillae Pink 0 0 0
Throat Pink White 0 0
API Result for LAM colony: 
unacceptable profile. S. 
maltophilia  SS-PCR negative
Patient P.012
Media Result/Colony Morphology
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D.O.B: 
02/02/1958
Age: 51 Female
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 26-Aug-09 02-Sep-09 P3 W8 9 Axillae 0 0 0 0
Throat White & Yellow White
2 02-Sep-09 02-Sep-09 P3 W9 9 Axillae Dark & light pink 0 0 0
Throat Pinky Orange White 0 0
3 08-Sep-09 08-Sep-09 P3 W10 9 Axillae Pink 0 0 0
Throat
Mixed pink & 
orange Yellow Blue 0
SS-PCR +ve S. maltophilia 
(N.1124)
4 27-Oct-09 30-Oct-09 P3 W16 9 Axillae Dark Pink 0 0 0
Throat Dark pink 0 0 0
5 10-Nov-09 10-Nov-09 P3 W18 9 Axillae 0 0 0 0
Throat Yellow 0 0 0
6 17-Nov-09 17-Nov-09 P3 W19 11 Axillae 0 0 0 0
Throat Pink 0 0 0
6 01-Dec-09 02-Dec-09 P4 W1 11 Axillae Pink 0 0 0
Throat Pink 0 0 0
7 07-Dec-09 08-Dec-09 P4 W2 11 Axillae Pink 0 0 0
Throat Pink 0 0 0
Media Result/Colony Morphology
Patient P.013 Comment: Patient developed throat colonisation with S. maltophilia
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D.O.B:  
14/10/48
Age: 60 Female
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 04-Sep-09 07-Sep-09 P3 W9 4 Axillae 0
Yellow & 
Pink Blue 0
SS-PCR +ve S. maltophilia 
(N.1119 & N.1127)
Throat 0 0 0
2 08-Sep-09 08-Sep-09 P3 W10 4 Axillae Pink 0 0 0
Throat
Pink & 
Yellow
Pink & 
Yellow Blue 0
API for Pink/LAM: 98.8% B. 
cepacia
Media Results/Colony Morphology
Patient P.014 Comment: Patient developed throat colonisation with S. maltophilia
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D.O.B: 
12/08/1947
Age: 62 Male
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 29-Oct-09 30-Oct-09 P3 W16 12 Axillae 0 0 0 0
Throat Pink White 0 0
2 30-Oct-09 03-Nov-09 P3 W17 12 Axillae Pink White 0 0
Throat Pink White 0 0
3 03-Nov-09 04-Nov-09 P3 W18 12 Axillae 0 0 0 0
Throat Pink 0 0 0
4 09-Nov-09 P3 W18 5 0 0 0 0
0 0 0 0
5 17/11/2009 P3 W19 4
On ward, too ill for 
samples
6 30/11/2009  P4 W1 4 Axillae 0 0 0 0
Throat White Yellow 0
7 02/12/2009 P4 W1 4 Axillae Pink 0 0 0
Throat White Yellow 0
8 08/12/2009 P4 W2 4 Axillae 0 0 0 0
Throat White Yellow 0
9 15/12/2009  P4 W3 4 Axillae 0 0 0 0
Throat Pink White Yellow 0
10 13/01/2010 P4 W7 5 Axillae 0 0 0 0
Throat 0 0 0 0
11 19/01/2010 P4 W8 5 Axillae 0 0 0 0
Throat 0 0 0 0
12 25/01/2010 P4 W9 5 Axillae 0 0 0 0
Throat 0 White Yellow 0
13 05/02/2010 P4 W10 5 Axillae 0 0 0 0
Throat 0 0 0 0
14 16/03/2010 P4 W16 3 Axillae 0 0 0 0
Throat 0 0 0 0
15 30/03/2010 30/03/2010 P4 W18 8 Axillae 0 0 0 0
Throat 0 0 0 0
16 09/04/2010 15-Apr-10 P4 W19 8 Axillae 0 0 0 0
Throat 0 0 0 0
17 14-Apr-10 14/04/2010 P4 W20 8 Axillae 0 0 0 0
Throat Pink White White/yellow 0
18 19/04/2010 21-Apr-10 PW 8 Axillae 0 0 0 0 PW = Post Water Sampling
Throat White white 0
19 19/05/2010 PW 7 Axillae Pink 0 0 0
Throat 0 0 0 0
20 26-May-10 PW 5 Axillae Pink 0 0 0
Throat 0 0 0 0
21 02-Jun-10 03-Jun-10 PW 5 Axillae 0 0 0 0
Throat 0 0 0 0
23 08-Jun-10 10-Jun-10 PW 5 Axillae 0 0 0 0
Throat 0 0 0 0
Patient P.015
Media Results/Colony Morphology
  
 
XX 
 
  
D.O.B: 
09/11/1951
Age: 58 Male
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 02-Nov-09 17/11/2009 P3 W17 9 Axillae Pink 0 0 0
Throat 0 0 0 0
2 17-Nov-09 17-Nov-09 P3 W19 9 Axillae Pink 0 0 0
Throat Pink 0 0 0
3 30/11/2009 P4 W1 9 Axillae Pink 0 0 0
Throat 0 0 0 0
4 02/12/2009 P4 W1 9 Axillae Pink White 0 0
Throat Colourless 0 0 0
5 15/12/2009 P4 W3 11 Axillae Pink 0 0 0
Throat Pink White 0 0
6 13/01/2010 P4 W7 11 Axillae Pink 0 0 0
Throat Pink White 0 0
7 02-Jun-10 03-Jun-10 PW 1 Axillae Pink 0 0 0 PW = Post Water Sampling
Throat Pink 0 0 0
8 08-Jun-10 10-Jun-10 PW 11 Axillae 0 0 0 0
Throat 0 0 0 0
P.016
Media Results/Colony Morphology
  
 
XXI 
 
 
  
D.O.B: 
03/12/1963
Age: 47 Male
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 09/04/2010 14-Apr-10 P4 W19 11 Axillae 0 0 0 0
Throat 0 0 0 0
2 14-Apr-10 14/04/2010 P4 W20 11 Axillae 0 0 0 0
Throat White 0 0
3 19-Apr-10 21/04/2010 PW 11 Axillae 0 0 0 0 PF = Post Water Sampling
Throat White 0 0
4 28-Apr-10 29/04/2010 PW 12 Axillae 0 0 0 0
Throat Pink White 0 0
5 02-Jun-10 03-Jun-10 PW 9 Axillae 0 0 0 0
Throat Rough White 0 0
6 08-Jun-10 10-Jun-10 PW 9 Axillae 0 0 0 0
Throat 0 0 0 0
Patient P.018
Media Results/Colony Morphology 
D.O.B: 
01/04/1962
Age: 48 Male
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 30-Mar-10 30/03/2010 P4 W18 12 Axillae 0 0 0 0
Throat 0 0 0 0
Patient P.017
Media Results/Colony Morphology
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D.O.B: 
06/11/1964
Age: 45 Female
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 09/04/2010 14-Apr-10 P4 W19 9 Axillae 0 0 0 0
Throat 0 0 0 0
2 14-Apr-10 14/04/2010 P4 W20 9 Axillae 0 0 0 0
Throat 0 0 0 0
3 17-Apr-10 21/04/2010 PW 9 Axillae 0 0 0 0 PW = Post Water Sampling
Throat 0 0 0 0
4 11-Apr-10 12/05/2010 PW 11 Axillae 0 0 0 0
Throat 0 0 0 0
5 18-Apr-10 19/05/2010 PW 11 Axillae 0 0 0 0
Throat Pink 0 0 0
6 26-May-11 PW 11 Axillae 0 0 0 0
Throat 0 0 0 0
7 02-Jun-10 03-Jun-10 PW 11 Axillae 0 0 0 0
Throat 0 0 0 0
8 08-Jun-10 10-Jun-10 PW 2 Axillae 0 0 0 0
Throat 0 0 0 0
Patient P.019
Media Results/Colony Morphology
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D.O.B: 
10/06/1980
Age: 29 Female
Sample 
No. 
Sample 
Taken
Sample 
Collected
Phase/
Week
Room Location Mac LAM VIA Ps-Cet Notes
1 14-Apr-10 14/04/2010 P4 W20 5 Axillae 0 0 0 0
Throat 0 0 0 0
2 19-Apr-10 21/04/2010 PW 5 Axillae 0 0 0 0 PW = Post Water Sampling
Throat 0 0 0 0
3 28-Apr-10 29/04/2010 PW 5 Axillae 0 0 0 0
Throat 0 0 0 0
4 04-May-10 05/05/2010 PW 2 Axillae 0 0 0 0
Throat 0 0 0 0
5 11-May-10 12/05/2010 PW 2 Axillae Pink 0 0 0
Throat 0 0 0 0
Patient P.020
Media Results/Colony Morphology
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Appendix 5. Publications and Presentations Arising from this 
Study 
 
Publications 
Wright C. L., Snelling A. M., Newton L., Kerr K. G. (2008). Water-
associated nosocomial infections. Br J Intensive Care Summer 64-67. 
 
Published Conference Proceedings 
Wright, C.L., Kerr, K.G., Newton, L. & Snelling, A.M. (2009). Prevalence 
and antibiotic resistance of Stenotrophomonas maltophilia in the water 
supply of a haematology ward. Clinical Microbiology and Infection 15 
(Suppl 4) p.S219. 
 
Wright, C.L., Newton, L., Kerr, K.G. & Snelling, A.M. (2010). Point-of-use 
water filters reduce contamination by opportunistic Gram-negative bacteria 
present in the water distribution system of a haematology ward.Clinical 
Microbiology and Infection 16 (Suppl 2) p. S439-S440. 
 
 
Wright, C.L., Kerr, K.G., Newton, L. & Snelling, A.M. (2010).  
A Two-Year Double Cross-over Study Investigating Point-Of-Use Filters for 
Reducing Gram-negative Nosocomial Pathogens from Hospital Water 
Journal of Hospital Infection Vol. 76 Supplement 1, Page S38 
 
Oral Conference Presentations 
Wright, CL; Newton, L; Kerr, KG; Snelling, AM 
A 2 Year Study Evaluating Point-of-Use Filtration as a Barrier Control 
Against Water-borne Gram Negative Pathogens in a UK Hospital Water 
System 
Australian Infection Control Association, 2010 
 
 
Poster Presentations 
Wright, C.L., Kerr, K.G., Newton, L. & Snelling, A.M. (2009). Incidence of 
Stenotrophomonas maltophilia in the water distribution system of a 
haematology ward. Society for General Microbiology, Spring Meeting, 
Harrogate, April 2009. 
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Oral Presentations on Behalf of Pall Medical 
 
September – October 2010 Six different hospital venues across Australia 
(Sydney (x3), Brisbane, Melbourne, Adelaide)  
January 2012  Bradford Royal Infirmary, update of study 
results. 
January 2012 York District Hospital, Presentation to 
infection control practitioners, nurses, estates. 
Background & results of study. 
March 2012  Pall Masterclass, London.  
 
General Oral Presentations about the Study 
 
October 2007  Bradford Royal Infirmary, Primary introduction 
of study to infection control, microbiology and 
ward staff. 
June 2008  Bradford Royal Infirmary, Presentation of 
study giving background and results to date to 
ward staff, microbiologists and infection 
control staff. 
May 2010  Bradford Royal Infirmary, BRI Estates. Study 
background and results to date. 
August 2010  Bradford Royal Infirmary, Haematology 
seminar, request of Victoria Drew (research 
nurse, BRI). 
September 2011  British Science Festival, Demonstration to 
general public on water research at Bradford 
University 
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Appendix 6. Water Supply/Distribution to Bradford Royal 
Infirmary 
 
Ward 7 
